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ABSTRACT 
 
DISCOVERY OF PYRIMIDINE-BASED HETEROCYCLES AS SINGLE AGENTS WITH 
COMBINATION CHEMOTHERAPY POTENTIAL AND AS INHIBITORS OF PURINE 
NUCLEOTIDE BIOSYNTHESIS FOR THE TREATMENT OF CANCER  
 
 
By 
Rishabh Mohan 
December 2017 
 
Dissertation supervised by Professor Aleem Gangjee 
This dissertation describes the design, synthesis and biological evaluation of monocyclic and 
bicyclic pyrimidine-base heterocycles as single agents with combination chemotherapy potential 
having both antiangiogenic effects and cytotoxic effects. This dissertation also describes selective 
tumor targeting with 5-substituted pyrrolo[2,3-d]pyrimidines analogs with heteroatom bridge 
substitution as GARFTase inhibitors. 
The work in this dissertation is centered on identifying structural features that are necessary for 
inhibition of tubulin polymerization as well as for inhibition of one or more of the receptor tyrosine 
kinases (RTKs)- vascular endothelial growth factor receptor-2 (VEGFR2), platelet derived growth 
factor receptor-β (PDGFRβ) and epidermal growth factor receptor (EGFR) in single entities. 
Single agents with both antiangiogenic activities as well as cytotoxicity would afford agents that 
circumvent pharmacokinetic problems of multiple agents, avoid drug-drug interactions, could be 
v 
used at lower doses to alleviate toxicity, be devoid of overlapping toxicities, and delay or prevent 
tumor cell resistance.  
This work reviews the synthesis of substituted monocyclic pyrimidines as well as pyrrolo[2, 3-
d]pyrimidines. This work also reviews the synthesis of multi-transporter (PCFT and FR) selective 
5-substituted pyrrolo[2, 3-d]pyrimidines as GARFTase inhibitors circumventing both dose-
limiting toxicity and tumor resistance associated with most prescribed antitumor agents like 
pemetrexed. 
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I. BIOLOGICAL REVIEW 
A. Microtubules 
Cytoskeletal protein polymers which include microfilaments (actin proteins), intermediate 
filaments (various proteins e.g. desmin, peripherin, keratin) and microtubules (tubulin 
proteins) are crucial for cytoskeletal function and provide mechanical support and 
resistance against physical stress. Microtubule targeting agents (MTAs) affect interphase 
cells significantly by disrupting transcription, translation, axonal transport, mitochondrial 
permeability, immune cell function, directional migration and centrosome clustering 
(Figure 1).1 In interphase cells, MTA treatment perturbs microtubule dynamicity as well as 
significantly disturbs interphase intracellular trafficking of protein and nucleic acid cargo 
in various types of cancer cells.2 For this reason, MTAs that interfere with these processes 
possess potent inhibitory activities against a wide variety of tumors.3 Drugs targeting 
microtubules have been highly successful in the clinic and have been integrated into 
therapeutic regimens against both solid tumors (e.g., breast, ovarian, non-small-cell lung 
cancer, and Kaposi’s sarcoma) and hematological malignancies (non-Hodgkin's 
lymphomas).4-5  
Microtubules are assembled in polarized arrays during the G1-, S-, and G2-phases (Figure 
2)2 with their (+) end pointing outward from the center and the (−) end is nucleated by the 
centrosome. These move to the two opposite sides of the cell during the mitosis phase, 
forming the mitotic spindle. 
 
2 
A.1 Structures of Microtubules 
Microtubule/tubulin is one of the most important and promising targets in cancer therapy.6 
Microtubules are tube-like protein filamentous fibers made of individual tubulin dimers. 
The tubulin heterodimer consists of one α- and one β-tubulin subunit (molecular weight = 
50 kDa).5 Tubulin dimers polymerize in a “head-to-tail” fashion between the α- and β-
tubulin to form protofilaments which further arrange in parallel to form a hollow cylindrical 
microtubule 
 
 
Figure 1. Interphase activities of MTAs (modified from ref. 1) 
3 
(a) Centrosome clustering. (b) voltage-dependent anion channel opening (c) disruption of 
delivery of mRNA along interphase microtubule tracks to polysomes and (d) induce 
mRNA release from polysomes. (e)  improve MHC class I expression by cancer cells 
(f) activation of dendritic cells, (g) cytotoxic T lymphocytes and (h) macrophages (i) 
impede vesicular traffic to the cell front (j) timely endocytosis of focal adhesion 
components (k) interference with transcription factor transport (l) up- or down-regulation 
of tumor suppressor or oncogenes, respectively.  
 
 
Figure 2. Microtubules organization during the cell cycle (modified from ref. 2). 
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structure (Figure 3). Each α- and β-tubulin heterodimer structure includes two GTP 
molecules, one of which is tightly bound and the other bound GTP molecule is freely 
exchangeable with unbound GTP. The non-exchangeable GTP is bound to α-tubulin, 
whereas GTP and GDP are exchangeable on β-tubulin. GTP which is exchangable is highly 
involved in the regulation of various functions of tubulin. Hydrolysis of GTP is necessary 
for microtubule depolymerization and binding of GTP is required for microtubule 
polymerization.7  
 
 
Figure 3. A.  Cervical cancer HeLa cell with individual microtubule filaments stained 
green and nucleus stained red. B. and C.  arrangement of 13 protofilaments. D. atomic-
5 
resolution model of a 13 protofilament microtubule. E.  apical side view of this model 
(modified from ref. 7) 
Microtubule associated proteins (MAPs) impact protein–microtubule interactions, 
microtubule cross-linking and overall microtubule stability. The fast growing plus end 
probes the cytoplasm in a search-and capture process to reach different targets but the slow 
growing minus end is anchored at the microtubule organizing center.3  
 
A.2 Microtubule Dynamics 
Microtubule dynamics are responsible for the functional role of microtubules in cells 
and are very tightly regulated.3 MAPs, kinases, phosphatases and nucleotides regulate these 
dynamics. Microtubule dynamics, if disturbed, can have serious consequences on the fate 
of a cell and therefore, disruption of microtubule dynamics is a very important strategy to 
develop anticancer agents.8 Tubulin polymerization involves slow formation of a short 
microtubule nucleus which is followed by a rapid phase of microtubule elongation through 
reversible and non-covalent addition of αβ-tubulin heterodimers. GTP binding to β-tubulin 
favors a dimer conformation that promotes polymerization.9 Upon the attachment of the 
GTP-bound tubulin dimer to the ends of the microtubule, GTP hydrolysis occurs, which 
further drives polymerization forming tubulin–GDP with the release of Pi which provides 
energy for the addition of a dimer. 
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Figure 4. A. Treadmilling of a microtubule, whereby tubulin dimers are added to the 
positive end of the microtubule. B. End view of atomic-resolution microtubule model. C. 
a side apical perspective. (modified from ref.7) 
 
The presence of a GTP cap i.e. GTP or GDP with unreleased phosphate (GDP-Pi).  at the 
end of the microtubule, stabilizes the open-sheet conformation of the growing microtubule 
plus end, and thus lengthens the microtubule. The GTP cap prevents shrinkage of the 
microtubule and the microtubule end shortens rapidly after loss of the GTP cap.10 
Two major forms of non-equilibrium dynamics occur in vitro and in cells, namely dynamic 
instability and treadmilling (Figure 4).4 Dynamic instability (Figure 5) is the switching of 
microtubules between phases of lengthening and shortening, and is defined by some 
factors:9, 11 1) the rate of growth and shrinkage 2) The transition from a growth or a pause 
state to a shortening phase (“catastrophe”) 3) The transition from a shortening phase to a 
7 
growth or a pause state (“rescue”). Another kind of microtubule dynamics behavior is 
treadmilling (Figure 6). This process is characterized by net growth at one end and balanced 
equivalent shortening at the opposite end. 
 
Figure 5. Microtubule growth and shrinkage (modified from ref. 12) 
 
Figure 6. Microtubule treadmilling (modified from ref. 13) 
 
 
8 
A.3 Microtubule Binding Agents: On the basis of their effects on microtubule stability 
they are classified as follows.7, 14 
1) Microtubule-destabilizing agents include natural products such as the Vinca alkaloids, 
estramustine, colchicine and its analogs and combretastatin. They inhibit microtubule 
polymerization and so, promote microtubule disassembly.7 
2) Microtubule-stabilizing agents include paclitaxel, docetaxel, epothilones and 
discodermolide. These agents induce microtubule polymerization and so, promote 
microtubule assembly.  
 
Microtubule binding agents can also be classified by their binding sites on tubulin.14 
1) The Vinca alkaloids including vinblastine, vincristine, vindesine, and vinorelbine and 
bind to the β-subunit of soluble tubulin heterodimers (Figure 7)15 and have been widely 
used in cancer chemotherapy for the treatment of leukemias, lymphomas, small cell lung 
cancer, and other cancers. The rapid and reversible binding of vinblastine to soluble tubulin 
induces a conformational change that prevents integration of the dimer into the 
microtubule.16 
9 
 
Figure 7. Vinca binding site and representative vinca alkaloids (modified from ref. 14) 
2) Taxanes and Epothilones 
 
Figure 8. Taxane binding site and representative taxanes (modified from ref. 14) 
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The second class of antimitotics, the taxanes, are exemplified by paclitaxel and 
docetaxel which bind poorly to soluble tubulin, but bind strongly to tubulin along the length 
of the microtubule.17 The binding site for paclitaxel is on the inside surface of the β-subunit 
of the microtubule (Figure 8).15, 18 Paclitaxel induces an increase in microtubule 
polymerization, thereby interfering with spindle microtubule dynamics and are termed as 
microtubule-stabilizing agents or polymerizing agents.19 The taxanes are widely used for 
breast cancer, ovarian cancer, non-small cell lung cancer, and Kaposi`s sarcoma. 
Ixabepilone was approved for the treatment of drug-refractory metastatic breast cancer in 
2007.18  
3) Colchicine binding site agents 
The third class is typified by colchicine binding site agents include podophyllotoxin, 
combretastatins and flavonols. Colchicine produces toxicity at doses that produce 
antimitotic effects, and so, is not used clinically in cancer treatment.20 The colchicine 
binding site is on β-tubulin at the interface between α- and β- tubulins (Figure 9).15   
Figure 9. Colchicine binding site and combreatastatins (modified from ref. 14) 
11 
Combretastain A4 (CA4) is a potent vascular-disrupting agents (VDA) in addition to 
microtubule targeting agent (MTAs).21-22 CA4 and CA4P have been developed as 
antivascular agents for clinical trials. Combretastatins also inhibit angiogenesis, and so, 
have been used to target target tumor vasculature selectively as an alternative to the 
conventional chemotherapy.7  
4. Additional binding sites: Several MTAs such as discodermolide,23 noscapine,24 
laulimalide,25 and estramustine7 show potent microtubule inhibitory effects but do not bind 
to the above mentioned three sites on tubulin.15, 18  
 
A.4 Resistances to microtubule-binding agents- overexpression of Pgp and increased 
levels of βIII-tubulin. 
       Multiple-drug resistance (MDR) is a one of the biggest causes of cancer chemotherapy 
failure, which includes the failure of microtubule-binding agents.5, 17, 26 Among different 
resistance mechanisms for this category of drugs, the most clinically significant are 
structural alteration of the microtubules and drug efflux by ATP binding cassette (ABC) 
proteins.27-28 The increased efflux of hydrophobic cytotoxic drugs that is mediated by one 
family of energy-dependent transporters (e.g., P-glycoprotein (Pgp)).29 In Pgp-
overexpressing SK-OV-3 MDR-1-6/6 cell lines, it is observed that the potency of paclitaxel 
was reduced by 800-fold versus parental cell lines.30 Interestingly, the combination of 
microtubule-binding agents with Pgp inhibitors failed to reverse resistance in clinical 
trials.31 Another concern is increased levels of βIII-tubulin which is a major cause of 
clinical resistance against taxanes in lung, breast and ovarian cancers.32-33 The potency of 
12 
paclitaxel decreases by five-fold in HeLa cells when they were adapted to express βIII-
tubulin.34 βIII-tubulin also causes resistance against a wide range of drugs with different 
mechanisms of action.35 
B. Angiogenesis 
Agiogenesis is the process of formation of new blood vessels from existing vascular beds.36 
It involves a complex cascade of cellular events that are tightly regulated by proangiogenic 
factors including several growth factors and antiangiogenic factors.37 An upregulated 
angiogenesis has been observed as one of the hallmarks of cancer, playing an essential role 
in tumor growth, invasion, and metastasis.  
During the early stages of development of a tumor, blood supply to the tumor tissue comes 
from the vasculature supplying the surrounding normal healthy cells. But, as the tumor 
grows beyond 2 mm in diameter, it requires its own blood supply to support its growth.38 
It becomes increasingly hypoxic, and triggers the release of vascular endothelial growth 
factor (VEGF), epidermal growth factor (EGF), and platelet derived growth factor (PDGF) 
among others. These growth factors act as proangiogenic signals to initiate angiogenesis. 
(Figure 10).36, 39-40 The new blood vessels grow and infiltrate into the tumor which results 
in tumor progression and metastases.41 The sustained growth of solid tumors is highly 
dependent on angiogenesis. Thus, antiangiogenesis is a potential approach and has been 
widely used in the treatment of cancer.42-43 
The growth of tumor tissue vasculature is chaotic and leaky. Therefore, tumor 
vasculature differs from normal tissue vasculature in several aspects including the 
hierarchy of organization and nature of endothelium.44 
13 
 
 
Figure 10. The angiogenic process (modified from ref. 45) 
 
B.1 Receptor Tyrosine Kinases (RTKs): 
The pro-angiogenic growth factors bind to transmembrane receptors of the protein kinase 
family identified as RTKs, and initiate signal transduction which initiates angiogenesis. 
These RTKs, namely vascular endothelial growth factor receptor (VEGFR), epidermal 
growth factor receptor (EGFR), and platelet derived growth factor receptor (PGFR) consist 
of an extracellular domain, a transmembrane domain and an intracellular kinase catalytic 
domain.46 Binding of the growth factor to the extracellular domain results in receptor homo 
14 
or heterodimerization and autophosphorylation of tyrosine residues within the catalytic 
domain. 
 
Figure 11. Representative RTK inhibitors approved for clinical use in USA. 
 
This triggers a cascade of events through phosphorylation of intracellular proteins that 
ultimately transmit the extracellular signal to the nucleus, eventually leading to 
angiogenesis. Dysregulation of these signaling pathways has been linked to malignancy 
and is designated as a hallmark of cancer.47 Inhibition of these RTKs offers a key 
therapeutic strategy for targeted cancer therapy.48 Several RTKs targeting small molecular 
inhibitors (Figure 11) including erlotinib, imatinib, gefitinib, sorafenib, sunitinib have  
15 
been approved as "targeted agents" for the clinical treatment of various types of cancer.48-
49 
A number of RTKs have been recognized to be involved in tumor induced angiogenesis. 
The key RTK families in cancer include the platelet derived growth factor receptor 
(PDGFR), epidermal growth factor receptor (EGFR), and the VEGFR families of RTKs 
VEGFR 
The VEGF family consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placenta 
growth factor (PLGF). Three types of VEGFRs have been identified, VEGFR1, VEGFR2 
and VEGFR3. VEGFR-2 (FlK-1/KDR) has been recognized as the principal receptor that 
mediates VEGF stimulation which is one of the most important growth factors that is 
involved in angiogenesis and vasculogenesis.50 Targeted VEGFR2 inhibition or disruption 
of produces an abrogation of angiogenesis, and decreased tumor growth.50-51 Sunitinib and 
semaxanib are some of the inhibitors of VEGFR2 which have displayed antiangiogenic 
activity.42, 52  
EGFR 
The EGFR family of receptors contain four members: EGFR-1, also identified as 
human EGF receptor HER-1), HER-2, HER-3, and HER-4. Among these, HER-2 lacks a 
known endogeneous ligand and HER-3 lacks kinase activity. The EGF family is comprised 
of eleven known members that bind to one of these four EGFR family receptors.53 
Overexpression of EGFR, and its growth factors lead to increased tumor cell proliferation, 
survival and invasiveness.54 EGFR signaling if inhibited, could promote selective apoptosis 
in tumor endothelial cells.55 Abnormal activity through overexpression or constitutive 
16 
action, has been linked to a number of cancers, including prostate, lung, and breast 
cancers.56 
PDGFR 
It is comprised of four structurally related polypeptides namely -AA, -BB, -CC, -DD, 
and -AB that exist as five different homodimers and heterodimer ligands.57 PDGF can bind 
to and activate two of its receptors PDGFRα and PDGFRβ54 which are expressed on 
pericytes, smooth muscle cells and provide mechanical support to vasculature. By 
stimulating the formation of microvascular pericytes, and stabilizing the newly formed 
blood vessels, PDGFR plays an  
important role in angiogenesis.38 
 
B.2 ATP Binding Site of RTKs 
The site that has been has been indicated as a promising target for rational drug design is 
the ATP binding site of RTKs. Diversity and homology among the ATP-binding sites of 
kinases has allowed the building of pharmacophore models for rational drug design in 
cancer chemotherapy.58-59 A twisted β-sheet of five antiparallel β-strands and one α-helix 
make up the N-terminal lobe. The C-terminal lobe is made up of four β-strands and eight 
α-helices.  
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Figure 12. ATP-binding site of RTKs (modified from ref. 60) 
RTK Catalytic Cleft: The catalytic cleft consists of two regions, the front cleft and the back 
cleft.61 The front cleft of the catalytic domain is occupied by the ATP-binding site, while 
the back cleft is comprised of elements responsible for the regulation of phosphorylation 
of peptide substrates.  
 
 A.  The Front Cleft: The front cleft consists of the ATP binding site and small, non-ATP 
contact regions. The ATP site is divided into the following subregions depending on the 
binding mode (Figure 12).59 
1. Adenine region: This region is predominantly hydrophobic and is bordered by the hinge 
region and the gatekeeper. Two key hydrogen bonds are formed by the interaction of the 
N1 and N6 amino nitrogens of the adenine ring with the NH and carbonyl groups of the 
peptide backbone of the hinge region residues of the RTKs.  
2. Ribose binding region: This pocket is adjacent to a hydrophilic, solvent exposed region 
and accommodates the sugar moiety of ATP. The ribose pocket accommodates the sugar 
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moiety of ATP and is adjacent to a  hydrophilic, solvent exposed region. This pocket 
includes three hydrophobic and hydrophilic residues. These hydrophobic residues (Ile, Val 
and Leu) have traditionally been exploited in developing EGFR inhibitors.  Our group has 
published many papers exploiting the hydrophobic residues of the sugar binding pocket of 
the ATP site.   
3. Phosphate binding region: This pocket is flexible, hydrophilic and solvent exposed, and 
is covered by Asp, Lys and Asn residues and the DFG motif. Being highly flexible and 
solvent exposed, this region is considered less important in improving inhibitor affinity and 
potency.  
4. Hydrophobic region II: This pocket serves as an entrance for ligand binding as it is not 
utilized by ATP, and so variation in the residues and conformation of this pocket has been 
reported for various kinase targets. To gain selectivity in the design of kinase inhibitors, 
this region has highly ben been used. 
 
B. The Back Cleft: The back cleft provides important binding regions for various kinase 
inhibitors. ATP does not bind in the pockets in the back cleft.60-61 The hydrophobic pocket 
in the back cleft adjacent to the adenine pocket is called Hydrophobic region I. This pocket 
has highly been explored in the design of inhibitors to gain selectivity for kinase targets 
with small gatekeeper residues.62 
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C. Combination Chemotherapy 
	
In order to bypass inhibition of a single biological target, cancer cells often find 
alternative compensatory signaling routes. These findings provide the rationale for the use 
of drugs able to target multiple unrelated proteins. It is not surprising that this strategy has 
found utility in complex disease states such as cancer with remarkable clinical success.63 
The concept of using a combination of drugs each with activity against a different 
biological target has been used in the treatment of several diseases.66 The central idea of 
combination chemotherapy is that by modulating multiple pathways simultaneously, the 
utilization of alternate survival pathways that allow tumor cells to evade the therapy can 
be prevented.64  
Antiangiogenic RTK inhibitors are cytostatic agents that prevent further growth of the 
tumor and are required to be used in combination with cytotoxic agents for complete 
abrogation of tumors.64-65 Of significant interest is the remarkable clinical success of 
combinations of antiangiogenic agents and cytotoxic agents.66-69 Sorafenib (5 µM) 
significantly enhanced the anti-cancer effect (25% growth inhibition compared to control) 
of low dose paclitaxel (125 pM) in microvascular endothelial cells, producing an additive 
effect on inhibition of cell growth. 
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D. Vascular Normalization Theory 
 
Antiangiogenic agents target endothelial cell-mediated angiogenesis, and indirectly stop 
growth of tumor cells by depriving them of nutrients, while cytotoxic agents kill cancer 
cells directly. However, destroying the tissue vasculature is expected to severely 
compromise the delivery of the cytotoxic agent to the solid tumor and render these 
compounds inactive. Surprisingly, synergistic antitumor effects via the use of 
antiangiogenic and cytotoxic drug combinations lead to the proposal of the "vascular 
normalization" theory.70-71 
Under healthy physiological conditions, a balance between endogenous proangiogenic 
and antiangiogenic factors maintains normal vessels. These vessels are arranged in a 
hierarchical manner (i.e., arteries, capillaries, and veins) forming an orderly distributed 
compact network, whereas tumor vasculature is disorganized and morphologically 
abnormal with a leaky endothelium.. In tumor environments, an abundance of 
proangiogenic growth factors results in vascular growth being vigorous and random in all 
possible directions at all junctures. Consequently, the difference in pressure between the 
arterioles and venules is reduced, resistance to blood flow is increased, and blood supply 
to the tumor is impaired.72 The vascular network appears haphazard with high vascular 
density in certain regions of the tumor and  lack of vasculature in others.73 Inefficient tumor 
blood flow due to abnormal vasculature can negatively affect the delivery of cytotoxic 
drugs and also cause systemic toxicities. However, as the targets of antiangiogenic agents 
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are located in contact with the bloodstream, these drugs are considered to suffer less from 
delivery obstacles than drugs targeting tumor cells in the extravascular space. 
 
 
Figure 13. Antiangiogenic therapy and vessel normalization (modified from ref. 70) 
 
The effect of antiangiogenic agents is twofold: first, they prune some of the abnormal 
vessels and second, due to their antiangiogenic nature, these agents can balance the effect 
of proangiogenic factors and result in a transient normalized vasculature (Figure 13). This 
transient normalization is both structural and functional. The normalized vasculature is 
central for blood flow with the least obstruction and blood supply to the tumor. As a result, 
there is improved delivery of the cytotoxic agent to the tumor thereby explaining, in part, 
the synergy observed in the use of antiangiogenic and cytotoxic drug combinations.  
Anti-VEGF treatment induces a transient normalization process that leads to pruning 
of immature vessels, and improvement of the integrity and function of the remaining 
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vasculature by enhancing perivascular cell and basement membrane coverage.74-75 
Normalization of tumor vasculature increases uptake and delivery of cytotoxic antitumor 
drugs.76-77 However, enhancement in the delivery of cytotoxic agents to the tumor is both 
dose- and time-dependent. The cytotoxic agent should be delivered to the tumor during the 
"window of normalization" in order to maximize the intratumoral cytotoxic drug levels. As 
a result, optimal scheduling of antiangiogenic therapy with chemotherapy and/or radiation 
therapy requires knowledge of the timing window during which the vessels transiently 
become normalized, and an understanding of the duration of the normalized vasculature. 
Improper understanding could cause the chemotherapeutic agent to miss the therapeutic 
window, and suboptimal effects or no effect of combination chemotherapy could result. 
 
E. Multiple target inhibition with single agents 
Multitargeted drugs are defined as rationally designed single chemical entities capable 
of selectively targeting two or more biological targets or processes.78 If the 
pharmacophores for the respective targets overlap, the common structural features of the 
lead compounds can be "merged" resulting in a designed multiple ligand.  As with 
combination chemotherapy, targeting different pathways in tumor cells using multitargeted 
agents can increase therapeutic effectiveness, as this strategy may prevent cancer cells from 
developing resistance, which is the principal cause of chemotherapy failure.79 Other 
advantages include a lower risk of drug-drug interactions in vivo and improved patient 
compliance resulting from reduction in the number of medications required. At the level of 
biochemical response, a single agent with multiple targets would be less prone to interact 
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with anti-targets compared to multiple separate agents which would be more prone to 
produce off-target toxicities. So, a single agent would have less adverse effects, if any, 
compared to multiple agents. Optimizing the pharmacokinetics of the lead compound while 
retaining a balanced target profile (i.e., optimizing the ratio of activities at the different 
targets and the effects of metabolism to ensure a therapeutic, but non-toxic, effect at each 
of these targets) is one of the challenges of the multitargeted agents.78 Several multitarget 
strategies have been studied in cancer therapy.80-81 A clinical strategy that has been 
successful is the combination of antiangiogenic and cytotoxic agents. 82-85 
F. Folic acid (FA) 
A p-aminobenzoic acid (PABA), a hetero-bicyclic pteridine, and a glutamic acid are the 
three structural units of folic acid (FA) (Figure 14). FA, an oxidized synthetic compound 
is used in dietary supplements. The word folate refers to the various reduced derivatives of 
FA naturally found in food. Folates occur in several reduced states of the pteridine ring 
(oxidized, 7,8-H2, and 5,6,7,8-H4).  
 
Figure 14. Structure of folic acid with the three principal moieties of the molecule. 
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1. Folate metabolism: 
 Folic acid metabolism cycle in mammals is a crucial process for the transfer of one-carbon 
units to amino acids, nucleotides, and other biomolecules. The proton coupled folate 
transporter (PCFT) in the intestines plays a major role for the folic acid uptake. Folates 
have to be reduced to tetrahydrofolate (THF) to act as a cofactor. The first step is the 
intracellular reduction of the folic acid, in presence of reductant nicotinamide adenine 
dinucleotide phosphate (NADPH) to the intermediate 7,8-dihydrofolate (DHF). This is 
followed by a similar reduction of DHF to THF. 
 
 Figure 15. De novo synthesis of purines 
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β-Glycinamide-ribonucleotide transformylase (GARFTase) and amino-
imidazolecarboxamide ribonucleotide transformylase (AICARFTase) are two folate 
related enzymes required for the de novo synthesis of purines, that utilize the cofactor N10-
formyltetrahydrofolate (N10-CHO-THF) to transfer one carbon units (Figure 15). N10-
CHO-THF and glycinamide ribosyl-5-phosphate (GAR) are converted to THF and formyl-
glycinamide ribosyl-5-phosphate (fGAR) respectively in the presence of glycinamide-
ribonucleotide formyl transferase (GART). The fGAR formed is then converted to amino-
imidazolecarboxamide ribosyl-5-phosphate (AICAR) in five steps. The enzyme 
AICARFTase then transforms AICAR to formyl-AICAR (fAICAR). THF is also released 
in this process. The term antifolates is a class of antiproliferatives that closely resemble 
FA, and so, interfere with the biosynthesis, utilization or metabolism of normal cellular 
folate cofactors involved in folate metabolism.86 
The fAICAR formed continues along the purine biosynthetic pathway leading to the 
formation of inosine-5’-monophosphate (IMP), the precursor of adenosine-5’-triphosphate 
(ATP) and guanosine-5’-triphosphate (GTP) necessary for ribonucleic acid (RNA) 
synthesis and of 2’-deoxyadenosine-5’-triphosphate (dATP) and 2’-deoxyguanosine-5’-
triphosphate (dGTP) necessary for DNA synthesis.87  
              Folates are hydrophilic anionic molecules, and so, cannot passively diffuse across 
biological membranes. Several sophisticated membrane transport systems are evolved in 
mammals to facilitate membrane translocation of these essential cofactors. A folate 
molecule is transported into the cell in its monoglutamate form and then, is metabolized 
by folyl-γ-glutamate synthetase (FPGS) by adding L-glutamic acid units to the γ-carboxylic 
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acid (up to eight glutamate moieties).88 The polyglutamate cofactor form is termed 
folypoly-γ-glutamate and this process is described as polyglutamylation. This leads to (i) 
increased intracellular retention of folates through metabolic trapping; (ii) enhanced 
binding of polyglutamylated tetrahydrofolate (THF)  
 
Figure 16. Representative examples of classical antifolates with principal targets. 
 
to folate-dependent enzymes at low concentrations; (iii) increased retention of folate 
cofactors in mitochondria.89-91 γ-Glutamyl hydrolase (GGH), present in the lysosome, 
catalyzes the hydrolysis of  polyglutamates back to their monoglutamate form.92  
Antifolates which contain L-glutamic acid at the side chain such as methotrexate (MTX), 
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aminopterin, pemetrexed (PMX, Alimta), raltitrexed (RTX, ZD1694, Tomudex), 
pralatrexate (PDX) (Folotyn, 10-propargyl-10-deazaaminopterin, N-(4-(1-((2,4-diamino- 
6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid), lometrexol etc. are known as 
classical antifolates (Figure 16).  
 
2. Membrane transport of folates: Mammalian cells have evolved genetically distinct 
systems to facilitate membrane transport of folates. Three major folate uptake systems, the 
reduced folate carrier (RFC), folate receptor (FRs) and the proton-coupled folate 
transporter (PCFT) have been described.88  Each plays a unique role in mediating folate 
transport across epithelia and into tissues.  
 
2.1. The Reduced Folate Carrier (RFC) 
RFC is the major cellular and tissue folate transporter in mammalian cells. It is 
ubiquitously expressed in mammals. RFC is also a major transporter of antifolate drugs 
used in therapy for several illnesses and for cancer chemotherapy. The effectiveness of 
chemotherapy with agents such as MTX, PMX, and RTX (Figure 18) is closely linked to 
levels and activity of RFC in both tumors and normal tissues. 93-94 
 
2.1.1. Structure of RFC 
RFC is the major membrane transporter of circulating folate cofactors94 and belongs 
to the major facilitator superfamily of hRFC. It is comprised of 591 amino acids and is 64-
66% conserved with rodent RFC. RFC is characterized by 12 transmembrane domains 
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(TMDs) and is N-glycosylated at Asn58 in the extraloop domain connecting TMDs 1 and 
2. A large loop domain connects TMD6 and TMD7, and is poorly conserved between 
species. The major role for the TMD6–7 loop domain is to provide appropriate spacing 
between the TMD1–6 and TMD7–12 segments for optimal membrane transport.88 
 
2.1.2. RFC distribution 
 In liver and placenta, high levels of RFC transcripts have been detected, with 
significant levels in other tissues, including leukocytes, kidneys, lungs, bone marrow, 
intestines, and portions of the CNS and brain. RFC was also detected at the basolateral 
membrane of the renal tubule epithelium, the apical brush-border membrane of the small 
intestine and colon, hepatocyte membranes, the apical surface of the choroid plexus, and 
the apical membrane of the cells lining the spinal canal.95 Low levels of RFC result in 
pathologic conditions such as cardiovascular disease, fetal abnormalities, neurological 
disorders, and possibly cancer.96 RFC is important for development since inactivating both 
RFC alleles in mice by targeted homologous recombination is embryonic lethal.97 
 
2.1.3. Transport mechanism of RFC 
RFC transports reduced folates via counter-transport with organic phosphate 
anions. The major circulating form of folate, 5-methylTHF, is its physiological substrate. 
RFC has high affinity (~50-100-fold) for reduced folates (Ki ~1-5 µM) and a low affinity 
for folic acid (Ki ~200 µM) as it is an integral transmembrane protein.98 RFC transport is 
characterized by a neutral pH optimum and so, it has significantly decreased transport 
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activity below pH 7. As folates are negatively charged, RFC actually produces a substantial 
electrochemical potential difference for folates across cell membranes.99 RFC-mediated 
transport is highly sensitive to the transmembrane anion gradient, in particular, the organic 
phosphate gradient. So, asymmetrical distribution of organic phosphates across cell 
membranes provides the driving force for RFC-mediated uphill transport of folates into 
cells.97 
 
2.1.4. RFC in antifolate chemotherapy 
The classical antifolates MTX, RTX, and PMX (Figure 16) are all actively 
transported into mammalian cells by RFC.100 However, RFC is ubiquitously expressed in 
mammalian cells and, is a major folate transporter for normal tissues and tumors. These 
elevated extracellular antifolate concentrations always result in dose limiting toxicity due 
to a lack of RFC transport selectivity for tumor cells over normal cells.  
 
2.2. The folate receptors (FRs) 
The FRs represent another mode of folate uptake into mammalian cells, and are a 
family of high affinity folate binding proteins. 
 
2.2.1. Structure of FRs 
The FRs are encoded by three distinct genes, designated α and β localized to 
chromosome 11q13.3-q13.5.101 Another FR gene, designated γ, maps at chromosome 
11q14.102 FRs α, β and γ are highly homologous proteins (68-79% identical amino acid 
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sequence) and contain from 229 to 236 amino acids with two (β, γ) or three (α) N-
glycosylation sites. In contrast to RFC, hFRα and hFRβ are anchored at the plasma 
membrane via a glycosyl-phosphatidylinositol (GPI) anchors, whereas FRγ is secreted 
due to the lack of a signal sequence for GPI anchor attachment. 
 
Figure 17. a. Two views of the FRα-folic acid complex, with FRα in green, folic acid in 
grey, N-acetylglucosamine in orange and the disulphide bonds depicted as yellow 
sticks.(modified from ref.103) 
 
Recently, the crystal structures of both FRα and FRβ were published. The crystal structure 
of FRα with folic acid at 2.8 Å resolution was reported by Karsten Melcher and co-workers 
(Figure 17).103 FRα has a globular structure stabilized by eight di FRa has an overall 
globular structure, consisting of four long α-helices (α1, α2, α3, α6), two short α-helices 
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(α4, α5), four short b-strands (β1–β4) and multiple loop regions. The tertiary structure of 
FRα is stabilized by eight disulphide bonds formed by 16 conserved cysteine residues. It 
also contains a deep open folate-binding pocket comprised of residues that are conserved 
in all folate receptor subtypes.103  
Charles E. Dann III and coworkers104 reported six different conformations of FRβ at neutral 
and acidic pH. The results suggest that the pH of the receptor environment plays a crucial 
role in the rearrangements of the structure that at neutral pH, folate binding cleft is poised 
in an open conformation and at the acidic pH which is experienced in the endosome, it is 
occluded which means that transport is most efficient at neutral pH and least efficient at 
acidic pH.104 
 
2.2.2. FRs distribution 
FRα is generally localized on the apical surface of polarized epithelial cells, 
particularly in the proximal tubule cells of the kidney, choroid plexus, retina, uterus and 
placenta. FRα is not in contact with circulating folate as it is predominantly expressed on 
the apical surface. This unusual polarized expression of hFRα protects normal tissues from 
FR-targeted therapies in the blood circulation. hFRβ is expressed in the placenta, spleen, 
and thymus and in the latter stages of normal myelopoiesis. hFRγ is secreted from 
lymphoid cells in the spleen, thymus, and bone marrow at low levels. The restricted 
distribution of FRs, the transcytosis mechanism used by hFRα, and the generally low 
expression levels of hFRβ play a crucial role in limiting toxicities in normal tissues with 
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FR-targeted therapeutics. Therefore, such agents circumvent the dose limiting toxicities 
exhibited by currently used non-selective antifolates, that are also transported by RFC.105 
 
2.2.3. Transport mechanism of FRs 
 
Figure 18. Endocytosis of FRs. 
 
When a folate molecule binds to a folate receptor on the cell surface, the process of 
internalization by FRs is initiated, which leads to conformational change and invagination 
of the plasma membrane at that site followed by the formation of vesicles (endosome) that 
migrate to the cytoplasm. This process is known as endocytosis (Figure 18). The interior 
of endosome becomes acidic (pH = 6.0-6.5) once it enters the cytoplasm. This decrease in 
pH leads to another conformational change of the FR complex resulting in the dissociation 
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of the folate from the complex. The endosome then migrates back to the cell surface, gets 
fused with the cell membrane and the same FRs is recycled.106-107 
 
2.2.4. FRs and antifolate chemotherapy 
FRα is overexpressed in up to 90% of ovarian cancers.108-109 Unlike tumor cells, 
FRα in normal tissues is inaccessible to the blood circulation.110 FRβ is expressed in a wide 
range of myeloid leukemia cells. FRβ in normal hematopoetic cells differs from that in 
leukemia cells in its inability to bind folate ligand.111 Unfortunately, for most classical 
folate-based therapeutics (including MTX, RTX and PMX), since substrates are shared 
between FRs and the ubiquitously expressed RFC, tumor selectivity is not present. That is 
why, if a FR-targeted ligand were itself cytotoxic without RFC activity, selective tumor 
targeting would ensue.112 
 
2.3. The proton-coupled folate transporter (PCFT) 
PCFT is a member of the superfamily of solute transporters. The gene encoding 
PCFT is located on chromosome 17q11.2. The major physiological role of PCFT is 
absorption of dietary folates through upper gastrointestinal tract where it functions 
optimally at acidic pH-5.5. It functions by coupling the flow of protons down an 
electrochemical concentration gradient to the uptake of folates into cells.113 Its activity at 
the low pH  and the structural specificity (high affinity for folic acid, and low affinity for 
PT523, a non-polyglutamable analog of aminopterin) distinguishes itself functionally from 
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the RFC (optimal activity at pH 7.4, very low affinity for folic acid and very high affinity 
for PT523).114 
 
 
2.3.1. Structure of PCFT 
 
Figure 19. Structure of PCFT (modified from ref.113). 
hPCFT consists of 459 amino acids with a molecular mass of 49.8 kDa. It is predicted to 
include 12 TMDs with N- and C-termini towards cytoplasm (Figure 19). The loop 
domain between the first and second TMDs must be extracellular because the two 
putative N-glycosylation consensus sites in this region are glycosylated. N-glycosylation 
does not appear to be required for either PCFT trafficking or function.113 
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2.3.2. PCFT expression patterns in human tissue 
PCFT is expressed in the apical membrane of the proximal jejunum and in many 
normal tissues including retina, brain liver, kidney and placenta,.115  The highest PCFT 
levels within the intestine are found in the proximal jejunum and duodenum. Here, it serves 
as the primary means of intestinal uptake of dietary folates at the acidic pH characterizing 
the upper small intestine.116  
 
2.3.3. Transport mechanism of PCFT 
The uphill flow of folates into cells is coupled with the downhill flow of protons 
via PCFT, and so, PCFT functions as a folate-proton symporter. Consistent with a proton-
coupled process, a transvesicular pH gradient results in an increased unidirectional 
transport of folate and substantial transmembrane folate concentration gradients from the 
low-pH to the high-pH compartment. One of the unique characteristics of PCFT involves 
its acidic pH optimum i.e. transport is maximal at pH 5-5.5, but as the pH increases above 
5.5, transport decreases significantly and above pH 7, there is no activity.117 
 
2.3.4. PCFT and antifolate chemotherapy 
The interstitial pH of solid tumors favors PCFT transport as it is acidic. A prominent 
low-pH transport route was identified in a substantial cohort of solid human tumors, and 
high levels of hPCFT transcripts were reported in a broad range of human tumors.118 
Whereas the role of tumor selectivity and PCFT in antifolate activity is still evolving, 
transport of classical antifolates by PCFT has been described previously,117 although 
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classical antifolate PMX shows high affinity for the carrier at both acidic and neutral 
pHs.119 PMX is transported by both PCFT as well as RFC,  and so its transport into normal 
tissues via RFC could be the major reason behind its lack of selectivity for tumor cells over 
normal cells. Thus, this provides a strong rationale for designing and developing folate-
based therapeutics that are substrates for transporters with limited transport in normal cells 
compared with tumors. Thus, both FRs and PCFT can be used for targeted cancer 
therapy.86,120 
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3. Glycinamide-ribonucleotide formyltransferase (GARFTase)   
 
 
Figure 20. Proposed mechanism for GARFTase catalysis of GAR to Fgar.121 
GARFTase, involved in purine synthesis, is one of the most important trifunctional 
enzymes.122 As mentioned above, it catalyzes the transfer of the formyl group from N10-
CHO-THF to the primary side-chain amino group of GAR to yield FGAR and THF (Figure 
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20). It ultimately incorporates C-8 into IMP. Inhibition of de novo purine biosynthesis via 
GARFTase inhibition is a viable approach for cancer chemotherapy.86, 123-124 
 
3.1. Structure of GARFTase 
The structure of hGARFTase has been reported at pH 4.2 (1.7 Å), pH 8.5 (2 Å), pH 
8.5 in the binary complex with the substrate β-GAR (2.2 Å) and at pH 7 in a binary complex 
with the co-substrate analog inhibitor 10-trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8-
tetrahydrofolic acid (10-CF3CO-DDACTHF) (2 Å)125 and folate inhibitors.126 Crystal 
structure of hGARFTase with pemetrexed and 6-substituted pyrrolo[2,3-d]pyrimidine 
antifolate with β-GAR substrate was reported recently.120  
 
3.2. Catalytic Mechanism of GARFTase 
The formyl group is transferred by a nucleophilic attack of the GAR amino group 
on the formyl carbon of the co-substrate leading to the formation of a tetrahedral 
intermediate. Kinetic studies of the E. coli enzyme127 and of the human enzyme128 and 
murine enzyme129 GARFTase domains suggested this mechanism. It isproposed that a 
“fixed” water molecule mediates the required proton transfer between substrate and 
cofactor, though, it has not been verified experimentally.130 A proposed mechanism for 
GARFTase is shown in Figure 20. The cofactor binds to the active site, and Asp144 forms 
a salt bridge with the imidazolium of His108. The formyl group is positioned to form 
hydrogen bonds with the protonated imidazolium group of His108 and Asn106. 
Tetrahedral intermediate is formed when the free base form of the amino group of GAR 
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attacks the activated formyl group. Catalytic water molecule mediates a proton transfer 
from GAR to the N10 of folate, followed by breakdown of the tetrahedral intermediate to 
form products. The positioning of this water molecule may be assisted by a hydrogen bond 
to the carboxylate of Asp144.121  
 
3.3. Binding of Inhibitors 
 Zhang et al.125 reported a 1.98 Å crystal structure of hGARFTase in a binary 
complex with the co-substrate analog inhibitor 10-CF3CO-DDACTHF (Table 2) at pH 7 
(PDB ID = 1NJS). The cofactor binding pocket of GARFTase is located at the interface 
between the the C-terminal of the structure and the N-terminal mononucleotide binding 
domain. The binding site for the folate cofactor moiety consists of three parts:  the pteridine 
binding cleft, the benzoylglutamate region, and the formyl transfer region. 
 
Figure 21. Crystal structure of hGARFTase. (PDB:4ZZ1 and PDB:4ZZ2)120 
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Gangjee and coworkers120 published the crystal structure of hGARFTase with 
pemetrexed and 6-substituted pyrrolo[2,3-d]pyrimidine antifolate (Figure 21)  and β-GAR 
substrate recently. According to the crystallographic models, antifolates form six hydrogen 
bonds via the pyrrolo[2,3-d]pyrimidine moiety with hGARFTase peptide backbone. 
Moreover, two hydrogen bond interactions with the peptide backbone, a bidentate polar 
interaction with Arg871, and three charge–charge interactions with Arg897 and Lys844 
are mediated via the glutamate tail of the antifolates.120 
 
Microtubules - Summary  
Microtubules are important for various functions like transcription, translation, 
permeability, centrosome clustering etc. in interphase cells. Microtubules is also important 
for trafficking of protein and nucleic acid cargo in cancer cells, and so MTAs are highly 
successful anticancer agents. These drugs disrupt microtubule dynamics leading to 
microtubule polymerization or depolymerization, and thus classified as microtubule 
stabilizing agents like Taxanes, and destabilizing agents like Vinca alkaloids or colchicine 
site agents. The problem with current agents is multidrug resistance caused by structural 
alteration of the microtubules and drug efflux by ATP binding cassette (ABC) proteins. 
The MTAs can be combined with antiangiogenic agents. Agiogenesis is the process of 
formation of new blood vessels from existing vascular beds. Release of the pro-angiogenic 
growth factors lead to their binding with transmembrane receptors of the protein kinase 
family identified as RTKs, namely, vascular endothelial growth factor receptor (VEGFR), 
epidermal growth factor receptor (EGFR), and platelet derived growth factor receptor 
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(PGFR). These initiates signal transduction and angiogenesis. 
Tumor vessels are often dilated, and have a haphazard distribution of vessels. The 
heterogeneity of tumor vasculature can be caused due to the excessive vessel leakiness 
leading to escape of plasma. This heterogeneity leads to hypovascular and hypervascular 
areas in tumor with sluggish blood flow in some regions and excessive in others. The 
heterogeneous blood perfusion occurs spatially as well as temporally. These static regions 
also lead to the hypoxic conditions in the cell as well as low extracellular pH. Due to this, 
the administered cytotoxic drugs cannot penetrate well in these static regions of a tumor 
cell.
 
According to vascular normalization hypothesis formulated by Jain and coworkers, 
the antiangiogenic agent transiently normalizes this vasculature by pruning the abnormal 
vessels and remodeling the remaining ones which leads to reduction in hypoxia and 
interstitial fluid pressure. As a result, there is improved delivery of the cytotoxic agent to 
the tumor thereby explaining, in part, the synergy observed in the use of antiangiogenic 
and cytotoxic drug combinations. Using multitargeted agents also increase therapeutic 
effectiveness, preventing cancer cells from developing resistance, which is the principal 
cause of failure of current chemotherapy.
 
Other advantages include a lower risk of drug-
drug interactions in vivo and improved patient compliance resulting from reduction in the 
number of medications required. At the level of biochemical response, a single agent with 
multiple targets would be less prone to interact with anti-targets compared to multiple 
separate agents which would be more prone to produce off-target toxicities. So, a single 
agent would have less adverse effects, if any, compared to multiple agents.  
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Folates- Summary 
The lack of tumor selectivity for all the currently clinically used antifolates reflects their 
cellular uptake by the reduced folate carrier (RFC) expressed ubiquitously by both normal 
tissues as well as tumors. In contrast, folate receptor (FR) α and β, and the proton-coupled 
folate transporter (PCFT) exhibit selective tumor tissue expression, and serve specialized 
physiological roles.113 FRs on normal cells are inaccessible to circulating folates or are 
non-functional in normal tissues. PCFT is expressed in the upper gastrointestinal tract 
where it functions only at acidic pH as the major intestinal transporter for absorption of 
dietary folates.131 Given this requirement of acidic pH for activity, PCFT transport is 
limited in normal tissues that are not at acidic pH (<6.9). A substantial cohort of solid 
tumors (eg. ovarian, non-small cell lung cancer) express PCFT, often in concert with FRs. 
FRα is accessible on tumors, thus, allowing tumor targeting by this mechanism. FRβ is 
expressed in hematological malignancies and in white blood cells of the myeloid lineage, 
including tumor-associated macrophages (TAMs). FRβ-positive TAMs may play an 
important role in the tumor microenvironment in reaction to tumor metastasis and 
angiogenesis by releasing proangiogenic factors suggesting that TAMs may constitute an 
additional potential therapeutic target in cancer for FRβ-targeted agents.132 There are no 
tumor targeted cytotoxic agents in clinical use, thus, all cytotoxic agents display dose-
limiting toxicity. New cytotoxic agents are needed which can target tumor cells selectively 
by virtue of their specificities for FRs and /or PCFT and thus, afford agents that do not 
suffer from dose-limiting toxicities.133 
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II. CHEMICAL REVIEW 
The chemistry related to the work described in this dissertation is reviewed in this 
section. 
1. Iodination  
2. Cyanation 
3. Trifluromethylation 
4. Pyrrolo[2,3-d]pyrimidines ring system formation 
1. Iodination 
• Using sodium iodide 
Scheme 1. Exchange of chlorides with iodides using sodium iodide and 
trimethylsilyl chloride. 
	
Reactions and conditions: a) NaI, TMS-Cl, MeCN, 180 °C, MW 
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Yang et al.134 and Lemoine et al.135 exchanged the chlorides in 11 and 13 respectively 
with iodides with NaI and TMS-Cl in acetonitrile at 180 °C in a microwave reactor 
(Scheme 1). 
• Using iodotrimethylsilane 
Scheme 2. Exchange of chlorides with iodides using  iodotrimethylsilane. 
 
Reactions and conditions: iodotrimethylsilane, MeCN, 81 °C, 4 h, 79% 
 
Zehnder et al.136 added iodotrimethylsilane to the suspension of 15 in MeCN to get to 
the 2-amino-4-iodo-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine 16 (Scheme 2). 
 
• Using hydroiodic acid 
Scheme 3. Exchange of chlorides with iodides using aqueous hydroiodic 
acid. 
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Reactions and conditions: aq. HI, MeCN, 0 °C- rt 
Hughes et al.137 treated 4-chloro-1-methyl-6,8-dinitropyrrolo[4,3,2-de]quinolin-2(1H)-one 
17 with hydroiodic acid to yield iodo 18 (Scheme 3). Yields were not mentioned. 
 
2. Cyanation 
• Using copper cyanide 
Scheme 4. Formation of 3-nitropicolinonitrile 
 
 
Reactions and conditions: CuCN, fusion 150 °C, 2 h, 68% 
 
Loidreau et al.138 reacted 2-bromo-3-nitropyridine 19 with copper cyanide to 3-
nitropicolinonitrile 20 (Scheme 4). 
 
Scheme 5. Transformation of iodide into the nitrile moiety using copper cyanide. 
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Reactions and conditions: CuCN, pyr, 80 °C 
ughes et al.137 transformed N,N'-(4-iodo-1-methyl-2-oxo-1,2-dihydropyrrolo[4,3,2-
de]quinoline-6,8-diyl)bis(2,2,2-trifluoroacetamide) 21 into the nitrile 22 employing copper 
cyanide in pyridine (Scheme 5). 
3. Trifluoromethylation 
 
 
Wang et al.139  used a novel strategy for aromatic trifluoromethylation by converting 
aromatic amino group into a trifluoromethyl group. It was the trifluoromethylation 
variation of the classic Sandmeyer reaction.   
Scheme 6. Treatment of iodide with copper and diphenyl-(trifluoromethyl)sulfonium 
trifluoromethanesulfonate 
 
  
Reactions and conditions:  CF3SO3-+S-(CF3)(Ph)2, Cu, DMF, 60 °C, 18 h, 80% 
 
Georgsson et al.140 generated the trifluoromethyl-substituted pyrrolo[2,3-c]pyridine 24 by 
treating ethyl 5-iodo-1H-pyrrolo[2,3-c]pyridine-2-carboxylate 23 with copper and 
diphenyl-(trifluoromethyl)sulfonium trifluoromethanesulfonate in DMF (Scheme 6). 
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Stout et al.141 attempted trifluoromethylation of 8a-hydroxy-8-methyl-octahydroimidazo-
cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazinedione 25 following the protocol of Baran and co-
workers142 (tBuOOH, aqueous NaSO2CF3, or ZnSO2CHF2, respectively) which smoothly 
converted the starting material to the trifluorinated analogue 26. 
Scheme 7. Trifluoromethylation using NaSO2CF3 
 
Reactions and conditions:  NaSO2CF3, tBuOOH, H2O, rt, 46 h, 49% 
 
4. Synthesis of 5-substituted pyrrolo[2,3-d]pyrimidines 
The synthetic procedures for substituted pyrrolo[2,3-d]pyrimidines are already well 
established as published by Gangjee and coworkers. 
a.  From Pyrroles 
 Pyrimidine is the primary precursor in the literature for the synthesis of pyrrolo[2,3-
d]pyrimidines (Figure 22) and the formation of bonds between atom 4a, 5 and atom 6 and 
7 is described in the literature.143-144 
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Figure 22.  pyrrolo[2,3-d]pyrimidine 
Scheme 8. Synthesis of pyrrolo[2,3-d]pyrimidines 30 and 34 and furo[2,3-d]pyrimidines 
31. 
 
Reactions and conditions:  a. DMF, 60 °C, 48 h, 20-45% 
 
Secrist and Liu145 reacted 2,6-diamino-4-hydroxypyrimidine 27 with various a-halo 
aldehydes and ketones (Scheme 8). Cyclization occurred via two modes to produce either 
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the pyrrolo[2,3-d]pyrimidine and/or the furo[2,3-d]pyrimidine. Thus a-halo ketones, 
chloroacetone 28 and 3-bromo-2-butanone 29, yielded both the furo[2,3-d]pyrimidine 30 
and the pyrrolo[2,3-d]pyrimidine 31, whereas 32 produced only the pyrrolo[2,3-
d]pyrimidine 34 on reaction with 33.   
Scheme 9.  Synthesis of pyrrolo[2,3-d]pyrimidines 38. 
 
Reactions and conditions:  a. guanidine HCl, HCl solution b. heat, 120 °C, 5 h 
 
Seela and Luepke143 reported 6-substituted 2-amino-3,7-dihydropyrrolo[2,3-d]pyrimidin-
4-one 38 synythesis from 1,3-dioxolane-2-propanoic acid, α-cyano-2-methyl-ethyl ester 35 
and guanidine 36 (Scheme 9).  
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Scheme 10. Synthesis of pyrrolo[2,3-d]pyrimidines 41 and 43 
 
Reactions and conditions:  55-60 °C, 30 min, 35-89% 
 
Noell and Robins146 reported the synthesis of unsubstituted pyrrolo[2,3-d]pyrimidines 41 
(Scheme 10) and 43 by the reaction of chloroacetaldehyde 40 with 2-amino-6-alkylamino-
4-hydroxypyrimidines 39 and 6-amino-1,3-dimethyluracil, 42 respectively. 
Scheme 11. 5-substituted, and 5,6-disubstituted pyrrolo[2,3-d]pyrimidine. 
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Reactions and conditions:  a) NaOAc, H2O, 50 °C, 20 h, 83% b) NBS, DMF, rt, 6 h , 88% 
Gibson et al.147 reported the synthesis of 5,6-disubstituted-pyrrolo[2,3-d]pyrimidine. 2-
Chloro-2-cyanoethanal 45 (Scheme 11) was reacted with 44 to furnish 7-yano-7-
deazaguanine 46. Substituents at C-5 and C-6 were obtained by brominating deazaguanine 
46 with N-bromosuccinimide in DMF to yield 7-cyano-8-bromo derivative 47. 
Taylor et al.148 reported synthesis of PMX (Scheme 12) involving cyclization of sodium 4-
[3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-4-nitrobutyl]benzoate 49. Acid 50 was 
converted to PMX and involved peptide coupling with diethyl L-glutamate using 2-chloro-
4,6-dimethoxy-1,3,5-triazine as the coupling agent in presence of N-methylmorpholine and 
final saponification.  
Scheme 12. Synthesis of pyrrolo[2,3-d]pyrimidine 50 from 6-amino-5-
pyrimidylacetaldehydes.
 
Reactions and conditions: a.  i) aq. NaOH, rt, 2 h ii) HOAc, overall 57%  b. i) L-Glu.HCl, 
NMM, CDMT, rt, 62% ii) I N NaOH, H2O, rt, 73% 
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Scheme 13. Synthesis of pyrrolo[2,3-d]pyrimidines via Fischer indole cyclization. 
 
Reactions and conditions:  a. HCl, reflux, 1 h or 98% HCOOH, rt, 1 h 
 
Wright, G. E. et al.149 reported acid-catalyzed (Fisher indole) cyclization of 6-
(phenylhydrazino)uracils 51 (Scheme 13) to 9H-pyrimido[4,5-b]indole-2,4-diones 52. 
Several authors150-154 have employed the Fischer indole cyclization of 4-
pyrimidinylhydrazones 53 (Scheme 13) to afford the pyrrolo[2,3-d]pyrimidine ring system 
54.  
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Scheme 14. Synthesis of pyrrolo[2,3-d]pyrimidine 60. 
 
 
Reactions and conditions: a. Pd(OAc)2, b. NaN3, EtOH, reflux, 12 h; c. 180 °C, 10 h, 62-
90% 
Kondo and coworkers155 synthesized pyrrolo[2,3-d]pyrimidine 60 (Scheme 14) via thermal 
cyclization of 4-azidopyrimidines 59 containing an olefinic moiety at the 5-position. 
Intermediates 58 were obtained by a palladium catalyzed cross-coupling between the 5-
iodopyrimidine 55 and appropriate stannanes 56 or 57, followed by nucleophilic 
displacement of the 4-chloro in pyrimidine 58 with sodium azide. Yields were only 
mentioned for the final step. 
Gangjee and co-workers156 reported the synthesis of 2-amino-4-methylpyrrolo[2,3-
d]pyrimidine (Scheme 15). Compound 61 and guanidine carbonate were refluxed with 
absolute ethanol in the presence of triethylamine or sodium methoxide to afford 62  which 
was converted to 63 under reflux conditions with phosphorus oxychloride. Condensation 
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of benzylamine with 63 in the presence of triethylamine under reflux in n-BuOH afforded 
the bicyclic compound 64.  Compound 64 was oxidized to aromatic compound 65 using 
MnO2. Sodium in liquid ammonium at -78 °C afforded the debenzylation of 65 to 66. 
Scheme 15. Synthesis of pyrrolo[2,3-d]pyrimidine 66. 
 
Reactions and conditions:  a. guanidine carbonate, EtOH, Et3N, reflux, 1 h , 69%; b. 
POCl3, reflux, 2 h, 68%; c. benzylamine, Et3N, n-BuOH, 90 °C, 3 days, 50%; d. MnO2, 
dioxane, reflux, 24 h, 45% e. Na/liq. NH3, -78 °C, 65%. 
 
Legraverend and coworkers157 reported the synthesis of pyrrolo[2,3-d]pyrimidines 71 
(Scheme 16) from 2-amino-4,6-dichloro-5-(2,2-diethoxyethyl)pyrimidine 68. 5-allyl-2-
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amino-4,6-dihydroxypyrimidine was prepared by the reaction of guanidine hydrochloride 
with diethyl allylmalonate, and then converted to the 4,6-dichloro derivative by treatment 
with POCl3.The (2-amino-4,6-dichloropyrimidin-5-yl)acetaldehyde 67 was obtained by 
ozonolysis of the allyl group. The acetal 68 was cyclized to 2-amino-4-chloro-7-alkyl-7H-
pyrrolo-[2,3-d]pyrimidine 70 by treatment with dilute aqueous HCl at room temperature. 
Compound 71 was then obtained by hydrolysis of the 4-chloro group of 70 using 1N HCl 
at 100 °C. 
Scheme 16. Synthesis of pyrrolo[2,3-d]pyrimidines 71. 
 
Reactions and conditions:  a. Et3N, BuOH, 100 °C, 2 days, 42%; b. 0.2N HCl, rt, 3 days, 
69%; c. 1N HCl, 100 °C, 6 h, 85%  
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Scheme 17. Synthesis of pyrrolo[2,3-d]pyrimidines 74. 
 
 
Reactions and conditions:  a. Et4NCl, Pd(PPh3)2Cl2, MeCN, reflux, 2 h, 11-71%; b. Conc. 
HCl, MeOH, reflux, 20-40 min, 71-96%. 
 
Sakamoto et al.158 synthesized pyrrolo[2,3-d]pyrimidines 74 (Scheme 17) by 
intramolecular cyclization of protected 5-acetaldehyde pyrimidines 73. Compounds 73 
were in turn synthesized by palladium(0) catalyzed coupling of the appropriate 2,4-
disubstituted-5-bromo-6-acetamido pyrimidines 72 with (Z)-1-ethoxy-2-
(tributylstannyl)ethane 75.  
b.  From Pyrroles 
Taylor et al.144 reported the synthesis of 4-amino-5-carboxylic acid-pyrrolo[2,3-
d]pyrimidine 78 (Scheme 18). Tetracyanoethylene 75 was converted by the action of 
hydrogen sulfide to 2,5-diamino-3,4-dicyanothiophene 76, which was rearranged to 5-
amino-3,4-dicyano-2-mercaptopyrrole 77 as described by Middleton, et al.159  Treatment 
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of 77 with methyl orthoformate followed by alcoholic ammonia afforded 4- amino-5-
cyano-6-methylmercaptopyrrolo[2,3-d]pyrimidines 78. Raney nickel desulfurization of 78 
then yielded 79. Exact yields and reaction conditions were not provided for the 
intermediates. 
Scheme 18. Synthesis of 4-amino-5-carboxylic acid-pyrrolo[2,3-d]pyrimidine 79. 
 
Reactions and conditions:  a. H2S; b. Alkali c. Orthoformate, NH3 in ethanol d. 1N 
NaOH, 35%. 
In another report, Taylor et al.160 synthesized 4-amino-5-methyl-pyrrolo[2,3-d]pyrimidine 
84 (R = CH3) (Scheme 19) from 2-amino-3-cyano-5-substituted pyrroles 82 which in turn 
were obtained from malononitrile and the appropriate a-aminoketones 80. Treatment of 
pyrrole 82 with triethylorthoformate followed by ammonia resulted in the imidine 
intermediates 83 which underwent cyclization with sodium methoxide in pyridine to afford 
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the pyrrolo[2,3-d]pyrimidine 84.  
Scheme 19. Synthesis of 4-amino-5-substituted pyrrolo[2,3-d]pyrimidines 84. 
 
Reactions and conditions:  a. malonitrile, EtOH, reflux, 67%; b. i. triethyl orthoformate, 
reflux, 5 h, ii. NH3; c. i. triethyl orthoformate, reflux, 5 h, ii. NH3, 34-78 %; d. NaOMe, 
pyridine, reflux, 1 h, 91% 
Taylor and coworkers161 reported the synthesis of a 5,6-dihydro-pyrrolo[2,3-
d]pyrimidine analog of PMX by a novel route (Scheme 20). A manganic triacetate 
dehydrate-mediated  radical cyclization of racemic methyl N-crotyl-N-[1-(3,4-phenyl)-eth-
1-yl)malonamide 89, afforded a diastereomeric mixture of the 3-carbomethoxy-2-
pyrrolidinone 90.162 Compound 87 was in turn obtained by alkylation of racemic 1-(3,4-
dimethoxy-phenyl)-ethylamine 84 with crotyl bromide 86 followed by a DMAP catalyzed 
acylation with methyl malonyl chloride 88. The pyrrolidinone 90 was converted to the 
59 
thiolactam 91 with P2S5 followed by cyclocondensation with guanidine to afford the N7-
protected 5,6-dihydro-5-allyl-pyrrolo[2,3-d]pyrimidine 92. Palladium catalyzed cross 
coupling with diethyl-4-iodobenzoyl-L-glutamate fortuitously afforded the ethano-bridged 
derivatives, and not the expected vinyl-bridged derivatives, by double bond migration. This 
compound was then elaborated to analogs of PMX. 
Scheme 20. Synthesis of N7-substituted analogs of PMX.
 
Reactions and conditions:  a. NaH, TBAI, THF, 0 °C-rt, 10 h, 82%; b. DMAP, Et3N, 
EtOAc, 0 °C-rt, 2 h, 88%; c. Mn(OAc)3. H2O, Cu(OAc)2, Acetic acid, rt, 18 h, 97%; d. 
P2S5, THF, reflux, 3 h, 68%; e. guanidine HCl, MeOH, rt, 30 min, 50%. 
Barnett et al.163 reported the synthesis of a 2-amino-4-oxo-5,6-dihydropyrrolo[2,3-
d]pyrimidine 98 (Scheme 21) via a guanidine cyclization of a preformed 3-carbethoxy-2-
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thiopyrrolidine intermediate 97 as the key step This intermediate was in turn prepared in 
several steps from 4-propionaldehyde benzoic acid tert-butyl ester 93. Compound 98 was 
reduced to the pyrrolo[2,3-d]pyrimidine intermediate 99, which was then elaborated to 
PMX in several steps. Reaction conditions are not provided in the publication. 
Scheme 21. Synthesis of pyrrolo[2,3-d]pyrimidine 99 and PMX. 
 
Reactions and conditions:  a. diethyl malonate, TiCL4/Py, THF; b. MeNO2, DBU, 72% 
over 2 steps; c. H2, Pd/C, 42%, d. P2S5, 77% e. TFA, guanidine, 64%; f. L-Glu, NMM, 
CDMT, DMF, 52%; g. IN NaOH, 92% 
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Girgis, Jørgensen, and Pedersen164 reported the synthesis of 2-methyl- pyrrolo[2,3-
d]pyrimidines 101 (Scheme 22). Compounds 101 were obtained in a one-step cyclization 
of the corresponding 2-acylamino-3-cyanopyrrole derivatives 100. The reaction was 
carried out by heating compound 100 in a mixture of phosphorus pentaoxide, N-N-
dimethylcyclohexanamine, and water. It is believed that the formation of 101 proceeds 
through the intermediacy of the amides 102 resulting from hydrolysis of the cyano function 
in 100 followed by intramolecular cyclodehydration under reaction condition. Yields were 
not mentioned in the publication for the intermediates. 
Scheme 22. Synthesis of 7-deazahypoxanthines 101. 
 
Reactions and conditions:  a. 85% H3PO4. 130 °C; b. 50 °C, 3-5 min c P2O5/DMCA/H2O. 
180 °C, 2 h, 43% 
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Chen et al. 165 reported an efficient synthesis of pyrrolo[2,3-d]pyrimidine 112 (Scheme 23). 
Knoevenagel condensation of malononitrile 103 and excess acetone in refluxing toluene or 
benzene gave 105.  Bromination of 105 using NBS and benzoyl peroxide in chloroform 
afforded 106 as a major component contaminated with undesired dibromo derivative 107 
and starting material which were separated using column chromatography. Cyclization of 
106 with aryl amine 110 afforded the substituted pyrrole intermediate 111. Compound 111 
was then cyclized to the pyrrolo[2,3-d]pyrimidine 112 using 85% phosphoric acid. 
Scheme 23. Synthesis of 2,5,-dimethyl-N7-substitutedpyrrolo[2,3-d]pyrimidine 112. 
 
Reactions and conditions:  a. NaOAc, AcOH, benzene, reflux, 4 h, 70.1% b. NBS, 
benzoyl peroxide, CHCl3, reflux, 15 h, 77%; c. rt, 15 h, 60%; d. 85% phosphoric acid, 
130 °C, 30 min, 81.1% 
c. From Furans 
Scheme 24. Synthesis of 2,5,6-trisubstituted pyrrolo[2,3-d]pyrimidines 115. 
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Reactions and conditions:  NaSO2CF3, tBuOOH, H2O, rt, 46 h 
           Taylor and coworkers166 (Scheme 24) reported that 2-amino-3-cyanofurans 113 on 
cyclization with amidines 114 afforded the corresponding pyrrolo[2,3-d]pyrimidines 115 
by an unexpected ring transformation/ring annulation sequence. 
 Several plausible mechanisms for the above amidine-mediated ring transformation 
during annulation reactions have been proposed. Michael addition of the amidine to the 2-
position of the furan ortho-aminonitrile 113 (Scheme 25) followed by furan ring cleavage 
generates an open-chain carbonyl derivative 116, which recyclizes to pyrrole, thus 
incorporating the 2-amino group of the furan aminonitrile starting material as the pyrrole 
NH. Subsequent intramolecular addition of the amidino substituent to the ortho-substituted 
nitrile group then completes the pyrimidine ring annulation to afford 115. Alternatively, 
deprotonation of the acidic 2-amino group of the furan O-aminonitrile 116 by the strongly 
basic amidine could be followed by C-O bond cleavage to generate an intermediate 
ketenimine which would lead to the substituted malononitrile 116. Further reaction with 
the amidine in the usual way would lead to a 2-substituted-4,6-diaminopyrimidine carrying 
a β-carbonyl substituent at C-5, and fused pyrrole ring would then be formed with a final 
ring closure.  
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Scheme 25. Plausible mechanisms for amidine-mediated ring transformation 
Various iodination reactions were reviewed in this section and electrophilic iodinating 
agents did not work well with pyrimidine systems, and the reason could be that the 
pyrimidine ring is an electron poor system. Various nucleophilic iodinating agents like 
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sodium iodide, iodotrimethylsilane, hydroiodic acid have also been reviewed. 57 % 
Hydroiodic acid in water worked successfully. One of the reasons might be the lower 
temperature (0 °C – rt) this reaction was attempted at. Other nucleophilic reactions were 
high temperature reactions at 80-180 °C. For the synthesis of pyrrolo[2,3-d]pyrimidines, 
the biggest concern was the formation of side product furo[2,3-d]pyrimidine. Solvent plays 
a major role for these kinds of reactions. For e.g., it was found that with DMF, both 
products pyrrolo[2,3-d]pyrimidine, and furo[2,3-d]pyrimidine are formed but with 
methanol-water mixture, only former product pyrrolo[2,3-d]pyrimidine is formed. 
Although many methods were tried as mentioned in the chemical review section, it was 
decided that using 2, 6-diamino-4-hydroxypyrimidines as starting material, it will not lead 
to any production of 6-substituted pyrrolo[2,3-d]pyrimidine with bromo-aldehyde 
intermediates. Taylor145 used the similar method for the synthesis of PMX as mentioned 
earlier. Fischer Indole cyclization has been specifically employed for the synthesis of 6-
substituted or 5,6 substituted products. Gangjee and co-workers156 synthesized 2-amino-4-
methylpyrrolo[2,3-d]pyrimidine with guanidine carbonate as starting material. The method 
works very well for synthesis of N-benzylated products with 4-methyl. Although synthesis 
of pyrrolo[2,3-d]pyrimidine is less popular, various reactions were reviewed and described 
earlier in the chemical review section. Taylor also synthesized pyrrolo[2,3-d]pyrimidine 
from 2-amino-3-cyano-5-substituted pyrroles. This reaction led to the formation of 5-
substitued product but without any substitution at 2-position. Same product was also 
formed from tetracyanoethylene which led to formation of 2,5-diamino-3,4-
dicyanothiophene which was rearranged to 5-amino-3,4-dicyano-2-mercaptopyrrole. 
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These reactions used basic conditions as well but took two more steps for the formation of 
the product 
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III. STATEMENT OF THE PROBLEM 
 
Antiangiogenic agents 
Beyond 2 mm3, a tumor requires additional oxygen and nutrients for maintenance 
and growth, and initiates the process of developing a blood supply system.37 Under hypoxic 
conditions, several proangiogenic factors are secreted, of which VEGF is the key mediator 
of angiogenesis.167 VEGF binds to its receptor VEGFR2, and stimulates the process of 
angiogenesis which supports rapid tumor growth and metastases.50 Developing VEGFR2 
kinase inhibitors is one of the key strategies to obtain antiangiogenic effects.168 These 
inhibitors arrest tumor growth, and cause tumor shrinkage.169 However, resistance to 
VEGFR2 inhibitors results in increased invasion and metastases.170 At the onset of 
VEGFR2 inhibition there are two effects:  
1. Regression of tumor vessels  
2. Transient normalization of surviving vessels.70-71  
 
Normalization 
Tumor vessels are often dilated, and have a haphazard distribution of vessels. The 
heterogeneity of tumor vasculature can be caused due to the excessive vessel leakiness 
leading to escape of plasma. This heterogeneity leads to hypovascular and hypervascular 
areas in tumor with sluggish blood flow in some regions and excessive in others. The 
heterogeneous blood perfusion occurs spatially as well as temporally. These static regions 
also lead to the hypoxic conditions in the cell as well as low extracellular pH. Due to this, 
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the administered drugs cannot penetrate well in these static regions of a tumor cell.73  
According to vascular normalization hypothesis formulated by Jain and coworkers, the 
antiangiogenic agent transiently normalizes this vasculature by pruning the abnormal 
vessels and remodeling the remaining ones which leads to reduction in hypoxia and 
interstitial fluid pressure. The treatment with bevacizumab (anti-VEGF antibody) and 
DC101 (anti-VEGFR2 antibody) reduced the size and length as well as permeability of 
these abnormally dilated and tortuous vasculature in human colon cancer and glioma 
xenografts as well as murine breast cancers so that it more closely resembled the normal 
vasculature.  Bevacizumab also reduced the intratumoral microvessel density (MVD), but 
not the density of mature vessels which are pericyte-covered MVD). This indicates that 
during normalization, only immature vessels, which lack pericytes are pruned, and not 
mature vessels.171 
Therefore, the ‘normalized’ vasculature with bevacizumab treatment has greater 
perivascular cells coverage with thicker and normal vasculature resembling basement 
membrane in breast cancers, squamous cell carcinomas and gliomas. It also leads to the 
normalization of tumor microenvironment characterized by reduced interstitial fluid 
pressure due to the decrease in the vessel leakiness. Pressure gradient is also restored across 
wall of the blood vessels as well as tumor interstitium. Overall antiangiogenic agents lead 
to increased drug penetration in tumors.  
Investigations into the combined use of VEGFR2 inhibitors with cytotoxic 
therapies have yielded more promising results than VEGF-targeting monotherapy.71, 172 
Combinations of cytotoxic agents and VEGFR2 inhibitors have shown synergistic effects 
69 
suggesting that there is improved delivery of the cytotoxic agent during this transient phase 
of vessel normalization.172  
             Yoshizawa et al.76 reported that paclitaxel (cytotoxic) in combination with the 
VEGFR2 inhibitor semaxanib (cytotoxic) enhanced tumor penetration and in vivo 
antitumor activity in Colon-26 solid tumor-bearing mice. Semaxanib treatment increased 
the distribution of paclitaxel in the core region of the tumor, and hence, decreased (the ratio 
of) its peripheral distribution. Thus, utilizing VEGFR2 inhibition-based vascular 
normalization afforded transient enhanced blood supply to the tumor and allowed the 
delivery of the cytotoxic agent.76  
Scheduling of the cytotoxic agent 
The effects of the antiangiogenic agent on the tumor and the intratumoral levels of the 
cytotoxic agent affect the outcome of combination chemotherapy.173 To maximize the 
intratumoral levels of the cytotoxic agent, administration of the cytotoxic agent needs to 
be appropriately scheduled to ensure that it is used during the period of transient vessel 
normalization by the antiangiogenic agent.174 Tumor-targeted drug delivery has the 
potential to improve cancer treatment by reducing off-target toxicities and increasing the 
efficacy of the cytotoxic agent.175 Judicious scheduling is an influential and critical factor 
because of the impact on intratumoral cytotoxic drug levels.169, 174, 176, 177 Hence, if not 
appropriately scheduled, the cytotoxic agent may miss the timing window of transient 
normalization.178 Also, administering separate antiangiogenic and cytotoxic agents may 
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not alleviate the issues of dose limiting toxicities of cytotoxic agents that are not tumor 
selective.  
Compounds with antiangiogenic and cytotoxic activities in single agents 
Single agents with both antiangiogenic and cytotoxic activities have several advantages: 
1. Antiangiogenic and cytotoxic activities in a single agent would allow the cytotoxicity 
to be manifested as soon as the antiangiogenic effects are operable. These 
multitargeted agents could exert their cytotoxic action as soon as, or even during 
transient tumor vasculature normalization due to the antiangiogenic effects. Several 
literature reports indicate the success of using antiangiogenic agents with metronomic 
doses of cytotoxic agents.66-69, 179  
2. These multitargeted single agents would circumvent the pharmacokinetic problems of 
two or more agents dosed separately, would avoid drug-drug interactions at receptor 
as well as chemical level, could be devoid of overlapping toxicities, and could delay 
or prevent tumor cell resistance.180 
3. Reduced cost and increased patient compliance are some of the other advantages of 
such single agents which are sometimes as significant contributors to chemotherapy 
failure as resistance, toxicity, and lack of efficacy.180  
4. Dose-limiting toxicity is one of the major issues with conventional cytotoxic 
chemotherapeutic agents. These single agents should avoid these toxicities since they 
do not need to be as potent as conventional chemotherapeutic agents.180  
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Gangjee et al.181-184 have reported the discovery of single agents with dual antiangiogenic 
and cytotoxic activities. The antiangiogenic effects of these compounds were due to 
inhibition of RTKs, and the cytotoxic effects were due to inhibition of dihydrofolate 
reductase181 or thymidylate synthase183 or an unknown target.184 For cytotoxic effects, 
tubulin was chosen as the main target as several clinical and preclinical combinations of 
tubulin inhibitors and VEGFR2 inhibitors have been successful.185-187 For a variety of 
different cancers including colorectal, breast, lung among others, several clinical trials are 
ongoing that involve FDA-approved antiangiogenic agents as well as those in 
development, and cytotoxic chemotherapeutic agents, and include microtubule targeting 
agents (MTAs) CA4P, paclitaxel, docetaxel, vincristine, vinblastine with antiangiogenic 
agents bevacizumab, axitinib, sorafenib, sunitinib, cediranib, pazopanib, vandetanib and 
vatalanib.188 Additionally, half of all human tumors have mutations in the p53 gene, and 
p53 status effects vulnerability of tumor cells to chemotherapy via cell cycle arrest. The 
most effective drugs in cell lines with p53 gene mutations are MTAs.189-190  
Several highly potent MTAs have failed in the early stage clinical trials due to 
toxicities. Discodermolides and cryptophycin 52 (LY355703) are recent examples of such 
agents.191-192 All clinically used MTAs share neurological toxicity as the most prominent 
dose-limiting side effect.5 Other common toxicities of microtubule-binding agents include 
myelosuppression and neutropenia. Neutropenia was observed in several combination 
chemotherapy clinical trials with other drugs and was mostly manageable.193-195 The 
myeloid toxicity, which is usually reversible, is seen with vinca alkaloids and taxanes.196-
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197 Thus, new agents are needed which are safe and effective, and have both antiangiogenic 
and cytotoxic activities in a single agent. 
 
Figure 22. Hybrid design from lead compounds 
7-Benzyl-pyrrolo[2,3-d]pyrimidines with general structure 122 (Figure 22) have been 
reported by Gangjee et al.198 as antiangiogenic, antimetastatic and antitumor agents. To 
engineer RTK inhibitory activity in 121·HCl, without loss of MTA activity, hybrid 
129·HCl was designed that  
incorporates the 7-benzyl group of 122 onto the pyrrolo[3,2-d]pyrimidine scaffold of 
121·HCl. This analog 129 was reported recently by Gangjee et al.180  
Compound 129·HCl maintained cytotoxic antitubulin activity of 121·HCl, and improved 
activity against VEGFR2 by 9-fold for antiangiogenic effects over 121·HCl (Figure 22). 
Compound 129·HCl has an inhibitory potency against VEGFR2 comparable with the 
clinically used sunitinib and clinically evaluated semaxinib. The cytotoxic effect, mediated 
by the microtubule targeting, was independent of overexpression of Pgp and βIII-tubulin 
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(two clinically relevant tumor resistance mechanisms). Thus, 129·HCl has combination 
chemotherapeutic potential in a single agent.180, 199  
 
The general RTK pharmacophore model consists of an Adenine region, a Sugar binding 
pocket and a Phosphate binding region which binds the adenine ring, the sugar moiety and 
the triphosphate moiety of ATP respectively. Additionally, there are two hydrophobic 
regions I and II, neither of which are used by ATP for binding. The 7-benzyl group in 
129·HCl could access the Sugar binding pocket as shown in binding mode 1 (Figure 23). 
Alternatively, the pyrrolo[3,2-d]pyrimidine compounds could adopt mode 2 in which the 
compounds are rotated around the 2-CH3-C2 bond. In this mode, the 7-benzyl group and 
the 4-anilino groups could occupy Hydrophobic region I and Sugar binding pockets 
respectively. These compounds could also adopt binding mode 3 in which the molecule is 
rotated by 60o (from mode 2). In this mode, the 7-benzyl group could orient towards the 
Hydrophobic region I and the 4-anilino groups could occupy Hydrophobic region II.  
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Figure 23. Predicted binding modes of 129·HCl in VEGFR2 [pdb: IYWN]200 
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Design of single agents with combination chemotherapy and multiple RTK inhibitory 
potential 
 The complexity of the angiogenic pathways implies that disrupting only a single 
mechanism of angiogenesis may not result in long term clinical success. Multiple RTKs 
are co-activated in tumors and redundant inputs drive and maintain downstream signaling, 
thereby limiting the efficacy of therapies targeting single RTKs.54, 201 Resistance to anti-
VEGF treatment is associated with increased PDGFR expression within the tumor, 
increased recruitment of pericytes to tumor vasculature, and increases in other 
proangiogenic factors.202 Preclinical models suggest that PDGF-mediated recruitment of 
pericytes may contribute to resistance to VEGF blockade. EGFR inhibition can lead to 
VEGFR2 up-regulation which subsequently promotes tumor growth signaling independent 
of EGFR and thus contributes to the resistance of EGFR inhibitors.203-204 The effect of 
EGFR inhibition can also be partially overcome by activation of PDGFR signaling and the 
subsequent transactivation of HER-3 (EGFR family) signaling to promote alternate tumor 
growth signaling.53, 203 Hence, targeting multiple RTKs maximizes the proportion of 
angiogenic signaling that is effectively targeted.201, 203 Moreover, high intratumoral 
heterogeneity has been reported with different subpopulations producing distinct growth 
factors. 205-207 Targeting a single RTK could be ineffective due to subpopulations of cells 
that are either not affected by the drug mechanism and possess or acquire a greater drug 
resistance.208 Hence, it was of interest to explore the effect of structural variation and its 
effect on activity against the RTKs VEGFR2, PDGFRβ and EGFR in addition to having 
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cytotoxic antitubulin effects. The aim of this work was to identify single agents with 
antitubulin and multiple RTK inhibitory potential. 
Thus, it was of interest to elucidate the effect of conformational flexibility on 
antiangiogenic/ MTA activities to achieve multikinase inhibition. Therefore, Series I 
(Figure 24) was designed as dual antiangiogenic and microtubule targeting agents with 
multikinase inhibition potential.  
 
Figure 24. Series I 
 
Compounds 130 and 131 were designed as open chain analogs of 129·HCl. Compounds 
130 and 131 would be conformationally flexible compared to lead 129·HCl, and so will 
have more freedom to bind in different binding modes to different targets which could 
afford multikinase inhibition. Compound 132 would be a more rigid structure than 130 or 
131, and was designed to determine the effect of conformational restriction on the 
inhibitory activity of 130 and 131. 
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Figure 25. Distances between pyrimidine and phenyl (between carbons a and b, Figure 24)  
for 129·HCl and 130-132. 
Figure 25 shows analogs 130-132  in their minimized forms using MOE2016.08.183 
Distances between the pyrimidine and  the side-chain phenyl (between carbons a and b, 
Figure 25) for 129·HCl and 130-132  were calculated. Compounds 131 and 132 could 
extend further in the binding pocket of multiple RTKs, and access the hydrophobic residues 
of RTKs better than 129·HCl as shown in Figures 27a-c. 
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Figure 26. Docked pose of 130 (green) overlaid with 129 (brown) in the colchicine site 
(PDB ID 4O2B).  
Docking studies: Compound 130 was docked in the colchicine site of tubulin (PDB: 4O2B, 
2.3 Å)209 using MOE2016.08183 (validated by re-docking the crystal structure ligands) to 
predict the potential binding of these analogs (Figure 26). The docked conformation of 129 
in the colchicine site of tubulin is based on its similarity to the bound conformation of 
colchicine210 (not shown in the model). It was observed that 130, open chain 
conformationally flexible analog of 129, binds in a similar manner as 129. The 4′-OMe 
phenyl group of 130 is oriented towards the triOMe containing A-ring of colchicine and 
interacts with Cys241 and HOH615. The N-Me of 130 is involved in hydrophobic 
interactions with Leu255 and Ala250. 2-Me is involved in hydrophobic interactions with 
Ala354 and Ala316. The 6-benzyl moiety makes hydrophobic interactions with Val181 
and Phe404. Compound 130 has a docked score of -6.34 kcal/mol, similar to that of the 
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lead 129 = -6.57 kcal/mol. This suggested that 130 should retain activity against tubulin as 
129 did. 
 
Figure 27a. Docked pose of 130 (green) overlaid with 129 (brown) in the ATP site of 
VEGFR-2 (PDB ID 1YWN).211 
Compound 130 was also docked in the ATP site of VEGFR2 (PDB: 1YWN, 1.75 Å).211 
using MOE2016.08.183 Figure 27a shows the docked pose of 130 and 129 in the ATP site 
of VEGFR2. In the best pose of 130 (docked score of -7.02 kcal/mol), the phenyl 4′-OMe 
is observed in the same location as the benzyl moiety of 129, and interacts with Leu1047 
and Ala1048. The benzyl moiety of 130 is oriented towards Val897 and Ile1042. It was 
observed that 130, because of its extra flexibility, could bind in multiple poses and, could 
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provide multikinase inhibition. Compound 129 because of the constraint imposed by the 
second ring, did not afford multiple poses. 
Due to the issues with the MOE server in the chemistry department of Duquesne University 
during the final parts of the dissertation writing, rest of the modeling in EGFR and 
PDGFRβ modeling was done using LeadIT2.1.3 and images were taken directly from there.   
 
 
 
Figure 27b. Docked pose of 130 in the ATP site of EGFR (PDB ID 4WKQ). 212 
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Figure 27c. Docked pose of 130 in the ATP site of homology model of PDGFRβ. 
 
 
Compound 130 was docked in the ATP site of EGFR (PDB: 4WKQ, 1.85 Å)212 and 
PDGFRβ (homology model) using LeadIT2.1.3 (Figures 27b and 27c). In the EGFR crystal 
structure, the phenyl 4′-OMe is observed interacting with Ala743 and Ile 744. The benzyl 
moiety of 130 is oriented towards the long side chain of Lys745. 2-Me is oriented towards 
Ser70. The best docked pose of 130 had a score of −16.12 kJ/mol. In the PDGFRβ 
homology model (docked pose of −15.56 kJ/mol.), the aniline is observed interacting with 
Val631 and Lys630. The anilino moiety of 130 is flipped in this case compared to that in 
EGFR or VEGFR. The benzyl moiety of 129 is oriented towards Val615 and 2-Me towards 
Ala632.  
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Figure 28. Compound 122 was synthesized as an intermediate. 
Table 1. Effects of 122 on tubulin, and inhibition of colchicine binding compared to 
121·HCl. 
 
R 
Inhibition of 
tubulin assembly 
IC50 (µM) ± SD 
Inhibition of colchicine 
binding 
(% Inhibition ± SD) 
 
1 µM 
inhibitor 
5 µM 
inhibitor 
CA4 0.96 ± 0.07 89 ± 0.6 99 ± 0.4 
121·HCl 10 ± 0.6 - - 
122 µ 63 ± 1 81 ± 0.3 
 
 
Compound 122 was an important intermediate in the synthesis of 130. Because 122 is an 
open chain, conformationally flexible analog of 121·HCl, docking studies were done to 
predict its potential binding modes. 
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Figure 29a. Docked pose of 122 (green) overlaid with 121 (brown) in the colchicine site 
(PDB ID 4O2B). 
 Docking studies: Compound 122 and 121 were then  docked in the colchicine site of 
tubulin (PDB: 4O2B209, 2.3 Å) using MOE2016.08183 (validated by re-docking the crystal 
structure ligands) to predict potential binding of these analogs for docking studies (Figure 
29a). The docked conformation of 121 in the colchicine site of tubulin is based on its 
similarity to the bound conformation of colchicine, not shown in Fig. 29a. It was observed 
that 122 binds in similar fashion as 121. The 4′-OMe phenyl group of 122 is oriented 
towards the triOMe containing A-ring of DAMA-colchicine and interacts with Cys241 and 
HOH728. The N-Me of 122 is involved in hydrophobic interactions with Leu255 and 
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Ala250. The 2-Me is involved in hydrophobic interactions with Ala354 and Ala316. 
Compound 122 has a docked score of -6.62 kcal/mol, which is similar to the docked score 
of 121: -6.95 kcal/mol.       
 
 
Figure 29b. Docked pose of 122 in the ATP site of EGFR (PDB ID 4WKQ).212 
 
Compound 122 was also docked in the ATP site of EGFR (PDB: 4WKQ, 1.85 Å)212 and 
PDGFRβ (homology model) using LeadIT2.1.3 (Figures 29b and 29c). In the EGFR crystal 
structure, the anilino moiety is observed interacting with Leu792 and Pro794. The 4N-Me 
of 122 is oriented towards the long side chain of Gly796 and Phe795. The best docked pose 
of 122 had a score of −5.25 kcal/mol.In the PDGFRβ homology model, the aniline is 
observed interacting with Tyr683 and Lys630. The 2-Me is oriented towards Gly616 and 
Val615. The best docked pose of 130 had a score of −5.94 kcal/mol. 
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Figure 29c. Docked pose of 122 in the homology model of PDGFRβ. 
 
Because 122 is an open chain, conformationally flexible analog of 121·HCl (Figure 28), 
its effects on the polymerization of purified bovine brain tubulin was evaluated (Table 1), 
and compared with CA4 and 121·HCl. CA4 is the active metabolite of the water soluble 
prodrug combretastatin A-4 phosphate (Zybrestat, Fosbretabulin), which has orphan drug 
status for ovarian cancer. Interestingly, 122 was found to be a potent inhibitor of bovine 
tubulin assembly with about 5-fold greater inhibitory activity than the parent 121·HCl, and 
only 2-fold less inhibitory activity than CA4. The best docked pose of 122 and 121 had 
scores of −15.99 kJ/mol and -15.61 kJ/mol. 
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Table 2. RTK and CAM inhibitory activities (IC50 ± SD) 
 
Compd. 
Kinase inhibition 
IC50 ± SD (nM) 
CAM 
angiogrenesis 
inhibition 
IC50 ± SD 
(µM) 
EGFR 
VEGFR-
2 
PDGFR-β 
121·HCl 29.5 ± 3.1 
182.3 ± 
20.6 
250.2 ± 
43.0 
ND 
122 415.4 ± 50.1 33.2 ± 4.1 183.2 20.6 ± 3.1 
PD153035 0.21 ± 0.002    
SU5416 - 12.9 - 0.041 ± 0.009 
Sunitinib 172.1 ± 19.4 18.9 ± 2.7 83.1 ± 10.1 1.3 ± 0.07 
Erlotinib 1.2 ± 0.2 124.7 ± 18.2 - 29.1 ± 1.9 
 
Although, 122 was not initially designed as an antiangiogenic agent, its potent activity 
against bovine tubulin assembly prompted us to evaluate its antiangiogenic effects in 
keeping with our aim of providing multitargeted agents. In VEGFR2 expressing cell line, 
it was determined that 122 was 5-fold more inhibitory compared to 121·HCl with 2-fold 
less potency than the standard sunitinib (Table 2). These results are remarkable as VEGFR2 
is the principal mediator of angiogenesis. In PDGFRβ inhibitory assay, 122 was 1.5-fold 
more active than 121·HCl. These results indicated that the open chain monocyclic, flexible 
pyrimidines not only preserve but increase dual potency against both targets tubulin and 
multiRTK.  
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Figure 30. Series II 
Compound 122 (with 6-Cl) was an intermediate in the process of synthesizing 130 (6- 
benzyl). The compound turned out to be an active compound in tubulin depolymerization 
assays as well as kinase inhibition assays. To further increase the activity by utilizing 
hydrophobic interactions with the hydrophobic residues in the active site, homologation of 
N5 of 122 was done, and 123-127 were designed.   
The discovery of 122 as a dual tubulin and RTK inhibitor prompted a SAR study, and 
Series II (Figure 30) was designed to address the effect of homologation at N5 of 122 
(compounds 123, 125-127) and chain branching (124,128) on potency at both tubulin and 
RTK sites.  
1. With this series, optimum chain length of the N5-substituent could be determined. 
This would effectively mimic the pyrrole ring of 121·HCl.  
2. The biological activities of Series II will allow a determination of the effect of 
increased hydrophobicity on tubulin, EGFR, VEGFR2 and PDGFRβ inhibition, 
and provide a SAR of N5-substituents for inhibition of tubulin and multiple RTKs. 
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3. Chain branching as in iBu makes the alkyl chain more compact, and cause less 
disruption of hydrogen bonding network of water, and can cause major changes in 
pharmacological activity.213  
4. Increased lipophilicity of the molecule due to the increased chain length may also 
permit better penetration into the cell membranes, and might be leading to better 
activities in cell assays.   
5. With compounds 123-127, we are utilizing these hydrophobic interactions: 
Hydrophobic residues in tubulin site - Ala316, V al315, V al181 and Ile378. 
Hydrophobic residues in VEGFR site Leu840 and Leu1035. Hydrophobic 
residues in EGFR site Ala719. Hydrophobic residues in PDGFR homology 
model Val665 and Phe845.   
89 
 
 
Figure 31. Docked pose of 125 (green) overlaid with 121·HCl (brown) in the colchicine 
site (PDB ID 4O2B).  
Compound 123-128 were docked in the colchicine site of tubulin (PDB: 4O2B209, 2.3 Å) 
using MOE2016.08183 (validated by re-docking the crystal structure ligands) to predict 
potential binding of these analogs for docking studies. The docked conformation of 
121·HCl (Figure 31) in the colchicine site of tubulin is similar to colchicine. It was 
observed that 125 binds in a similar fashion as 121·HCl, and mimics the pyrrole ring of 
121·HCl better than 122.  
The N-ethyl chain extends to the hydrophobic pocket consisting of Ala316, Val315, 
Val181 and Ile378. Compound 125 has a docked score of -7.29 kcal/mol, which is better 
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than that of the lead 121·HCl: -6.95 kJ/mol, and 122: -6.62 kcal/mol because of the extra 
hydrophobic interactions.  
 
 
 
Figure 32a Docked pose of 125 (green) overlaid with 121·HCl (brown) in the ATP site 
of VEGFR-2 (PDB ID 1YWN).211 
 
Compound 123-128 were also docked in the ATP site of VEGFR2 (PDB: 1YWN, 1.75 
Å).211 Figure 32a shows the docked pose of 125  in the ATP site of VEGFR2. The 
pyrimidine scaffold of 125 forms hydrophobic interactions with Lys866, Val914 and 
Cys1040. The N4-methyl forms hydrophobic interactions with Leu838 and Val846. The 
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4′-OMe of 125 is oriented towards Leu1047 and Ala1048. The best docked pose of 125 had 
a score of −6.85 kJ/mol. 
 
Figure 32b. Docked pose of 127 (green) overlaid with 121·HCl (brown) in the ATP site 
of VEGFR-2. PDB: 3BE2. 212 
 
Figure 32b shows the docked pose of 127 in the ATP site of VEGFR2 (PDB: 3BE2212, 1.75 
Å) using LeadIT2.1.8. The pyrimidine scaffold of 127 is oriented parallel to the hinge 
region amino acids, and occupies the adenine binding region of the ATP site of VEGFR2. 
The N1 nitrogen of 127 forms a hydrogen bond interaction with the hydroxy group of 
Thr916. 2-methyl interacts with Ile1044. The 4′-OMe of 127 interacts with Phe845. The 4-
anilino ring interacts with Phe1047. The 4N-methyl is oriented towards the hydrophobic 
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site formed by Val848. The propyl chain at N5 of 127 is involved in hydrophobic 
interactions with Leu840 and Leu1035. The best docked pose of 127 and 121 had scores 
of −17.27 kJ/mol and -17.51 kJ/mol. 
.  
Figure 32c. Docked pose of 127 (yellow) overlaid with 121 (green) in the ATP site of 
EGFR (PDB ID 1M17). 214 
 
Figure 32c shows the docked pose of 127 in the ATP site of EGFR (PDB: 1M17 – 2.6Å).214 
The pyrimidine scaffold of 127 forms hydrophobic interactions with Leu820, Leu694. The 
N4-methyl forms hydrophobic interactions with Val702.The 4′-OMe of 127 is oriented 
towards Lys721 and Phe832. The 5N-butyl chain is oriented towards Ala719, Thr830 and 
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Thr766. The best docked pose of 127 and 121 had scores of −17.13 kJ/mol and -16.74 
kJ/mol. 
 
 
Figure 32d. Docked pose of 127 (yellow) overlaid with 121 (green) in the homology 
model of PDGFRβ. 
 
Figure 32d shows the docked pose of 127 in the homology model of PDGFRβ.  The N4-
methyl forms hydrophobic interactions with Ala848 and Phe845.The 4′-OMe of 127 is 
oriented towards Leu606. The 5N-butyl chain is oriented towards Val665 and Phe845. The 
best docked pose of 127 and 121 had scores of −16.71 kJ/mol and -16.99 kJ/mol. 
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Thus, the molecular modeling studies provided support for the synthesis and biological 
evaluation of 123-128. 
 
Results found: 
So, in sum, with compounds 123-127, we are utilizing these hydrophobic interactions: 
Hydrophobic residues in tubulin site - Ala316, V al315, V al181 and Ile378. Hydrophobic 
residues in VEGFR site Leu840 and Leu1035. Hydrophobic residues in EGFR site 
Ala719. Hydrophobic residues in PDGFR homology model Val665 and Phe845.   
Replacement of 6-Cl of 122 with 6-Me was not tolerated and so 6-Cl was not replaced for 
further target compounds. Compared to the pyrrolo[2,3-d]pyrimidine compound 121,  the 
lone pair of 5-NH2 in 122 is not part of the ring system and so available for hydrogen 
bonding with residues in the active site of various targets as a hydrogen bond donor as well 
as acceptor. Compound 121 doesn’t have a hydrogen bond acceptor due to the nitrogen 
lone pair being part of the pi system. Compound 122 NH2 lone pair might be involved in 
conjugation with the pyridine ring but still can form hydrogen bond with the residues at 
the active site. 
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 Also, 123 with a 6-Cl might be more active than 121 because of the electron withdrawing 
nature of the 6-chloro group in 122. Any electron donating group at 6-position like OH, 
NH2 or alkyl groups were not tolerated. Replacement of Cl with similar bulk Me was also 
not tolerated. But replacement with other electron withdrawing groups at 6-position like 
trifluoromethyl was tolerated. So, we believe, it is because of the electron withdrawing 
nature of the Cl, or 5-NH2 being involved in hydrogen bonding as a hydrogen bond acceptor 
(although it is a hydrogen bond donor too), which is leading to the improved activity 
compared to 121. 
In molecular modelling studies, compound 122-128 bound better in the crystal structure of 
target protein than the lead compound 121, and had better scores (about 1-2 units higher). 
 
 
Design rationale for Series III 
 
Figure 33. Series III 
 
Table 3. tPSA and cLogP of 122 and 133-136. 
 
Cmpd. tPSA (Aº) CLogP 
122 63.21 3.5 
133 66.29 2.8 
134 74.57 2.7 
135 66.29 4.1 
136 89 3.2 
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Series III was designed to determine the effects of electron withdrawing N-acetyl, N-
pivylyl, and nitro group in the 5 position of pyrimidine ring on the biological activity 
(Figure 33). The polar amide bond in the acetyl and pivalic groups is capable of forming a 
hydrogen bond because of the presence of both donor as well as acceptor moieties. Figure 
34 shows pivalic carbonyl oxygen of 135 forming a water-mediated (HOH623) hydrogen 
bond with the carbonyl of Thr353. Table 3 shows the calculated LogP as well as tPSA 
(Topological Polar Surface Area) values of 133-136 (calculated using ChemBioDraw Ultra 
15.1.0.144). Compound 133 with N-acetyl would be less lipophilic (Table 3), and 135 with 
N-pivalic group would be more lipophilic than 122. The nitro moiety at the 5-position (136) 
has highest tPSA. 
  
 
 
 
 
Figure 34. Docked pose of 135 (green) in the colchicine site (PDB ID 4O2B). Surface: 
black hydrophilic and red lipophilic. 
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Table 4. Effects of 121·HCl on tubulin and VEGFR2 in cellular assays 
 Inhibition of 
bovine tubulin 
assembly 
IC50 (µM) ± SD 
MDA-MB-435 
IC50 ± SD 
(nM) 
VEGFR2 kinase 
inhibition 
IC50 ± SD (nM) 
121·HCl 10 ± 0.6 96.6 ± 5.3 183 ± 3.4 
CA4 0.96 ± 0.07 3.47 ± 0.6 - 
Sunitinib - - 18.9 ± 2.7 
 
 
 
Table 5. Compound 121·HCl overcomes overexpression of Pgp and βIII-tubulin. 
 
Efforts to elucidate the plausible binding modes of multiple RTK-inhibitors led Gangjee et 
al.215 to the discovery of a highly potent water-soluble antitumor pyrrolo[2,3-d]pyrimidine 
121·HCl (Figure 22).216-217 It was discovered to be a colchicine site binding, microtubule 
depolymerizing agent that inhibited the growth of cancer cells with IC50 in the nanomolar 
range (Table 4). The effects of 121·HCl were evaluated in two pairs of multidrug resistant 
cell lines (Table 5). Compound 121·HCl was evaluated in the parental HeLa cells and in 
an engineered cell line overexpressing βIII tubulin (WTβIII). In addition, 121·HCl was 
Compd.  
IC50 ± SD 
in HeLa 
cells (nM) 
IC50 ± 
SD in 
WTβIII 
(nM) 
Rr 
value 
IC50 ± SD in 
SK-OV-3 
cells (nM) 
IC50 ± SD in 
SK-OV-3 
MDR1-M6/6 
cells (nM) 
Rr 
value 
121.HCl 179 ± 8.7 158 ± 13 0.8 219 ± 40 448 ± 110 2.1 
CA4 5.6 ± 0.3  5.7 ± 0.4 1.0 6.9 ± 0.1 3.0 ± 0.3 0.4 
Paclitaxel 1.9 ± 0.3 32.9 ± 5.8 17.3 6.3 ± 0.4 1,187.2 ± 265.2 188 
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evaluated for their ability to inhibit the growth of SK-OV-3 cells overexpressing Pgp in 
comparison to the parental line.218-222  
 
Figure 35. Series IV 
 
It was of interest to identify the structural features that are crucial for tubulin and RTK 
inhibition. Hence, 137-139, conformationally flexible, open chain analogs of 121·HCl 
were designed to elucidate the minimal structural requirements to retain tubulin and RTK 
inhibition (Series IV, Figure 35). The methyl and ethyl groups in the open chain analogs 
138 and 139 mimic the pyrrolo ring of pyrrolo[3,2-d] pyrimidine 121·HCl .  
 
Both pyrrolo[2,3-d]pyrimidine223 and pyrrolo[3,2-d]pyrimidine224 derivatives have been 
reported to possess potent inhibitory activity against tubulin. Hence, 140 with amino at 
both 5- as well as 6-position was designed.  
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Figure 36. Docked pose of 140 (green) overlaid with 129·HCl (brown) in the colchicine 
site (PDB ID 4O2B) showing the distance between 6-amino protons and Asn258 side 
chain.  
The amino protons at 6-position interact with Asn258 side chain amide oxygen with a 
hydrogen bond (Figure 36, distance calculated using MOE2016.08 = 2.74 Aº).  
 
 
 
Figure 37. Series V 
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To determine whether the excellent tubulin/VEGFR-2 dual activity of compound 122 is 
due to the electron withdrawing nature of the 6-chloro group in 122, Series V (Figure 37) 
was designed to evaluate the effect of electron-withdrawing substituents at 6-position by 
substituting the 6- chloro group in 122 with electron withdrawing groups, -CN, -I, and –
CF3, 141-143 respectively.    
 
Table 6. tPSA and cLogP of 122 and 141-143 
 
Cmpd. cLogP tPSA (Aº) 
122 3.53 63.21 
141 2.51 87 
142 3.64 63.21 
143 3.73 63.21 
 
 
In series IV, electron donating groups like alkyl and amino groups were designed but the 
compounds turned out to be less active/ in active. 6-hydroxy has already been synthesized 
in our group and was found to be inactive. Because of this reason, in series V, electron 
withdrawing groups (lipophilic and hydrophilic) were designed. 
The biological activities of compounds 141-143 will allow a determination of the effect of 
electronics and size on EGFR, VEGFR2 and PDGFRβ as well as tubulin inhibition.  Table 
6 shows the calculated LogP  as well as tPSA values of 141-143 (calculated using 
ChemBioDraw Ultra 15.1.0.144). Compound 141 is  less lipophilic compared to 122 with 
a higher polar surface area (Table 6). The nitrile moiety is more electron withdrawing 
compared to the chloro moiety in 122.213 Compound 142 would be more lipophilic and 
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bulkier than 122. The iodo in 142 also has the potential to form a stronger halogen bond 
compared to a chloro.225 
Compound 143 with a lipophilic trifluromethyl moiety would be a stronger electron 
withdrawing group than the chloro group due to the presense of three fluroine atoms, 
thereby, altering the electronics of the pyrimidine ring system making it more electron 
poor.  
 
 
Figure 38. Series VI 
 
To evaluate the importance of the 2-methyl of 122,  Series VI (Figure 38) was designed 
by replacing the 2-methyl with different groups. To determine, if the 2-methyl is 
specifically required for hydrophobic interactions, compounds 144 (desmethyl) and 145-
147 (2-ethyl) were designed. These compounds would evaluate the steric effect at the 2-
position on biological activity. 
Gangjee et al.226 have reported that a 2-amino group on fused pyrimidine ring systems 
improves hinge region binding and provides multiple-RTK inhibition. Compounds 148-
150 (Figure 38) were designed by replacing the 2-methyl group in 122 with a 2-amino 
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group which could potentially increase binding to the hinge region of EGFR or PDGFRβ 
via hydrogen bonds, without loss of tubulin and VEGFR2 inhibitory activities.  
 
 
Figure 39. Series VII 
 
Series VII (Figure 39) addresses the effect of bioisosterism, conformational restriction and 
flexibility on biological activity by introducing various substituted anilines in the 4-
position of the pyrimidine ring of 122 in place of the 4´-OMe aniline.  
 
Figure 40. Design rationale and biological activity for 301. 
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When the 4ʹ-methoxy group of 301 was replaced with a 4ʹ-thiomethyl group (Figure 
40), it led to a 2-fold increase in activity against tubulin, and a 1.5-fold increase in 
inhibition of cell proliferation. Therefore, 151 with a 4ʹ-thiomethyl group (Series VII) was 
designed. 
 
Figure 41. Dihedral angle α : C5-C4-4N-C1ʹ (bond rotation about bond a) 
 
Figure 42. Dihedral angle β : C5-C4-C1ʹ-C2ʹ (bond rotation about bond b) 
 
 
104 
Table 7. Dihedral angles of compounds 122, and 151-155 
Compound 
Dihedral 
angle α 
Dihedral 
angle β 
Compound 
Dihedral 
angle α 
Dihedral 
angle β 
122 45.7 78.3 151 48.1 65.0 
152 50.7 65.2 153 44.9 78.3 
154 176.9 47.7 155 172.2 45.8 
 
Bond rotations about 2 rotatable single bonds, b and c in the lead molecule 122 
(Figure 39) were restricted in compounds 152 and 153 (Series VII), respectively, thus, 
affording a much more rigid structure than 122 but still maintaining the phenyl and alkyl 
substitutions on the N4 as in 122. This substitution could also restrict the rotation around 
the N-phenyl bond, thus providing conformational rigidity and perhaps improved potency. 
Diheredral angles α (Figure 41) and β (Figure 42) were calculated for 122 and 
compounds 151-155 using MOE2016.08 in their energy minimized conformations. The 
results clearly tell that compounds 154 and 155 without 4N-Me have a higher dihedral 
angle α suggesting that phenyl is not on top of the 5-amino but on the other side.  
Conformational restriction of the phenyland 4ʹ methoxy moieties in 152 and 153 
respectively could lock the compound in a conformation that is conducive to selective RTK 
(VEGFR2 or other) inhibition without loss of tubulin inhibitory activity. Conformational 
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restriction of the flexible 4-anilino moiety of 122 would minimize the entropic loss 
associated with the 4-anilinio moiety adopting the preferred conformation for binding to a 
specific RTK. This could enhance potency for RTK and/or tubulin.227  
Compounds 154 and 155 (Series VII) were designed to evaluate the importance of the 4-
NCH3, and to increase the free rotation about the 4-position C-N bond (bond a) as well as 
the 1’-position C-N bond (bond b) in 122 and 151, respectively.  
 
Rationale explained further: As phenyl ring of 122 can exist in multiple conformations, 
this can result in unexpected entropic costs while binding to the colchicine bind site of 
tubulin. High entropic cost would offset any possible enthalpic gains that may have been 
achieved while binding to the active site. Hence, compounds 152 and 153 were designed 
as conformationally restricted analogs of 122 restricting the rotation about the bonds b and 
c respectively (Fig. 39, pg 87). A series of restricted analogs have already been designed 
and synthesized for other scaffolds like thieno[2,3-d]pyrimidines and pyrrolo[2,3-
d]pyrimidines, and it is found that the replacement of 4’-methoxyaniline moiety with 
bicyclic 6-methoxy-tetrahydroquinoline (152) and 4-N-methyl- 2'-3'-dihydrobenzofuran 
moiety (153) are the most active as they maintain the phenyl and alkyl substitution at N4 
of 122. Also, the 4-methoxy group of 152 and 153 maintained the hydrogen bonding 
interaction with Cys241 in tubulin binding site. 
Compound 151 was designed as a bioisostere of 122 by replacement of 4ʹ-methoxy group 
with a 4ʹ-thiomethyl group to determine the bulk tolerance (O vs S) as well as the 
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importance of hydrogen bonding.  Sulfur being a bulkier hydrophobic group could increase 
the activity by increasing the hydrophobic interactions at the colchicine site 
The S-Me compound 151 was also designed because it showed improved activity in other 
scaffolds. For instance, when the 4ʹ-methoxy group of 300 (Fig. 40) was replaced with a 
4ʹ-thiomethyl group (301), it led to a 2-fold increase in activity against tubulin, and a 1.5-
fold increase in inhibition of cell proliferation. Therefore, 151 with a 4ʹ-thiomethyl group 
was designed.  
The N-Me of 122 is involved in hydrophobic interactions with Leu255 and Ala250 at the 
colchicine binding site of tubulin. To gain the kinase inhibitory activity by improving 
hydrogen bonding interactions with the hinge region, N-methyl at the 4-position of 122 
was replaced with the N-H (compounds 154 and 155) that would provide additional H-
donor binding in RTK active sites. 4N of 154 and 155 would still maintain its hydrogen 
bond acceptor capabilities. This in turn would make it possible to inhibit multiple RTKs. 
Moreover, in RTK inhibitors, such as gefitinib, erlotinib, lapatinib, N-H is involved in 
hydrogen bonding interaction with the kinase region in multiple RTKs. Same strategy has 
been used while designing 154 and 155. 
 
Omitted compounds-  
The SAR for tubulin inhibition has already been established for other scaffolds in Dr. 
Gangjee’s group. Meta and ortho compounds have already been designed and synthesized 
before for other scaffolds. It was concluded with the biological results that only para-
methoxy group is active for tubulin depolymerization as it can form a hydrogen bond 
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interaction with Cys241 in the colchicine binding site of tubulin while meta and ortho 
analogs cannot. A series of conformationally restricted analogs have already been designed 
and synthesized for other scaffolds like thieno[2,3-d]pyrimidines and pyrrolo[3,2-
d]pyrimidines, and it is found that the replacement of 4’-methoxyaniline moiety with 
bicyclic 6-methoxy-tetrahydroquinoline and 4-N-methyl- 2'-3'-dihydrobenzofuran moiety 
lead to the most active analogs as they maintain the phenyl and alkyl substitution at N4 of 
122. Also, the 4-OR of 152 and 153 maintained the hydrogen bonding interaction with 
Cys241 in tubulin binding site. 
Homologation of 4N has been reported for other scaffolds but it was found to be 
detrimental for the inhibitory activity. 
 
Design rationale for 4,6-disubstituted compounds 
 
 
 
 
Figure 43. Design rationale for 156. 
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The potent inhibitory activity of 129·HCl, a N4-,7-disubstituted analog, in cell lines 
overexpressing VEGFR2 led to the design of 156 (Figure 43) with 4´-methoxy-N-
methylaniline in the 6-position to determine its effects on the cell lines overexpressing 
multikinases.  The 6-benzyl moiety in 129·HCl occupies hydrophobic region I or sugar 
binding pocket in different modes (described above, Figure 23). Similarly, the 4´-methoxy-
N-methylaniline moiety at the N6-position of 156 could also access different pockets in the 
ATP binding site to afford multikinase inhibition. 
 
Figure 44. Docked pose of 156 (green) overlaid with 129·HCl (brown) in the ATP site of 
VEGFR-2 (PDB ID 1YWN).211 
Docking studies: Figure 44 shows the docked pose of 156 and 129·HCl in the ATP site of 
VEGFR2 (PDB: 1YWN, 1.75 Å).211 In the best docked pose of 156 (docked score of -7.94 
109 
kcal/mol), the 4´-methoxy-N-methylaniline at the 6-position occupies the site where the 
benzyl moiety of 129·HCl binds, and interacts with Leu1047 and Ala1048. The 4′-OMe of 
the N6 substitution of 156 is oriented towards Arg840 and could involve a hydrogen 
bonding interaction. 
Compound 156 was found to have single digit nanomolar inhibition in cell lines 
overexpressing VEGFR2 and was greater than a 4-fold increase in activity compared to 
lead 129·HCl albeit with loss of inhibition of tubulin activity. 
Figure 45. Series VIII 
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Because of the loss of tubulin activity in 156, Series VIII (Figure 45) with 157-160 was 
designed to regain the lost tubulin inhibitory activity while retaining or further improving 
the potent VEGFR2 inhibitory activity. 
 
Compounds 157 and 158 without N-methyl can have hydrogen bonding interactions with 
the tubulin protein in the colchicine binding site due to two additional hydrogen bond 
donors, one at the N4 and the other at the N6. This might restore the tubulin inhibitory 
activity. 
 
 
Figure 46. General pharmacophore model of pyrimidines with potential binding mode of 
157. 
 
In addition, binding modes of 157 and 158 with N4-H and N6-H are proposed (Figure 46) 
to enable inhibition of an increased spectrum of RTKs compared to 156. In an attempt to 
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design similar multikinase inhibitors, a general RTK pharmacophore model was used as 
opposed to a specific crystal structure of a specific RTK to approach multikinase 
inhibition.183 It was envisioned that removing the N-methyl at the 4- and 6-positions would 
provide additional hydrogen bond donors which could provide additional H-donor binding 
in RTK active sites in multiple binding modes relative to the corresponding N-methyl 
compounds. This in turn would make it possible to inhibit multiple RTKs. Compounds 159 
and 160 were designed to regain the lost tubulin inhibitory activity by the replacement of 
4´-OMe at 4- and 6-positions of 156 with 4´-SMe, and 4,6-bis-4´methoxyanilino moiety 
with 4,6-bis-6´-methoxy-3,4-dihydroquinolino moiety respectively. 
 
 
Design rationale for Series IX 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                                     
Figure 47. Series IX 
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Gangjee et al.228 reported the bicyclic pyrrolo[2,3-d]pyrimidine compound 161, with the 
N-methyl-4’-methoxyaniline moiety at the 4-position, as a potent microtubule 
depolymerizing agent (Figure 47). 
 
Table 8. Disruptive effect on microtubule polymerization in A-10 cells, and inhibition of 
proliferation of MDA-MB-435 cells for 161. 
Compound EC50 (nM) in A-10 cells 
IC50 (nM) (MDA-MB-
435) 
Inhibition of 
colchicine binding 
(% Inhibition ± SD) 
161 5.8 µM 183 nM 70 % 
 
 In the preclinical screening program of the National Cancer Institute 60-cancer cell line 
panel, 161 was found to inhibit the proliferation of most of the cancer cell lines with a GI50 
of less than 500 nM. It also caused a dramatic reorganization of the interphase microtubule 
network, which was similar to the effects of CA4-P (Table 7).228  
Unlike paclitaxel, it maintained most of its potency against P-gp-overexpressing cell lines 
and showed slightly better activities against β-III-tubulin-overexpressing cancer cell 
lines.228 Moreover, it displaced 70% of the [3H] colchicine at a concentration of 5 µM. 
Thus, it was determined to be a colchicine binding agent. Prior to this work,228 there were 
sparse reports on pyrrolo[2,3-d]pyrimidine-based colchicine-site binding agents. This 
discovery was an inspiration to explore the SAR of this class of compounds as MTAs.  
Based on the above data, 161 was an excellent lead compound for further development and 
Series IX (Figure 47) addresses the effect of substituting the N-methyl-4’-methoxyaniline 
moiety with various anilines in the 4-position of the pyrrolo[2,3-d]pyrimidine ring of 161.  
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Compound 162 (Figure 47), a conformationally restricted aniline with a fused bicyclic 4-
N-methyl-2'-3'-dihydrobenzofuran moiety at the 4-position of 2-methyl-7H-pyrrolo[2,3-
d]pyrimidine was designed. Bond rotation about rotatable single bond, b in the lead 
molecule 161 was restricted in compound 162, thus, affording a much more rigid structure 
than 161 but still maintaining the phenyl and alkyl substitutions on the N4 as in 161. 
Conformational restriction of the flexible 4-anilino moiety would minimize the entropic 
loss associated with the 4-anilinio moiety adopting a preferred conformation for binding to 
tubulin. This could enhance potency for tubulin. Another advantage could be reduced drug 
metabolism.227 The electron poor 4’-methoxypyridine moiety was designed in place of the 
4’-methoxyaniline moiety of 161 in 163.  Napthols 164 and 165 would determine if the 4’-
methoxy and 4N-methyl are necessary for activity. It was hypothesized that fusion of 
another aromatic ring at the appropriate positions of the pyrrolo[2,3-d]pyrimidine 161 
would improve tubulin inhibitory potency. Compound 166 with a 5’-methoxy-N-methyl-
2-naphthalenamine moiety would determine if additional bulk would lead to increase in 
biological activity. Compound 167 was designed by replacing the 4'-methoxy of the lead 
161 with a 4'-thiomethyl moiety as discussed earlier in Figure 40.  
Rationale explained further: As phenyl ring of 161 can exist in multiple conformations this 
can result in unexpected entropic costs while binding to the colchicine bind site of tubulin. 
High entropic cost would offset any possible enthalpic gains that may have been achieved 
while binding to the active site. Hence, compounds 162 were designed as conformationally 
restricted analog of 161 restricting the rotation about bond b (Fig. 47, pg 94). A series of 
restricted analogs have already been designed and synthesized for other scaffolds like 
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thieno[2,3-d]pyrimidines and pyrrolo[2,3-d]pyrimidines, and it is found that the 
replacement of 4’-methoxyaniline moiety with bicyclic 6-methoxy-tetrahydroquinoline 
and 4-N-methyl- 2'-3'-dihydrobenzofuran moiety are the most active as they maintain the 
phenyl and alkyl substitution at N4 of 161. 6-methoxy-tetrahydroquinoline replacement 
has already been done by Dr. Lin in our group.  Also, the 4-OR of 162 maintained the 
hydrogen bonding interaction with Cys241 in tubulin binding site. 
A series of compounds with electron withdrawing groups eg halogens, OCF3 at para 
position were synthesized by Dr. Lin. Compound 163 with an electron poor 4’-
methoxypyridine moiety was designed to determine if an electron poor ring would be 
beneficial for the inhibitory potency. 4’-methoxypyrimidine moiety has already been 
synthesized by Dr. Lin.  
Nitrogen containing heteroaromatic rings are ubiquitously present in drug-like molecules 
and 59% of U.S. FDA approved small-molecule pharmaceuticals contain at least one 
nitrogen heterocycle. Substituting a CH group with a N atom (as in 163) can lead to 
improvements in functional activities such as biochemical potency, cellular potency, and 
target selectivity. It redistributes electron density in the ring and introduces dipole moment 
(µ= 2.2 D), hydrogen bond capability, and polarity into the molecule. Other students in our 
group will be performing a systematic N atom scan (N-scan) by exchanging the trivalent 
CH groups in the phenyl side chain of the ligand 161 with trivalent N atoms, one at a time, 
to determine its optimal placement for desired pharmacological improvements. 
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A series of compounds replacing phenyl with substituted naphthalenyl moiety has already 
been synthesized by Dr. Lin in our group. Compounds 164-166 were designed to determine 
the bulk tolerance in the colchicine site of tubulin. The increased bulk can form 
hydrophobic interactions with hydrophobic residues Ala250, Leu248, Ile1042 and Val914.  
The 4N-Me analog of 164 has already been synthesized by Dr. Lin. To determine the role 
of N-Me in hydrophobic interactions and to also determine if N-H would be involved in 
any hydrogen bonding interactions as a donor, 164 was designed.  
The 4N-Me and 4’O-Me analog of 165 has been synthesized by Dr. Lin. To determine if 
these methyl groups are conducive to microtubule depolymerization, 165 with 4NH and 
4’OH were designed. These extra H groups can also lead to improved activity because of 
extra hydrogen bonding interactions with the target as hydrogen bonding donors. 
Compound 166 with a 5’-methoxy-N-methyl-2-naphthalenamine moiety was designed 
because of the improved biological results in other scaffolds when 4’-methoxyaniline 
moiety was replaced with a 5’-methoxy-N-methyl-2-naphthalenamine moiety. It was found 
that position of 5’-methoxy group in the naphthalene ring plays a big role in the biological 
activity against tubulin polymerization. 5’-methoxy group maintains the hydrogen bonding 
interaction with Cys241.  
The replacement of 4’-OMe with 4’S-Me in 167 was done to determine the bulk tolerance 
(O vs S) as well as the importance of hydrogen bonding. Sulfur being a bulkier hydrophobic 
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group could increase the activity by increasing the hydrophobic interactions at the 
colchicine site of tubulin. 
The S-Me compound 167 was also designed because it showed improved activity in other 
scaffolds. For instance, when the 4ʹ-methoxy group of 300 (Fig. 40) was replaced with a 
4ʹ-thiomethyl group (301), it led to a 2-fold increase in activity against tubulin, and a 1.5-
fold increase in inhibition of cell proliferation 
Oxazolo[5,4-d]pyrimidines as microtubule targeting agents  
Figure 48. Design rationale for Series X 
Compounds 168 and 169 (Figure 48) were recently reported82-83, 180 by Gangjee et al. as 
potent MTAs that bind in the colchicine site of tubulin. Compounds 170-171 were designed 
as hybrids of these molecules to determine the effect of oxazolo compounds on tubule 
polymerization.  
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Pyrimido[4,5-g]pteridine as a potential MTA. 
 
Figure 49. Design rationale for dimer 172 
A number of tricyclics183, 229-230  have been reported by Gangjee et al. which act as MTAs. 
The dimer 172 (Figure 49) was obtained via self-condensation of 122, and it was of interest 
to evaluate its effects on tubulin polymerization. 
 
Selective tumor targeting with 5-substituted pyrrolo[2,3-d]pyrimidines with 
heteroatom bridge substitution  
 
The lack of tumor selectivity for all the currently clinically used antifolates, including 
methotrexate (MTX), pemetrexed (PMX), pralatrexate (PDX), and raltitrexed (RTX), 
reflects their cellular uptake by the reduced folate carrier (RFC) expressed ubiquitously by 
both normal tissues as well as tumors.231 In contrast, folate receptor (FR) α and β, and the 
proton-coupled folate transporter (PCFT) exhibit selective tumor tissue expression, and 
serve specialized physiological roles.113 FRs on normal cells are inaccessible to circulating 
folates or are non-functional in normal tissues. PCFT is expressed in the upper 
gastrointestinal tract where it functions only at acidic pH as the major intestinal transporter 
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for absorption of dietary folates.131 Given this requirement of acidic pH for activity, PCFT 
transport is limited in normal tissues that are not at acidic pH (<6.9). A substantial cohort 
of solid tumors (eg. ovarian, non-small cell lung cancer) express PCFT, often in concert 
with FRs. FRα is accessible on tumors, thus, allowing tumor targeting by this mechanism. 
FRβ is expressed in hematological malignancies and in white blood cells of the myeloid 
lineage, including tumor-associated macrophages (TAMs). FRβ-positive TAMs may play 
an important role in the tumor microenvironment in reaction to tumor metastasis and 
angiogenesis by releasing proangiogenic factors suggesting that TAMs may constitute an 
additional potential therapeutic target in cancer for FRβ-targeted agents.132 There are no 
tumor targeted cytotoxic agents in clinical use, thus, all cytotoxic agents display dose-
limiting toxicity. New cytotoxic agents are needed which can target tumor cells selectively 
by virtue of their specificities for FRs and /or PCFT and thus, afford agents that do not 
suffer from dose-limiting toxicities.133 
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Figure 50. PMX, lead compound 302 and target compounds 173-176. 
PMX is currently among the most prescribed antitumor agents used in the clinic.232 The 
principal indications for PMX are malignant pleural mesothelioma (with cisplatin) and 
non-small cell lung cancer. Neutropenia is the major dose-limiting toxicity associated with 
PMX, and reflects in part, its nonselective uptake into normal cells, via RFC, expressed in 
normal as well as tumor cells.233 Gangjee et al. 234 previously reported a 5-substituted 
pyrrolo[2,3-d]pyrimidine antifolate with a 5-carbon bridge and a phenyl L-glutamate side 
chain, 302 (Figure 50). These compounds were part of a series of chain extension analogs 
of clinically used PMX to improve tumor cell potency as well as specificities for FRs and 
/or PCFT. Although, 302 was found to be 3.5-fold more potent in KB tumor cells than 
clinically used PMX,  and showed potent inhibition of CHO cells expressing FRα (IC50 = 
33.5 nM), it had reduced activity toward CHO cells expressing PCFT, and high activity 
toward CHO cells expressing RFC, thus, it lacked selectivity for FR and/or PCFT. Previous 
studies of related 6-substituted pyrrolo[2,3-d]pyrimidines established that the nature and 
length of the bridge plays an important role in determining tumor cell potency and 
selectivity.124 Thus, it was of interest to insert heteroatom into the carbon bridge of 302 to 
determine if O or S substitution of C would afford better activity. Compounds 173-176 
(Figure 50) were designed and their impact on drug potency and transport selectivity was 
determined. The novel analogs were tested as growth inhibitors against CHO cells 
expressing human FRα (RT16), FRβ (D4), RFC (PC43-10), and PCFT (R2/PCFT4) as well 
as KB tumor cells in culture. 
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Molecular Modeling Studies 
 
 
Figure 51. Superimposition of the docked poses of 174 (grey) and PMX (green) in the 
folate binding site of human FRα (5IZQ) .124 
Compounds 173-176 and PMX were docked in the folate binding cleft of FRα (PDB 
5IZQ)124using MOE2013.0801183  software to predict potential binding of these analogs for 
uptake by FRα. Figure 51 shows the superimposition of docked poses of 174 and PMX in 
the human FRα active site. Compound 174 displayed similar interactions in the pocket, 
maintaining important protein contacts between the bicyclic scaffolds and benzoyl L-
glutamate tail, as also seen in the crystal structure ligand 6-substituted pyrrolo[2,3-
d]pyrimidine (not shown) and docked standard compound PMX. 
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Figure 52. Superimposition of the docked poses of 173 (green) and 6-substituted 
pyrrolo[2,3- d]pyrimidine 304 (grey) in the 10-formyl tetrahydrofolate binding site of 
GARFTase (4ZZ1).120  
 
In the docked pose of 174 (Figure 51), the 2-hydroxy of 174 interacts with Ser174. The 4-
oxo moiety forms hydrogen bonds with the side chain NH of Arg103 and the side chain 
OH of Ser174. The pyrrolo[2,3-d]pyrimidine scaffold is stacked between the side chains 
of Tyr60 and Trp171. The L-glutamate moiety of 174 is oriented similar to the 
corresponding L-glutamate in PMX. The γ-carboxylic acid of 174 interacts with the 
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protonated amine of Lys136 and the side chain OH of Ser101. The bridge of 174 forms 
hydrophobic interactions with Tyr60, Phe62, Trp102, and His135. The docking score of 
174 was −13.29 kJ/mol (rmsd = 1.68), somewhat better than the docked scores of PMX 
(−12.36 kJ/mol, rmsd = 1.68), and suggests better or similar activity for 174 at FRα.  
Figure 52 shows docked 173 in the crystal structure of human GARFTase (PDB 
4ZZ1)120complexed with 6-substituted pyrrolo[2,3- d]pyrimidine 304. Compounds 173-
176 were docked into the X-ray crystal structure of human GARFTase to predict potential 
activities for GARFTase inhibition.. The pyrrolo[2,3-d]pyrimidine scaffold of 173 binds in 
the region occupied by the bicyclic scaffold of the bound molecule 304 in GARFTase. 
Hydrogen bonds between the N1 nitrogen of 173 and the backbone of Leu899; 2-NH2 of 
173 and the carbonyls of Glu948 and Leu899, N3 of 173and the backbone C=O of Ala947, 
and 4-oxo of 173 and the backbone C=O of Asp951 stabilize the scaffold. The pyrrolo[2,3-
d]pyrimidine scaffold of 173 forms hydrophobic interactions with Leu892, Ile898 and 
Leu899. The docking score of 173 was −14.18 kJ/mol. Similarly, compounds 174-176 had 
similar docked scores indicating potent GARFTase inhibition. Thus, the molecular 
modeling studies provided support for the synthesis and biological evaluation of 173-176. 
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IV. CHEMICAL DISCUSSION
 
 
Figure 53. Retrosynthesis of target compound 130 
Synthesis of 130 was envisioned to be accompished via a simple Suzuki coupling as benzyl 
boronic esters/acids are easily avaliable (Figure 53). The intermediate 122 could be  
synthesized via nucleophilic substitution reaction229 of 177 with N-methyl 4-methoxy 
aniline. 
Scheme 26. Formation of Meisenheimer complex235 
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Synthesis of  122 and 156 
 
 
With the above synthetic strategy for the synthesis of 130, key intermediate 122 was 
synthesized by treating 177 with 1.1 equivalents of N-methyl-4-methoxyaniline and 
catalytic amounts of hydrochloric acid. The reaction was also attempted without addition 
of any HCl but leads to 25-30% less yields. Reactions with catalytic amounts of HCl 
provided  better yields as HCl protonates the pyridine nitrogen next to the C-Cl bond 
(Scheme 26).236 
Scheme 27. Synthesis of 156 and 122 
 
Reagents and conditions: N-methyl-4-methoxyaniline, cat. HCl (conc.), 2 h, 150 oC, MW,  
dioxane 
The  reactions were attempted in a microwave reactor at 150 ºC as described in the 
literature.237 However, it was found that higher temperature afforded a disubstituted 
product 156, and significantly reduced the yield (15 % product formation, Scheme 27).  
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Table 9.  Effect  of variation in temperature 
Equiv of Nucleophile used Temperature Major product formed? 
1.1 150 ºC Disubstituted product 
1.1 120 ºC Monosubstituted  product 
 
Scheme 28. Synthesis of 122 
 
Reagents and conditions: N-methyl-4-methoxyaniline, cat. HCl (conc.),  2 h, 120 ˚C, 
MW,  dioxane 
Lower temperatures (Table 8) were then used, and the reaction temperature was optimized 
to significantly decrease formation of 156, affording 122 in 75% yield (Scheme 28). 
A 1H NMR study was also done in DMSO-d6 to determine the conformation of 122. 
According to the 1H NMR spectrum, the 5-NH2 protons of 122 are more shielded and come 
at 4.0 ppm compared to the 5-NH2 protons of starting material 177 which come at 5.92 
ppm. This suggested a nearby diamagnetic anisotropic cone. Due to the bulk of the 4N-Me 
group, the conformation of 122 is restricted, and the phenyl ring of 122 positions itself on 
the top of the 5-NH2 protons (as shown in Scheme 28) leading to the observed shielding 
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effect.83 
It was observed that lower temperature, less reaction time and less equivalents should be 
used to produce monosubstituted reactions. 
 
Synthesis of 130 
Compound 122 was subjected to a Suzuki coupling using potassium benzyltrifluoroborate 
to afford 130.238 The reaction was performed in a microwave for 5-10 min with palladium 
triphenylphosphine as the catalyst and cesium carbonate as the base to afford benzyl 
product 130. The reaction was carefully monitored by thin layer chromatography (TLC).  
A new product (red spot) was observed on TLC with other side products, and after 
extracting the product with ethyl acetate and drying under sodium sulfate, column 
chromatography afforded the product. Purification of 130 required extensive column 
chromatography. Variations  in temperature, time, catalyst, solvent and boronic reagents 
were carried to afford a pure product (Scheme 29).   
Scheme 29. Variations  in temperature, time, catalyst, solvent and boronic reagents 
 
Reagents and conditions:  Pd catalyst,  Cs2CO3, MeCN : Water = 1 : 1, MW 
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Table 10. Variations  in temperature, time, catalyst, solvent and boronic reagents 
 
 
 
 
 
 
 
 
After the pure product was isolated using conditions mentioned  in entry 7 (Scheme 29). 
1H NMR analaysis of the isolated product showed the absence of any amino protons at the 
5-position of 130. 1H NMR analysis also showed the absence of benzyl methylene protons 
or the phenyl protons.  
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Figure 54. 1H NMR of Suzuki coupling product which yielded 172 instead of 130. 
 
Compound 178 was synthesized to determine whether its Rf  was similar to the final product 
but was found to be different, and so, one possibility was the formation of a dimer product 
172 (Scheme 30).  
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Scheme 30. Possible products with suzuki coupling 
  
The pure isolated product was further analyzed for CHN and mass spectrometry which 
proved the formation  of a dimer product 172.The mass of 122 was 270.09 while the mass 
of the dimer 172 was 482.55. The % of element C in the isolated product was found to 
64.5% which confimed that 172 was formed. If it were 122, the % of element C wpuld 
have been 56.3%. 
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Scheme 31 Synthesis of 172 
 
Reagents and conditions: a. Pd(PPh3)4, Cs2CO3, MeCN: Water = 1 : 1, 120 °C, 30 min, 
MW  b. Pd(PPh3)4, MeCN: Water = 1 : 1, Cs2CO3, MW, 120 °C,30 min 
Scheme 32. Synthesis of 172 without palladium catalyst and boronic reagent was 
unsuccessful 
 
Reagents and conditions: acetonitrile/H2O, Cs2CO3, MW, 120 °C, 30 min. 
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To evaluate 172 in biological assays, it was resynthesized. It was observed that the reaction 
fails without addition of any palladium catalyst and/or boronic reagent (Schemes 31-32). 
Interestingly, it was found that the boronic ester/salt is required for the formation of the 
dimer. 
Reason Suzuki coupling might have failed:  Although the actual mechanism is still 
unresolved, the boronic reagent and palladium could be involved in the oxidative addition 
and transmetallation steps of the Suzuki coupling. But before reductive elimination occurs 
to form 130, the 5-amino could attack and form the dimer 172.  
Scheme 33. Failure of the protection of the 5-amino using pivalic anhydride.
 
Reagents and conditions: Pivalic anhydride, 130 oC, 12 h 
The 5-amino of 122 was then protected using pivalic anhydride to prevent dimer formation 
but the protection failed to afford 135 (Scheme 33).  
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Figure 55. 1H NMR of pivalic protection isolated product yielded 171 instead of 135. 
 
After the pure product was isolated (observed on TLC) , 1H NMRs of isolated product 
showed absense of 5-NH. One possibility was formation of a bicyclic oxazolo[5,4-
d]pyrimidino compound 171 (Scheme 34). Elemental (CHN) analysis and mass 
spectrometry confirmed the presence of the oxazole (Figure 55). The mass of product 
formed was 326.17, which is the correct mass of 171 (with loss of one Cl and one H ), 
while the mass of the 135 is 362.15. The % of element C was found to be 66% which 
confirmed the formation of 171. 
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Scheme 34. Synthesis of 171 
  
Reagents and conditions: Pivalic anhydride, 130 oC, 12 h 
Table 11.  Effect  of variation  in temperature 
 
 
 
 
 
 
Lower temperatures were then used, and the reaction temperature was optimized to 
significantly decrease the formation of 171, and to afford 135 so that the target benzyl 
compound 130 could be synthesized (Table 9). 
It was observed that  low temperatures lead to pivalyl protection (78% yield), and higher 
temperatures lead to bicyclic oxazolo formation (60% yield). 
Synthesis of 133 
The reaction of 122 with acetic anhydride will serve two purposes: 
1. Compound 170 (Scheme 35) could be synthesized at higher temperatures which 
could function as a potent microtubule targeting agent. This would afford novel 
Temperature Product 
105 ºC N-pivylyl formation 
150 ºC 
oxazolo[5,4-d]pyrimidinyl 
formation 
134 
oxazolo[5,4-d]pyrimidinyl compounds that have not been reported as MTAs in the 
literature. 
2. At lower temperature, acetyl protection could be achieved which would prevent 
dimer formation under Suzuki conditions. 
Scheme 35. Synthesis of 133 and 134. 
 
Reagents and conditions  a. Acetic anhydride, 100 oC, overnight  b.  Acetic 
anhydride, 150 oC, overnight 
 
The 5-amino group in 122 was reacted with acetic anhydride at both lower and higher 
temperatures (Scheme 35). Very interesting results were obtained.  
Low temperatures, without basic conditions, afforded  the N-acetyl product 133. Higher 
temperatures without any base afforded N-acetyl-acetamide 134 instead of 170 (Table 10).  
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Table 12. Effect  of variation  in temperature. 
 
 
Reagent Temperature Product 
No base 100 ºC N-acetyl formation 
No base 150 ºC N-acetyl-acetamide formation 
Base, CuI 110 ºC Oxazole formation 
 
Scheme 36. Synthesis of 170 
  
Reagents and conditions: CuI, DMEDA, K2CO3, Toluene, reflux, 6 h, 55% yield 
Finally, the synthetic method by Xu et al.239-240 which reported intramolecular C-O cross-
coupling of the o-halogenopyrimidine amide 133 via Cu-mediated cyclization afforded 
exclusively the oxazolo[5,4-d]pyrimidino 170 in 55 % yield (Scheme 36).   
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Synthesis of 150 
Scheme 37. Attempted Suzuki coupling with 133 and 135.  
 
 
 
Reagents and conditions: a) acetonitrile/H2O, Cs2CO3, Pd(PPh3)4, MW, 120  oC, 30 min 
 
Acetylated (133) (Scheme 37) and  pivylated (135) products were subjected  to Suzuki 
coupling to afford 130. Unfortunately, the reactions under Suzuki conditions did not work.  
 
Reasons for the failure of the Suzuki reaction with 133 and 135. 
1. The bulk of the acetyl and pivylyl groups could make the attack of the boronic salt 
difficult during the transmetallation step of the Suzuki coupling. 
2. Chlorides are not good leaving groups for coupling reactions like the Suzuki. Better 
groups like bromides or iodides are necessary.241-242 
 
137 
Base plays a major role in the transmetallation step of the Suzuki coupling.242  The presence 
of a base might also be the main reason for the formation of dimers in Suzuki coupling as 
it makes the 5-amino a better nucleophile (Scheme 31). Hence, Negishi coupling was 
attempted on 122 as this coupling does not require base and could prevent dimer formation 
(Scheme 38).  
Scheme 38. Attempted Negishi coupling with 122 was unsuccessful. 
 
Reagents and conditions  Pd(PPh3)4, THF, 60 oC, 2 h (inert) 
Compound 122 was treated with 0.5 M solution of  benzyl zinc bromide in THF under 
Negishi conditions to yield 133.243  The reaction was carried out under inert conditions. 
There was no sign of any product or side product formation. No base was used, and that 
could be the reason for failure of products even dimer formation. The absence of a good 
leaving group like a bromide/iodide might be the reason  behind the failure of the Negishi 
reaction.  
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Scheme 39. Synthesis of 142 with sodium iodide was unsuccessful. 
 
Reagents and conditions:  a) N-methyl-4-methoxyaniline, cat. HCl (conc.),  2 h, 120 oC, 
MW,  dioxane  b) NaI, TMS-Cl, MeCN, 180 °C, MW 
 
Synthesis of 142 - Iodination 
The next step was to introduce an iodo moiety at the 6-position. Yang et al. 134 and Lemoine 
et al.135 introduced the iodo by reacting chloride with NaI and TMS-Cl in acetonitrile at 
180 °C in a microwave reactor. The same method was followed but it failed for  the 
pyrimidine scaffold (Scheme 39). 
Scheme 40. Synthesis of 142 
 
Reagents and conditions:  a) N-methyl-4-methoxyaniline, cat. HCl (conc.),  2 h, 120 oC, 
MW,  dioxane , 75 % yield b) 57 % HI (aq.), MeCN, 0 oC- rt, 48% yield 
139 
Finally, the method used by Hughes et al.137 worked successfully for the substitution of the 
chloro group with an iodo group with 57% aqueous hydroiodic acid in acetonitrile (Scheme 
40). Compound 122 was treated with a 57% aqueous solution of hydroiodic acid at 0 ºC to 
afford 142 in 48% yield. 
 
Replacement of the chloro moiety with an iodo was  a crucial step for the final synthesis 
of the target 6-benzyl compound 130. 
 
Synthesis of 130 
Scheme 41. Synthesis of 130 
 
Reagents and conditions: Pd(PPh3)4, THF, 60 oC, 2 h (inert), 35% yield 
 
Compound 142 (Scheme  41) was treated with 0.5 M solution of  benzylzinc bromide in 
THF under Negishi conditions to afford 130 in  35% yield The reaction was carried out 
under inert conditions.  
Why Negishi coupling might have worked: 
140 
1. The use of zinc metal could help in forming a coordination complex with nitogen 
of pyrimidine leading to reduction in electrophilicity of  C-Cl, and facilitating 
coupling reaction. This coordination was not possible with Suzuki coupling. 
2. No base was used, and that must be the reason for the lack of formation of any 
side products like dimer formation. 
 
Synthesis of 151 
Scheme 42. Attempted synthesis of 131 under Suzuki conditions. 
 
Reagents and conditions: acetonitrile/H2O, Cs2CO3, Pd(PPh3)4, MW, 120 oC, 30 min 
 
Suzuki coupling for phenylethyl product formation 
Attempted syntheses of 131 under Suzuki conditions  (Scheme 42) were unsuccessful.  
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Scheme 43. Attempted Negishi coupling for the synthesis of 131. 
 
 
Reagents and conditions: Pd(PPh3)4, N2, 60 °C, THF 
 
 
Negishi coupling for phenylethyl product 131 formation. 
Although the treatment of 142 with 0.5 M solution of phenylethyl zinc bromide and  
palladium catalyst worked, it led to side product formation which could not be isolated 
using column chromatography (Scheme 43). 
 
As both Suzuki and Negishi coupling reactions failed to afford 131, Sonogoshira coupling 
was attempted. 
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Scheme 44. Attempted Sonogoshira reaction with the chloropyrimidine 122. 
 
Reagents and conditions: CuI, PdCl2(PPh3)2, NEt3, dry DCE, 100 °C, 2 h 
 
Sonogoshira reaction for phenylethyl product formation. 
 
The Sonogoshira reaction was not successful with the chloropyrimidine (Scheme 44). 
However, the iodide 142 did afford 131 under the same cconditions. 
 
Scheme 45. Synthesis of 131  
 
Reagents and conditions: a) CuI, PdCl2(PPh3)2, NEt3, dry DCE, 100 °C, 2 h, 65 % yield b) 
H2 (50 psi), 10 % Pd/C, rt, 35 % yield. 
143 
Compound 142 was coupled with phenylacetylene under Sonogoshira coupling conditions 
to afford 132 in 65% yield which was then catalytically hydrogenated at 50 psi using 10%  
Pd/C to yield 131 (Scheme 45).  
 
Synthesis of 154-159 
Scheme 46. Synthesis of 123, 125-128 
 
Reagents and conditions : a) N-methyl-4-methoxyaniline, cat. HCl (conc.),  2 h, 120 oC, 
MW,  dioxane , 75 % yield b) NaH, alkyl halide, DMF, 2 h, 0º C-rt, 35- 78% yields c) 
Diethyl ether, HCl (g), 90 % yield. 
2-Methyl-4,6-dichloropyrimidine 177 (Scheme 46) was subjected to nucleophilic aromatic 
substitution using N-methyl-4-methoxyaniline and catalytic amount of conc. HCl in 
144 
dioxane to afford 122.244 Reactions involving microwave irradiation afforded 15-25% 
better yields than conventional bench-top conditions. Compound 122 was deprotonated 
with sodium hydride, and treated with the appropriate alkyl halide to afford the 
corresponding N5-alkylated compounds 123-128 in 35-78 % yields. Reactions involving 
combinations of cesium carbonate or potassium carbonate and dimethylformamide with 
microwave irradiation did not show complete consumption of starting material. The use of 
excess base or alkyl halide did not afford the alkylated product exclusively. To increase 
water solubility, the products were converted to the HCl salt using HCl gas and ether. The 
composition of element chloro was found to be 19.15% for 127·HCl 
(C17H23ClN4O.1.0HCl) which confirmed the formation of the HCl salt.  
Synthesis of 124 
Scheme 47. Synthesis of 124
	
Reagents and conditions: NaH, MeI, DMF, 2 h, 0º C- rt 
Base equiv. MeI equiv. Ratio (% yield) 
0.9 0.9 123:124 = 70:30 
145 
2.0 2.0 123:124 = 50:50 
Deprotonation of 122 with 0.9 equiv. of sodium hydride, and treatment with 0.9 equiv. of 
MeI afforded a mixture of yield of (70%) 123 and 30% of the N5-dialkylated 124 (Scheme 
47). The products could be easily separated using column chromatography due to different 
Rfs on TLC (Rf = 0.62 for 123 and 0.65 for 124). CHN elemental analysis confirmed the 
formation and separation of both products with C = 58.06%, H = 5.97%, N = 18.76%, Cl 
= 11.85% for 123 and C = 59.16%, H = 6.37%, N = 17.71%, Cl = 11.23% for 124. 1H 
NMR analysis for 124 showed a sharp peak at 2.14 ppm which integrated for 6 protons 
while for 123, the sharp peak at 2.26 ppm integrated for 3 protons only. Increasing 
equivalents of base and alkylating agent from 0.9 to 2 equiv. increased yield of 124 to 50% 
of the mixture.  
Synthesis of 136 
Scheme 48. Synthesis of 136 
 
 
Reagents and conditions : N-methyl-4-methoxyaniline, cat. HCl (conc.), 3 h, 160 oC, MW, 
dioxane, 82% yield. 
 
2-Nitro-4,6-dichloropyrimidine 178 (Scheme 48) was subjected to a nucleophilic aromatic 
substitution reaction using 4-methoxy aniline and catalytic amount of conc. HCl in dioxane 
146 
to afford 136 in 82% yield.244 The higher yield was obtained due to the presence of a strong 
electron withdrawing nitro group which makes the 4-position of 178 highly electrophilic. 
Synthesis of 137 
2-Methyl-4,6-dichloropyrimidine 177 (Scheme 49) was subjected to a nucleophilic 
aromatic substitution using 4-methoxy aniline and catalytic amount of conc. HCl in 
dioxane to afford 122.244 The use of Pd/C as for hydrogenation  afforded 137 in 65 % yield. 
 
2-Methyl-4,6-dichloropyrimidine 177 (Scheme 49) was subjected to a nucleophilic 
aromatic substitution using 4-methoxy aniline and catalytic amount of conc. HCl in 
dioxane to afford 122.244 The use of Pd/C as for hydrogenation  afforded 137 in 65 % yield. 
Scheme 49. Synthesis of 137 
 
Reagents and conditions : a) N-methyl-4-methoxyaniline, cat. HCl (conc.),  2 h, 120 oC, 
MW,  dioxane, 75 % yield  b) H2 (50 psi), 10 % Pd/C, rt, 65 % yield. 
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Synthesis of 138-139 
 
Scheme 50. Synthesis of 138-139 
 
 
 
Reagents and conditions : a) N-methyl-4-methoxyaniline, cat. HCl (conc.), 2 h, 120 oC, 
MW, dioxane b) Al(Me)3, Pd(PPh3)4, THF, 90 oC, 2 h, 65 % yield c) N-methyl 4-
methoxyaniline, cat. HCl (conc.), 2 h, 120 oC, MW,  dioxane  d) Al(Et)3, Pd(PPh3)4, THF, 
90 oC, 2 h, 58 % yield. 
 
2-Methyl-4,6-dichloropyrimidine 177 (Scheme 50) was subjected to a nucleophilic 
aromatic substitution reaction using 4-methoxyaniline and catalytic amount of conc. HCl 
in dioxane to afford 122 which was then coupled with the appropriate trialkyl aluminium  
148 
reagent using palladium catalyst to afford 138 and 139  in 65% and 58 % yields 
respectively. 
Synthesis of 140 
 
Table 13.  Maximum temperature afforded with different types of ammonia solution . 
 
 
 
Ammonia type used 
 
Max. Temperatute 
attained in microwave 
(MW) 
 
Yield 
Aqueous (35 %) 120 oC No product formed 
Ammonia in MeOH (7 N) 140 oC 10% 
Ammonia in EtOH (2 N) 160 oC 65% 
 
Scheme 51. Synthesis of 140 
 
 
149 
Reagents and conditions : a) NH3 in ethanol solution, 160 °C, 3 h , MW, 42% yield b N-
methyl N-methyl-4-methoxyaniline, cat. HCl (conc.),  2 h, 120 oC, MW,  dioxane, 75 % 
yield. 
 
For the amination of 177 (Scheme 51) at the 6-position, it was treated with aqueous 
ammonia solution at 100 ºC  to afford 179 (Table 11).  The reaction was unsuccessful, and 
so ammonia in methanol and ethanol were attempted to achieve higher reaction 
temperatures. Ammonia in ethanol afforded microwave tempeartures 20º  to 40º higher and 
also afforded better yields compared to ammonia in methanol (Table 11). Compound 179  
(Scheme 51) was subjected to a nucleophilic aromatic substitution using 4-methoxyaniline 
and catalytic amount of conc. HCl in dioxane to afford 140. However, this reaction 
failed.244  
Why reaction may have failed:  The displacement of the 6-Cl of 177 with an amino group 
makes the 4C-Cl of 179 less electrophilic which could be the reason of the failure of the 
displacement reaction. The reverse sequence of addition was attempted which worked 
successfully to afford 140. First, displacement with aniline was carried out to afford 122 in 
75 % yield, followed by amination with a solution of ammonia in ethanol to afford 140 in 
42 % yield. 
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Synthesis of 141 
 
Diazonium salt formation 
 
Scheme 52. Synthesis of 181 
 
 
 
Reagents and conditions : a) Pivalic anhydride, 120 °C, 3 h, 65 % yield b) NH3 in ethanol 
solution, 160 °C, 3 h , MW, 42 % yield c) i. NaNO2, H2O, HCl, 0 °C ii. CuCN, H2O, 60 
°C, 15 min. 
 
Compound  135 (Scheme 52) was treated with an ethanol solution of ammonia to yield 180 
which in turn was converted to a diazonium salt using sodium nitrite under acidic 
conditions, and then converted to the nitrile using copper cyanide. The use of acid in this 
reaction led to the cleavage of the methoxy group into the phenol (182 formation). 
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Fusion method 
 
Scheme 53. Attempted synthesis of 141 using fusion method 
 
 
Reagents and conditions : a) N-methyl 4-methoxy aniline, cat. HCl (conc.),  2 h, 120 oC, 
MW,  dioxane  b) CuCN, fusion, 150 °C, 2 h  
 
The failure of the previous synthesis of 141 prompted Fusion method in which the 
reaction of 122 and  copper cyanide was performed in a sealed microwave vial at 150 °C  
without the use of any solvent but it too failed to afford 141 (Schemes 53).138 
Why the reaction may have failed: The lack of solvent might be the reason behind failure 
of the reaction, as optimum collision between molecules is required to cause bond 
formation. 
Scheme 54. Attempted synthesis of 141 using CuCN-DMSO mixture. 
 
 
Reagents and conditions : CuCN, DMSO, argon, 100 oC, 12  
152 
Next, DMSO was added as a solvent to determine the effect of adddition of a high boiling 
solvent, however this too failed to afford 141 (Scheme 54).  
 
Scheme 55. Attempted synthesis of 141 using DABCO as base 
 
 
Reagents and conditions : CuCN, DABCO, DMSO : H2O , 9:1, 65 °C, 30 h 
 
 
Another reaction with DMSO-water mixture, and DABCO as base was attempted to afford 
141 but was also unsuccessful (Scheme 55). 
 
 
Rosenmund-von Braun reaction 137 
 
Scheme 56. Attempted synthesis of 141 using Rosenmund-von Braun reaction. 
 
 
 
Reagents and conditions : CuCN, DMF, 180 oC, 12 h 
 
153 
Next, the Rosenmund-von Braun reaction with copper cyanide in a polar solvent like DMF 
and NMM at higher temperatures (180 oC) was attempted but also failed to yield the desired 
nitrile product 141 (Scheme 56).137 
Why the reaction may have failed: The 6-Cl is not electrophilic enough for reaction to 
occur. The high temperature and longer hours did not work successfully here. 
Another reason: Rosenmund-von Braun reaction works better with iodides rather than 
chlorides, so next iodides should be attempted 
 
Scheme 57. Synthesis of 141 
 
 
 
Reagents and conditions : CuCN, DMF, 180 oC, 12 h, 22 % yield. 
 
Another high boiling solvent, NMP, was used instead of DMF but also failed to afford 
141.The Rosenmund-von Braun reaction works better with iodides rather than chlorides,137 
and so, 142 (Scheme 57) with a 6-I was treated with copper cyanide iwhich in a high boiling 
solvent like DMF finally worked successfully with complete disappearance of the starting 
material on TLC affording the desired nitrile 141. 
154 
It was found that for the substitution reactions, it always better to do reactions on iodides 
or bromides than chlorides as iodides/bromides are better leaving groups. Chlorides are 
better for SNAr kind of reactions, where electrophilicity plays more important role. 
 
Scheme 58. Attempted variation of the classic Sandmeyer reaction. 
 
 
Reagents and conditions :  a) Pivalic anhydride, 120 °C, 3 h b) NH3 in ethanol solution, 
160 °C, 3 h , MW c)  t-BuNO2, ACN, HCl, 0 °C, 15 min. d) AgCF3, -78 °C, 3 h 
 
Synthesis of 143- Trifluromethylation reaction. 
 
Wang et al.139  used a novel strategy for aromatic trifluromethylation by substituting an 
aromatic amino group with a trifluromethyl. This was a trifluromethylation adaption of the 
classical Sandmeyer reaction. 
155 
 
To 180 (Scheme 58) dissolved in acetonitrile, was added dropwise a solution of tert-butyl 
nitrite and HCl to afford the diazonium salt 183. The change in Rf on TLC confirmed the 
presense of a new intermediate. To this, in situ generated AgCF3, which was formed by the 
addition of silver fluoride into TMSCF3, was added, however the reaction failed to afford 
183a (Scheme 58).  
 
Trifluromethylation using Ruppert-Prakash reagent 139 
 
Scheme 59. Synthesis of  trifluoromethylcarbene 185 
 
Scheme 60. Attempted synthesis of 143 
 
 
Reagents and conditions :  KF, CuI, TMSCF3, NMP, 70 °C, 12 h 
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Then, trifluromethylation was attempted using spray-dried potassium fluoride and copper 
iodide. TMSCF3 Compound 184 with potassium fluoride leads to the formation of 
trifluoromethylcarbene 185 (Scheme 59) which then reacts with chloride 122 or iodide 142 
but the reaction failed to afford 143 (Scheme 60).139 
Reason behind failure of the reaction: As seen in the earlier case with nitrile formation, 
chlorides are not good leaving groups, and so iodides were used this time. The reaction 
might have failed as the 6-C position is  not electrophilic enough. Also super-dry potassium 
floride is required for this reaction, and spray drying was not possible in the lab conditions, 
and that might have been the reason behind reaction failure. Radical reactions (single 
electron transfer) could be tried next. 
Scheme 61. Attempted synthesis of 143 
 
 
 
 
Reagents and conditions : CF3SO3-+S-(CF3)(Ph)2, Cu, DMF, 60 °C, 18 h 
 
Another trifluoromethylation method  used by Georgsson et al.140 was attempted in which 
copper was added to a solution of diphenyl(trifluoromethyl)sulfonium 
trifluoromethanesulfonate and 142 in DMF under N2 but was unsuccessful (Scheme 61).245 
It was proposed (S)- (trifluoromethyl)diphenylsulfonium triflate is first reduced by copper 
157 
via single electron transfer which then decomposes rapidly to produce the CF3 radical, 
which further generates CuCF3. 
 
Scheme 62. Attempted synthesis of 143 
 
Reagents and conditions:  NaSO2CF3, tBuOOH, H2O, rt, 46 h 
Stout et al.141 attempted trifluoromethylation following the protocol of Baran and co-
workers142 (tBuOOH, aqueous NaSO2CF3, or ZnSO2CHF2) which smoothly converted the 
starting material to the trifluorinated analogues. However, when this method was attempted 
on the pyrimidine scaffold 137, it failed to afford 143 (Scheme 62). 
Reason behind reaction failure: Both radical reactions failed to work. One reason might be 
that 6-C position is not electrophilic enough. As seen earlier in Suzuki or Negishi coupling 
case, reactions worked well when metals were used which could coordinate with 
pyrimidine nitrogen resulting in increased electrophilicity at 6-Cl. 
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Scheme 63. Synthesis of 143 
 
 
 
Reagents and conditions :   phenanthroline/CuCF3 complex, DMF, 80 °C, 8 h , MW, 85 % 
yield 
 
Trifluoromethylation was finally achieved when iodide 142 (Scheme 63) was treated with 
phenanthroline−CuCF3 complex  reagent 186, and DMF as solvent using microwave 
irradiation at 80 ºC for 8 hours.246  
After attempting various aromatic substitution reactions, it was observed that- 
1. Iodides or bromides should be used as they are better leaving groups compared to 
chlorides 
2. Fluorides/chlorides are better for SNAr reactions, as electrophilicity is more 
important there. 
3. If iodides do not work, radical reactions could be attempted. To make position more 
electrophilic in pyrimidines, nitrogen could be coordinated with metals like zinc, 
copper which form a complex with nitrogen, and decrease electrophilicity of 
position next to it, facilitating substitution/coupling reactions. 
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Synthesis of 144-147 
Appropriate 4,6-dichloropyrimidine-5-amines 190 and 191 (Scheme 64) were treated with 
4-methoxyaniline and catalytic amount of conc. HCl to afford the corresponding 144 and 
145 in 70-75 % yields. Compound 145 was then deprotonated with sodium hydride and 
treated with the appropriate alkyl halides to afford the corresponding N5-alkylated 146-
147 in 35-65% yield. 
Scheme 64. Synthesis of 144-147 
 
Reagents and conditions: a) N-methyl-4-methoxyaniline, cat. HCl (conc.), 2 h, 120 oC, 
MW, dioxane b) NaH, MeI or EtI, DMF, 2 h, 0 ºC-rt, 35-65 % yield. 
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Synthesis of 148-150 
 
Scheme 65. Synthesis of 149 
  
Reagents and conditions : a) N-methyl-4-methoxyaniline, cat. HCl (conc.),  2 h, 120 oC, 
MW,  dioxane, 72 % yield  b) NaH, MeI, DMF, 2 h, 0 ºC-rt, 22 % yield 
 
4,6-Dichloropyrimidine-2,5-diamine 187 (Scheme 65) was subjected to a nucleophilic 
aromatic substitution244 using 4-methoxyaniline and catalytic amount of conc. HCl in 
dioxane to afford 148 in 72 % yield. Reactions involving microwave irradiation rather than 
bench top worked with 15-25% better yields. Compound 148 was deprotonated with 
sodium hydride and treated with the appropriate alkyl hydride and treated with the 
appropriate alkyl halides to afford the corresponding N5-alkylated compounds 149-150 
(Schemes 65 and 66). Reactions involving combinations of cesium carbonate or potassium 
carbonate and dimethylformamide with microwave irradiation did not show complete 
consumption of starting material. The use of excess base or alkyl halide also did not afford 
the alkylated product exclusively. 
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Scheme 66. Synthesis of 150 
 
Reagents and conditions : a) N-methyl-4-methoxyaniline, cat. HCl (conc.),  2 h, 120 oC, 
MW,  dioxane, 72 % yield    b) ethyl iodide, DMF, 2 h, 0º C-rt, 53 % yield 
 
 
Two side products the 5-N,N-dimethylated 188 and the 2-N,5-N,N-trimethylated 189 were 
formed when 148 was deprotonated and treated with the methyl iodide which were easily 
isolated using column chromatography. The CHN elemental analysis confirmed the 
presence of 149 with C = 54.83%, H = 5.86%, N = 22.55%, Cl = 11.36 %. The Rf of 149 
was also 0.1-0.2 units lower than 188 and 189. In 1H NMR analysis, the 4-NH2 peak of 148 
can be seen at 4.7 ppm integrating for 2 protons, and the 2-NH2 peak at 2.98 ppm (exact 
peak positions known as they were compared with 2-methyl and 4-methyl compounds). In 
149, the 4-NH2 gets methylated, and the peak shifts to 4.84 ppm integrating for only 1 
162 
proton. The 2-NH2 peak shifts to 2.92 ppm still integrating for 2 protons. This confirmed 
that the methylation happened at 4-position.  
Synthesis of 151-155 : Starting materials 193 and 196 were synthesized for the synthesis 
of target compounds 151 and 153 respectively (Scheme 67). Compound 192 was first 
deprotonated with sodium hydride and treated with methyl iodide to afford the alkylated 
product 193 in 45% yield. However, an equal amount of dimethyl product 194 was formed 
as well. To obtain pure monomethylated product (193), 192 was treated with formaldehyde 
and sodium methoxide to yield the imine which was then reduced using sodium 
borohydride to afford pure 193 in 90% yield.  
Scheme 67. Synthesis of anilines 193 and 196. 
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Reagents and conditions: a) NaH, MeI, DMF, 2 h, 0º C-rt b) i. (HCHO)n, NaOMe, MeOH  
ii. NaBH4, 85-90 % yield. 
Compound 195 (Scheme 67) was treated with formaldehyde and sodium methoxide to 
yield imine which was then reduced using sodium borohydride to afford 196 in 85 % 
yield. 
Scheme 68. Synthesis of 151-155 
 
 
 
Reagents and conditions: appropriate anilines, cat. HCl (conc.), 2 h, 120 oC, MW, dioxane, 
20-85 % yield 
Nucleophilic aromatic substitution reaction of 2-methyl-4,6-dichloro-5-aminopyrimidine 
177 (Scheme 68) with appropriately substituted amines in dioxane afforded compounds 
151-155 in 20-85% yields.229 Displacement reactions with bulky nucleophiles N-methyl-
2,3-dihydrobenzofuran-5-amine and 6-methoxy-1,2,3,4-tetrahydroquinoline required 
164 
longer reaction times compared to the other amines for complete disappearance of starting 
material estimated from TLC. Displacement reactions with 4-methoxyaniline and 4-
(methylthio)aniline afforded better yields than the methylated counterparts. Reactions 
involving microwave irradiation afforded 15-25% better yields than conventional bench-
top conditions. 
Synthesis of 157-160 
 
Scheme 69. Synthesis of 157-160 
 
 
 
 
 
Reagents and conditions : appropriate anilines,  cat. HCl (conc.),  5 h, 150 oC, MW,  
butanol, 32-65% yields. 
Table 14. Chemical shift of 5-NH2 protons using 1H NMR (DMSO-d6-400MHz) 
Compound Chemical shift Compound Chemical shift 
122 3.99 155 5.18 
151 4.32 156 3.04 
152 4.50 159 3.5 
153 3.98 160 3.72 
165 
154 5.11 177 5.92 
A 1H NMR study was also done in DMSO-d6 to compare the conformation of 122 with 
154. The N-C4 bond (‘a’ bond, Scheme 68) connecting the phenyl ring and the pyrimidine 
ring in 164 is freely rotatable, while it is restricted in 122 due to the presence of 4N-Me 
group. According to the 1H NMR spectrum, the 5-NH2 protons of 154 are less shielded 
(chemical shift at 5.11 ppm) than  
the 5-NH2 of 4N-methylated 122 (chemical shift at 3.99 ppm). This suggested a nearby 
diamagnetic anisotropic cone in 122 which is missing in 154. Due to the bulk of the 4N-
Me group, the conformation of 122 is restricted, and the phenyl ring of 122 positions itself 
on the top of the 5-NH2 protons (conformation shown in Scheme 28) leading to the 
observed shielding effect. Due to the absence of 4N-Me group in 154, 4N-H places itself 
on the top of the 5-NH2 protons, and so no shielding effect is observed as was found in the 
case of 122.83 
Some effects observed are- 
1. The 5-NH2 protons of all the final products are more shielded compared to the 5-NH2 
protons of the starting material 177 which come at 5.92 ppm. This suggested a nearby 
diamagnetic anisotropic cone due to the placement of aniline on top of 5-NH2. 
2. The 4-NMe compounds (122, 151-156, 159-160) are shielded compared to the 4N-H 
compounds 154 and 155. Due to the bulk of the 4N-Me group, the conformation of the 
final compounds (other than 154 and 155) is restricted, and so, the phenyl ring positions 
itself on the top of the 5-NH2 protons leading to the observed shielding effect.83 
3. The disubstituted compounds 159 and 160 with 4,6-N-diMe are much more shielded 
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than their monosubstituted counterparts 122 and 151. This might have happened because 
both aniline rings might position themselves on the top of the 5-NH2 leading to a greater 
diamagnetic anisotropic cone, and hence a stronger shielding effect.  
Synthesis of 162-167 
 
Scheme 70. Synthesis of 198, 200 and 203a 
 
Reagents and conditions: a) i. (HCHO)n, NaOMe, MeOH ii. NaBH4, 75-85 % yields b) 
NaH, MeI, DMF, 2 h, 0º C-rt, 69% 
167 
Starting materials 198, 200 and 203a were synthesized for the synthesis of 163, 164 and 
166 respectively (Scheme 70). Compounds 197, 199 and 201 were treated with 
formaldehyde and sodium methoxide to afford the imines which were then reduced using 
sodium borohydride to afford corresponding 198, 200 and 202 respectively in 75-85% 
yields. Compound 202 was then deprotonated with sodium hydride, and treated with the 
methyl iodide to afford the corresponding alkylated product 203a in 79% yield. 
 
Scheme 71. Synthesis of 206 
 
 
 
Reagents and conditions:  a) 1. NaOMe, MeOH, rt, 30 min, 2. DMF, 100 °C, 6 h, b) NaOEt, 
EtOH, reflux, 4 h, Acetamidine HCl, c) H2SO4, EtOH, reflux, 2 
To synthesize the pyrrolo[2,3-d]pyrimidine scaffold 206 (Scheme 71), the acidic proton of 
ethyl cyanoacetate 203b was deprotonated using sodium methoxide and alkylated to afford 
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204 which was then cyclized using acetamidine hydrochloride to yield 205. Under acidic 
conditions, 205 cyclized to afford 206.228, 247 
Scheme 72. Synthesis of 162-167 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
 
 
 
 
Reagents and conditions: appropriate anilines, Dioxane, HCl, 140 °C, 2 h, MW, 42-65% 
yield. 
 
Direct cyclization of 6-amino-2-methylpyrimidin-4(3H)-one was also attempted with 
chloroacetaldehyde to afford 206 , but was unsuccessful.228 
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2-Methyl-pyrrolo[2,3-d]pyrimidine was subjected to nucleophilic aromatic substitution 
reaction using appropriate anilines and catalytic amount of conc. HCl in dioxane to afford 
162-167 in 42-65% yields (Scheme 72).244 
A 1H NMR study was done in DMSO-d6 to determine the conformation of 162-167 and 
was compared with the starting material 206 as shown in Table 13. 
Table 15. Chemical shift of aromatic 5-CH proton in 1H NMR (DMSO-d6-400MHz) 
Compound Chemical shift Compound Chemical shift 
206 6.52 165 5.9 
162 4.6 166 4.45 
163 4.75 167 4.65 
164 6.01   
 
The aromatic 5-CH proton of all the final products is more shielded compared to the same 
proton in the starting material 206 suggesting a nearby diamagnetic anisotropic cone. So, 
that’s why, we believe that the phenyl ring positions itself on the top of the 5-CH proton 
leading to the observed shielding effect.83 
 
 
Synthesis of 173-174 
 
 
 
Commercially available esters 207a-207b (Scheme 73) were alkylated with 6-bromo-1-
hexanol to afford alkylated intermediates 208a-208b. The intermediates were then 
oxidized using Dess-Martin Oxidation to the respective aldehydes 209a-209b. α-
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Bromination of the aldehydes with bromine-dioxane mixture at 0 ºC afforded the 
corresponding α-bromo aldehydes 210a-210b. The 
 
 
Scheme 73. Synthesis of 173-174 
 
 
 
Reagents and conditions: a) K2CO3, DMF, rt, 10 h b) Dess-martin reagent, DCM, rt, 5 h c) 
Br2, dioxane, DCM, rt, 2 h d) H2O/MeOH 1:1, CH3COONa, 50° C, 5 h e) 1 N NaOH f) 
NMM, CDMT, DMF, rt, 5 h g) 1 N NaOH 
 
Commercially available esters 207a-207b (Scheme 73) were alkylated with 6-bromo-1-
hexanol to afford alkylated intermediates 208a-208b. The intermediates were then 
oxidized using Dess-Martin Oxidation to the respective aldehydes 209a-209b. α-
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Bromination of the aldehydes with bromine-dioxane mixture at 0 ºC afforded the 
corresponding α-bromo aldehydes 210a-210b. The 5-substituted pyrrolo[2,3-
d]pyrimidines 211a-211b were then synthesized by condensation of 210a-210b with 2,4-
diamino-6-hydroxypyrimidine at 45 °C in the presence of sodium acetate. Subsequent 
hydrolysis with 3 N NaOH afforded key intermediates 2-amino-4-oxo-pyrrolo[2,3-
d]pyrimidin-5-yl-alkoxybenzoic acids 211a-211b, followed by coupling with (L)-diethyl 
glutamate esters using N-methylmorpholine and 6-chloro-2,4-dimethoxytriazine as the 
activating agents, to afford diesters 212a-212b. Final saponification of the diesters with 1 
N NaOH yielded the target 5-substituted pyrrolo[2,3-d]pyrimidines 173-174.  
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Synthesis of 175-176 
 
Scheme 74. Synthesis of 215 
 
  
Reagents and conditions: a) K2CO3, MeCN, rt, 10 h b) Dess-martin reagent, DCM, rt, 5 h 
c) 1. oxalyl chloride, DMSO, THF 2. TEA d) 1. NaBr, TEMPO, DCM/H2O (4:1), 0 °C 2. 
6% NaOCl, NaHCO3, 0 °C, 2 h..  
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Scheme 75. Synthesis of 218 
 
 
 
Reagents and conditions: a) EtOH, H2SO4, reflux, 6 h b) Cs2CO3, DMF, rt, 10 h c) Dess-
martin reagent, DCM, rt, 5 h d) 1. NaBr, TEMPO, DCM/H2O (4:1), 0 °C 2.  6% NaOCl, 
NaHCO3, 0 °C, 2 h e) PCC, DCM, 30 min, rt 
 
For the synthesis of the target compound 175, compound 207a (Scheme 74) was alkylated 
with 4-bromo-1-butanol to afford alkylated intermediates 214. The intermediate were then 
oxidized using Dess-Martin Oxidation but failed to afford 215. Similarly, for the synthesis 
of target compound 176, compound 207b (Scheme 75) was alkylated with 4-bromo-1-
174 
butanol to afford alkylated intermediates 217. Dess-Martin oxidation failed to afford 218 
and so different oxidation methods were attempted for the oxidation of both 214 and 217 
as summarized in Table 14 
Table 16.  Different oxidation methods used and their results. 
 
 
Swern oxidation afforded multiple products which were difficult to isolate using column 
chromatography. TEMPO oxidation worked successfully to afford 215 (Scheme 74). 
Compound 217 under TEMPO oxidation conditions cleaved to yield alcohol 216 (Scheme 
75). PCC oxidation was attempted which worked successfully to afford 218 (Scheme 75).  
With these reactions, it was observed that for heteroatoms, various kind of oxidation 
reactions should be attempted. Different reaction conditions ranging from - 78 ºC to rt 
should be tried. Different reactions could also range from partially acidic to basic 
conditions. TEMPO recation is run under partial acidic conditions, DMP under neutral, and 
Swern under basic conditions as TEA is used. Sulfur as a heteroatom could have formed a 
Type Reagents Temperature Product 
DMP DMP rt Multiple spots 
Swern DMSO, Oxalyl chloride, TEA - 78 ºC Multiple spots 
TEMPO TEMPO, 6% NaOCl, NaHCO3 
0 ºC 215  
PCC PCC in DCM rt 218 
175 
complex with DMP, and this might be the reason behind failure of the reaction. With PCC, 
that complex did not form, and reaction worked successfully. 
 
Synthesis  of 175 
α-Bromination of the aldehyde 215 (Scheme 76) with bromine-dioxane mixture at 0 ºC 
afforded the α-bromo aldehydes 216 (Scheme 76). The 5-substituted pyrrolo[2,3-
d]pyrimidines 217 was then synthesized by condensation of 216 with 2,4-diamino-6-
hydroxypyrimidine at 45 °C in the presence of sodium acetate. Subsequent hydrolysis with 
3 N NaOH afforded key intermediate 2-amino-4-oxo-pyrrolo[2,3-d]pyrimidin-5-yl-
alkoxybenzoic acid 218, followed by coupling with (L)-diethyl glutamate esters using N-
methylmorpholine and 6-chloro-2,4-dimethoxytriazine as the activating agents, to afford 
diesters 219. Final saponification of the diesters with 1 N NaOH yielded the target 5-
substituted pyrrolo[2,3-d]pyrimidines 175.  
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Scheme 76. Synthesis of 175 
 
 
Reagents and conditions: c) Br2, dioxane, DCM, rt, 2 h d) H2O/MeOH 1:1, CH3COONa, 
50° C, 5 h e) 1 N NaOH f) NMM, CDMT, DMF, rt, 5 h g) 1 N NaOH 
 
 
 
 
 
 
  
177 
V. EXPERIMENTAL 
 
 
All evaporations were carried out in vacuum with a rotary evaporator. Analytical samples 
were dried in vacuo in a CHEM-DRY drying apparatus over P2O5 at 50 °C. Melting points 
were determined either using a MEL-TEMP II melting point apparatus with FLUKE 51 
K/J electronic thermometer or using an MPA100 OptiMelt automated melting point system 
and are uncorrected. Nuclear magnetic resonance spectra for proton (1H NMR) were 
recorded on the Bruker Avance II 400 (400 MHz) or Bruker Avance II 500 (500 MHz) 
NMR systems with TopSpin processing software. The chemical shift values (δ) are 
expressed in ppm (parts per million) relative to tetramethylsilane as an internal standard: 
s, singlet; d, doublet; dd, doublet of doublet; t, triplet; q, quartet; m, multiplet; br, broad 
singlet; td, triplet of doublet; dt, doublet of triplet; quin, quintet. Thin-layer 
chromatography (TLC) was performed on Whatman® PE SIL G/UV254 flexible silica gel 
plates and the spots were visualized under 254 and 365 nm ultraviolet illumination. 
Proportions of solvents used for TLC are by volume. All analytical samples were 
homogeneous on TLC in at least two different solvent systems. Column chromatography 
was performed on the silica gel (70 to 230 meshes, Fisher Scientific) column. Flash 
chromatography was carried out on the CombiFlash® Rf systems, model COMBIFLASH 
RF. Pre-packed RediSep® Rf normal-phase flash columns (230 to 400 meshes) of various 
sizes were used. The amount (weight) of silica gel for column chromatography was in the 
range of 50-100 times the amount (weight) of the crude compounds being separated. 
Elemental analyses were performed by Atlantic Microlab, Inc., Norcross, GA. Element 
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compositions are within ± 0.4% of the calculated values. Fractional moles of water or 
organic solvents frequently found in some analytical samples could not be prevented 
despite 24 to 48 hours of drying in vacuo and were confirmed where possible by their 
presence in the 1H NMR spectra. High Perfomance Liquid Chromatography (HPLC) was 
performed on Waters® 600E Multisolvent Delivery System, components: Waters® 600 
Controller (model code: 600), 600E Pump (model code: 60F), Waters® 2487 Dual λ 
Absorbance Detector. Mobile phase was an aqueous blend of water with a miscible, polar 
organic solvent acetonitrile.  
6-chloro-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (122) 
2-Methyl-4,6-dichloropyrimdine (2g, 11.23 mmol, 1 equiv) and the N-methyl-4-
methoxyaniline (13.48 mmol, 1.2 equiv) were dissolved in dioxane (15 mL). To this 
solution, was added 37 % HCl (cat.). The mixture was heated at 120 ºC in microwave and 
stirred for 1.5 h. Then the reaction mixture was cooled to room temperature. Neutralization 
was done by the addition of aq. NH4OH. The butanol is then stripped off. Silica gel was 
added and the solvent evaporated to obtain a plug. Purification by column chromatography 
using hexanes and ethyl acetate (10:1 to 1:2) afforded a brown solid in 75 % yield. TLC Rf 
0.5 (EtOAc: Hex; 1:1), 1H NMR (CDCl3, 400MHz): δ 2.55 (s, 3H, 2CH3), 3.44 (s, 3H, 
4NCH3), 3.84 (s, 3H, 4’OCH3), 2.55 (s, 2H, NH2), 6.90-6.92 (d, 2H, J = 8.8 Hz), 7.06-7.08 
(d, 2H, J = 8.8 Hz), Anal. calcd. for C13H15ClN4O: C = 56.02%, H = 5.42%, N = 20.10%, 
Cl = 12.72%, Found C = 56.29%, H = 5.51%, N = 20.00%, Cl = 12.55%, M.P.= 109-110º 
C. 
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6-chloro-N4-(4-methoxyphenyl)-N4,N5-2-trimethylpyrimidine-4,5-diamine (123) 
Sodium hydride (29 mg, 1.1 equiv, 1.18 mmol) was added to a 3-neck flask. DMF (10 mL) 
was added under inert conditions. The N-methyl-4-methoxyaniline (300 mg, 1 equiv, 1.08 
mmol) compound is then added at 0 ºC. After 20 minutes when the nucleophile is 
generated, methyl iodide (260 mg, 1.5 equiv, 1.84 mmol) is added dropwise and reaction 
was run at room temperature for 2 hours. DMF is then stripped off and the reaction mixture 
was neutralized to pH 8. The compound was then extracted in the organic layer using ether 
and dried under sodium sulfate. Silica gel was added and the solvent evaporated to obtain 
a plug. Purification by column chromatography using hexanes and ethyl acetate (10:1 to 
1:2) afforded a light brown solid in 35 % yield. TLC Rf 0.62 (EtOAc: Hex; 1:1), 1H NMR 
(400 MHz, DMSO-d6): δ 2.26 (s, 3H, 5-NHCH3), 2.39 (s, 3H, 2CH3), 3.31 (s, 3H, 4NCH3), 
3.74 (s, 3H, 4’OCH3), 6.87-6.89 (d, 2H, J = 8.8 Hz), 6.98-7.00 (d, 2H, J = 8.8 Hz), Anal. 
calculated for C14H17ClN4O . 0.08C6H14:  C = 58.03%, H = 6.09%, N = 18.69%, Cl = 
11.83%, Found C = 58.06%, H = 5.97%, N = 18.76%, Cl = 11.85%, M.P. = 67-68º C. 
6-chloro-N4-(4-methoxyphenyl)-N4,N5,N5,2-tetramethylpyrimidine-4,5-diamine 
(124) 
Sodium hydride (29 mg, 1.1 equiv, 1.18 mmol) was added to a 3-neck flask. DMF (10 mL) 
was added under inert conditions. The N-methyl-4-methoxyaniline (300 mg, 1 equiv, 1.08 
mmol) compound is then added at 0 ºC. After 20 minutes when the nucleophile is 
generated, the alkyl halide (252 mg, 1.5 equiv, 1.61 mmol) is added dropwise and reaction 
was run at room temperature for 2 hours. DMF is then stripped off and the reaction mixture 
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was neutralized to pH 8. The compound was then extracted in the organic layer using ether 
and dried under sodium sulfate. Silica gel was added and the solvent evaporated to obtain 
a plug. Purification by column chromatography using hexanes and ethyl acetate (10:1 to 
1:2) afforded a brown solid in 50 % yield. TLC Rf 0.65 (EtOAc: Hex; 1:1), 1H NMR 
(CDCl3, 400MHz): δ 2.14 (s, 6H, 5-N-diCH3), 2.54 (s, 3H, 2CH3), 3.37 (s, 3H, 4NCH3), 
3.83 (s, 3H, 4’OCH3), 6.87-6.89 (d, 2H, J = 8.8 Hz), 7.08-7.10 (d, 2H, J = 8.8 Hz). Anal. 
calculated for C15H19ClN4O. 0.08C6H14: C, 59.27; H, 6.46; N, 17.86; Cl, 11.30, Found C = 
59.16%, H = 6.37%, N = 17.71%, Cl = 11.23%, M.P. = 71-73º C. 
6-chloro-N5-ethyl-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine 
(125) 
Compound 122 (100 mg, 0.25 mmol) was taken in a 3-neck round bottom flask covered 
with a septum, an adapter and a stopper. NaH (9.47 mg, 1.1 equiv) was added quickly and 
was diluted with 3 mL of DMF. The reaction is kept under argon for the entire time. After 
10 min, ethyl iodide (84 mg, 1.5 equiv, 0.54 mmol) was added and remaining DMF (2 mL) 
was added quickly after that. The reaction was allowed to run under argon for 4 hrs at room 
temperature. DMF was stripped off using high pressure. The product was then extracted 
using ethyl acetate and dried under sodium sulfate for half an hour. Ethyl acetate was then 
evaporated using rotary evaporator at 36 ºC. Silica gel was added and the solvent 
evaporated to obtain a plug. Purification by column chromatography using hexanes and 
ethyl acetate (10:1 to 1:2) afforded a light brown solid in 68 % yield. TLC Rf 0.72 (EtOAc: 
Hex; 1:1), 1H NMR (400 MHz, DMSO-d6): ∂ 0.64 (t, 3H, CH3), 2.40 (s, 3H, 2-CH3), 2.62-
2.64 (q, 2H, 5-N-CH2), 3.74 (s, 3H, NCH3), 3.32 (s, 3H, OCH3), 6.88-6.90 (d, 2H, J = 8.8 
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Hz), 7.02-7.04 (d, 2H, J = 8.8 Hz), Anal. calculated for C15H19ClN4O: C, 58.73; H, 6.24; 
N, 18.26; Cl, 11.55; Found C = 58.70%, H = 6.22%, N = 18.38%, Cl = 11.46%, M.P. = 84-
85◦ C. 
6-chloro-N4-(4-methoxyphenyl)-N4,2-dimethyl-N5-propylpyrimidine-4,5-diamine 
(126·HCl) 
Sodium hydride (29 mg, 1.1 equiv, 1.18 mmol) was added to a 3-neck flask. DMF (10 mL) 
was added under inert conditions. The N-methyl-4-methoxyaniline (300 mg, 1 equiv, 1.08 
mmol) compound is then added at 0 ºC. After 20 minutes when the nucleophile is 
generated, propyl iodide (252 mg, 1.5 equiv., 1.61 mmol.) is added dropwise and reaction 
was run at room temperature for 2 hours. DMF is then stripped off and the reaction mixture 
was neutralized to pH 8. The compound was then extracted in organic layer using ether 
and dried under magnesium sulfate. Silica gel was added and the solvent evaporated to 
obtain a plug. Purification by column chromatography using hexanes and ethyl acetate 
(10:1 to 1:2) afforded a brownish semi solid in 78 % yield. The product was converted into 
a HCl salt using HCl gas in ether solution. TLC Rf  0.88 (EtOAc: Hex; 1:1), 1H NMR 
(DMSO-d6, 400MHz): δ 0.65(t, 3H,CH3, J = 7.6 Hz), 0.98-1.02 (m, 2H, CH2), 2.40 (s, 3H, 
2-CH3), 2.52-2.55 (m, 2H, CH2, J = 7.6 Hz), 3.33 (s, 3H, 4’OCH3),  3.45 (s, 1H, 5-NH), 
3.74 (s, 3H, 4NCH3), 6.87-6.89 (d,2H, J = 8.8 Hz), 6.99-7.01 (d,2H, J = 8.8 Hz), Analysis 
calculated for C16H21ClN4O.0.4H2O.1.0HCl, C = 52.72%, H = 6.31, N = 15.37%, Cl = 
19.45%, Found C = 53.04%, H = 5.92, N = 15.34%, Cl = 19.13%, M.P. for 126·HCl = 107 
◦ C.  
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N5-butyl-6-chloro-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine 
(127·HCl) 
Sodium hydride (29 mg, 1.1 equiv, 1.18 mmol) was added to a 3-neck flask. DMF (10 mL) 
was added under inert conditions. The aniline (300 mg, 1 equiv, 1.08 mmol) compound is 
then added at 0 ºC. After 20 minutes when the nucleophile is generated, butyl iodide (252 
mg, 1.5 equiv, 1.61 mmol) is added dropwise and reaction was run at room temperature for 
2 hours. DMF is then stripped off and the reaction mixture was neutralized to pH 8. The 
compound was then extracted in organic layer using ether and dried under magnesium 
sulfate. Silica gel was added and the solvent evaporated to obtain a plug. Purification by 
column chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded a brownish 
semisolid in 62 % yield. The product was converted into a HCl salt using HCl gas in ether 
solution.  TLC Rf 0.90 (EtOAc: Hex; 1:1) 1H NMR (CDCl3, 400MHz): δ 0.80-0.84 (t, 3H, 
CH3, J = 7.6 Hz), 1.05-1.17 (m, 4H, CH2), 2.56(s, 3H, CH2), 2.65-2.67 (m, 2H, CH2), 2.84 
(s, 1H, NH), 3.43 (s, 3H, 4NCH3), 3.83 (s, 3H, 4’OCH3), 6.87-6.89 (d,2H, J = 8.8 Hz), 
6.99-7.01 (d, 2H, J = 8.8 Hz). Analysis calculated for (C17H23ClN4O.1.0HCl) C = 55.14%, 
H = 6.26, N = 15.13%, Cl = 19.15%., Found C = 54.86%, H = 6.52, N = 15.08%, Cl = 
18.92%, M.P. for 127·HCl = 119-123 ◦ C.  
6-chloro-N5-isobutyl-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine 
(128) 
 
Sodium hydride (29 mg, 1.1 equiv, 1.18 mmol) was added to a 3-neck flask. DMF (10 mL) 
was added under inert conditions. The aniline (300 mg, 1 equiv, 1.08 mmol) compound is 
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then added at 0 ºC. After 20 minutes when the nucleophile is generated, isobutyl iodide 
(252 mg, 1.5 equiv, 1.61 mmol) is added dropwise and reaction was run at room 
temperature for 2 hours. DMF is then stripped off and the reaction mixture was neutralized 
to pH 8. The compound was then extracted in organic layer using ether and dried under 
magnesium sulfate. Silica gel was added and the solvent evaporated to obtain a plug. 
Purification by column chromatography using hexanes and ethyl acetate (10:1 to 1:2) 
afforded a light brown semi solid in 65 % yield. TLC Rf 90 (EtOAc: Hex; 1:1) 1H NMR 
(CDCl3, 400MHz): δ 0.72 (s, 3H,CH3), 0.74 (s, 3H,CH3), 1.25-1.33 (m, 1H, CH), 2.49-
2.52 (t, 2H, CH2), 2.55(s, 3H, CH2), 2.96 (m, 1H, NH), 3.44 (s, 3H, 4NCH3), 3.82 (s, 3H, 
4’OCH3), 6.87-6.89 (d,2H, J = 8.8 Hz), 6.99-7.01 (d, 2H, J = 8.8 Hz). HPLC –98.47% pure, 
LRMS calculated for C17H23ClN4O = 334.85, found 334.85. 
6-benzyl-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (130) 
0.5 M solution of benzyl zinc chloride (5.7 mL, 4 equiv, 2.87 mmol) and 
tetrakis(triphenylphosphine)palladium (0.05 equiv, 36 µmol) was added to a sloution of 
iodopyrimidine (1equiv, 540 µmol) in dry THF at 60 ºC for 12 h under inert conditions. 
The reaction was stopped  and THF was stripped off. Silica gel was added and the solvent 
evaporated to obtain a plug. Purification by column chromatography using hexanes and 
ethyl acetate (10:1 to 1:2) afforded a brown semisolid in 35 % yield. TLC Rf 0.20 (EtOAc: 
Hex; 1:1) 1H NMR (DMSO-d6, 400MHz): δ 2.57 (s, 3H, 2CH3), 3.49 (s, 3H, 4NCH3), 3.79 
(s, 3H, 4’OCH3), 4.08 (s, 2H, CH2), 4.23 (s, 2H, NH2), 6.99-7.01 (d, 2H, aromatic), 7.22-
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7.32  (m, 7H, aromatic). HPLC –97.23% pure, HRMS calculated for C20H23N4O [M + H]+ 
335.1874, found 335.1862. 
N4-(4-methoxyphenyl)-N4,2-dimethyl-6-phenethylpyrimidine-4,5-diamine (131) 
The aniline 152 (1g, 2.9 mmol, 1 equiv) was hydrogenated using 5% Pd/C (200 mg, 20% 
w/w) in 15 mL methanol for 7 h under 50 psi. Palladium was then filtered using Celite® 
and washed several times with methanol. Methanol was then striped off. Silica gel was 
added and the solvent evaporated to obtain a plug. Purification by column chromatography 
using hexanes and ethyl acetate (10:1 to 1:2) afforded 131 in 35 % yield as a brownish 
semisolid. TLC Rf 0.35 (EtOAc: Hex, 1:1); 1H NMR (400 MHz, DMSO-d6): δ 2.41(s, 3H), 
2.80-2.84 (dd, J = 6.0Hz, J = 9.6Hz, 2H), 2.92-2.96 (dd, J = 6.1Hz, J = 10.2Hz, 2H), 3.25 
(s, 3H), 3.73 (s, 3H), 3.85 (s, 2H), 6.88 (m, 4H), 7.18 (m, 1H), 7.26 (s, 2H), 7.27 (s, 2H), 
HPLC –96.9% pure, HRMS calculated for C21H25N4O [M + H]+ 349.2031, found 
349.2030. 
N4-(4-methoxyphenyl)-N4,2-dimethyl-6-(phenylethynyl)pyrimidine-4,5-diamine 
(132) 
Copper iodide (0.16 equiv, 3.38 mmol) and bis(triphenylphosphine)palladium chloride 
(0.05 equiv, 67.5 mmol) were added to a solution of iodopyridine (1 equiv, 1.35 mmol) in 
10 mL trimethylamine under nitrogen gas and the resulted compound was stirred for 30 
min. Then phenylacetylene (2.5 equiv, 3.38 mmol) was added dropwise to the solution, 
and was stirred for 30 minutes. Silica gel was added and the solvent evaporated to obtain a 
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plug. Purification by column chromatography using hexanes and ethyl acetate (10:1 to 1:2) 
afforded 132 in 65% yield as a dark brown solid. TLC Rf 0.50 (EtOAc: Hex, 1:1); 1H NMR 
(400 MHz, DMSO-d6) δ 2.41 (s, 3H), 3.34 (s, 3H), 3.76 (s, 3H), 4.19 (s, 2H), 6.95-6.97 (d, 
J = 8.9Hz, 2H), 7.07-7.09 (d, J = 8.9Hz, 2H), 7.42 (d, J = 1.3Hz, 1H), 7.44 (d, J = 2.3Hz, 
1H), 7.63-7.66 (m, 2H) Anal. calcd. for C21H20N4O: C, 73.23; H, 5.85; N, 16.27; Found C 
= 73.13%, H = 5.90, N = 16.11%. 
N-(4-chloro-6-((4-methoxyphenyl)(methyl)amino)-2-methylpyrimidin-5-
yl)acetamide (133) 
Compound 122 (50 mg, 0.18 mmol) was dissolved in 6 mL acetic anhydride and the 
reaction was run at 120 ºC for 5 h. The solvent was stripped off. Silica gel was added and 
the solvent evaporated to obtain a plug. Purification by column chromatography using 
hexanes and ethyl acetate (10:1 to 1:2) afforded a white solid in 75 % yield. TLC Rf 0.25 
(EtOAc: Hex; 1:1),  1H NMR (DMSO-d6, 400MHz): δ 1.6 (s, 3H, NAc.), 2.61 (s, 3H, 
2CH3), 3.42 (s, 3H, 4NCH3), 3.82 (s, 3H, 4’OCH3), 5.70 (s, 1H, NH),  6.94-6.96 (d, 2H, J 
= 8.8 Hz), 7.22-7.25 (d, 2H, J = 8.8 Hz) Analysis calculated for C15H17ClN4O2 : C = 
56.16%, H = 5.34, N = 17.47%, Cl = 11.05%; Found C = 56.33%, H = 5.52, N = 17.37%, 
Cl = 10.88%, M.P. = 158-159 ºC. 
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N-acetyl-N-(4-chloro-6-((4-methoxyphenyl)(methyl)amino)-2-methylpyrimidin-5-
yl)acetamide (134) 
Compound 122 (50 mg, 0.18 mmol) was dissolved in acetic anhydride (6 mL) and the 
reaction was run at 150 ºC for 5 h. The solvent was stripped off. Silica gel was added and 
the solvent evaporated to obtain a plug. Purification by column chromatography using 
hexanes and ethyl acetate (10:1 to 1:2) afforded a white solid in 45 % yield. TLC Rf 0.75 
(EtOAc: Hex; 1:1), 1H NMR (CDCl3, 400MHz): δ 1.99 (s, 6H, NPiv.), 2.61 (s, 3H, 2CH3), 
3.42 (s, 3H, 4NCH3), 3.82 (s, 3H, 4’OCH3), 6.94-6.96 (d, 2H, J = 8.8 Hz), 7.22-7.25 (d, 
2H, J = 8.8 Hz). Analysis calculated for C17H19ClN4O3: C, 56.28; H, 5.28; N, 15.44; Cl, 
9.77; Found C = 56.37%, H = 5.33%, N = 15.41%, Cl = 9.59%, M.P. = 179-181 ºC. 
N-(4-chloro-6-((4-methoxyphenyl)(methyl)amino)-2-methylpyrimidin-5-
yl)pivalamide (135) 
Compound 122 (50 mg, 0.18 mmol) was dissolved in pivalic anhydride (6 mL) and the 
reaction was run at 120 ºC for 2 h. The solvent was stripped off. Silica gel was added and 
the solvent evaporated to obtain a plug. Purification by column chromatography using 
hexanes and ethyl acetate (10:1 to 1:2) afforded a grey solid in 78 % yield. TLC Rf 0.28 
(EtOAc: Hex; 1:1); 1H NMR (DMSO-d6, 400MHz): δ 1.39 (s, 9H, CH3), 2.55 (s, 3H, 
2CH3), 3.78 (s, 3H, 4NCH3), 3.87 (s, 3H, 4’OCH3), 6.94-6.96 (d, 2H, J = 8.8 Hz), 7.22-
7.25 (d, 2H, J = 8.8 Hz). Analysis calculated for C18H23ClN4O2:  C, 59.58; H, 6.39; N, 
15.44; Cl, 9.77; Found C = 59.57%, H = 6.45, N = 15.25%, Cl = 9.65%, M.P. = 193-194º 
C. 
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6-chloro-N-(4-methoxyphenyl)-N,2-dimethyl-5-nitropyrimidin-4-amine (136) 
2-methyl-4,6-dichloro-5-nitropyrimdine (1 g, 4.81 mmol), 4-methoxyaniline (792 mg, 5.77 
mmol, 1.2 equiv) and catalytic amount of conc. HCl were added to a microwave vial in 15 
mL dioxane and heated at 120 ºC for 2 h. The reaction was stopped and dioxane was 
stripped off and reaction mixture neutralized to pH 8. Silica gel was added and the solvent 
evaporated to obtain a plug. Purification by column chromatography using hexanes and 
ethyl acetate (10:1 to 1:2) afforded a yellowish solid in 82 % yield. TLC Rf 0.70 (EtOAc: 
Hex; 1:1)  1H NMR (DMSO-d6, 400MHz): δ 2.62 (s, 3H, CH3), 3.53 (s, 3H, 4NCH3), 3.84 
(s, 3H, 4’OCH3), 6.86-6.88 (d, 2H, J = 8.8 Hz), 7.07-7.09 (d, 2H, J = 8.8 Hz), Analysis 
calculated for C13H13ClN4O3.0.2773CH3(CH2)4CH3 (Hexane was during the purification 
step): C, 52.95; H, 5.11; N, 16.84; Cl, 10.65; Found C = 53.04%, H = 4.74, N = 16.87%, 
Cl = 10.46%, M.P. = 91-93º C. 
N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (137) 
The aniline 122 (50 mg, 0.18 mmol) was hydrogenated using 5% Pd/C (10 mg, 20% w/w) 
in methanol (10 mL) for 7 h under 50 psi. Palladium was then filtered using Celiteâ and 
washed several times with methanol. Methanol was then striped off. Silica gel was added 
and the solvent evaporated to obtain a plug. Purification by column chromatography using 
hexanes and ethyl acetate (10:1 to 1:2) afforded a light brown solid in 65 % yield. TLC Rf 
0.40 (EtOAc: Hex; 1:1) 1H NMR (400 MHz, CDCl3): δ 2.70 (s, 3H, 2CH3), 3.54 (s, 3H, 
4NCH3), 3.86 (s, 3H, 4’OCH3), 4.22 (s, 2H, NH2), 6.92-6.94 (d, 2H, J = 8.8 Hz), 7.15-7.17  
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(d,2H, J = 8.8 Hz), 8.15 (s, 1H),  (C13H16N4O), HPLC –99.2% pure, HRMS calculated for 
C13H17N4O [M + H]+ 245.1404, found 245.1404, M.P. = 183-185º C. 
 
N`4-(4-methoxyphenyl)-N4,2,6-trimethylpyrimidine-4,5-diamine (138) 
 
To a solution of 153 in 10 mL THF was added trimethylaluminium (1M solution in THF, 
2 equiv, 718 µmol) and tetrakis(triphenylphosphine)palladium (0.1 equiv) and reaction was 
run under reflux and inert conditions. THF was then striped off. Silica gel was added and 
the solvent evaporated to obtain a plug. Purification by column chromatography using 
hexanes and ethyl acetate (10:1 to 1:2) afforded a light brown solid in 65 % yield. TLC Rf 
0.6 (EtOAc: Hex; 1:1), 1H NMR (400 MHz, DMSO-d6): δ 2.18 (s, 3H, 6CH3), 2.37 (s, 3H, 
2CH3), 3.24 (s, 3H, 4NCH3), 3.75 (s, 3H, 4’OCH3), 3.81(s, 2H, NH2), 6.89 (m, 4H), HPLC 
–97.8% pure, C14H19N4O [M + H]+ 259.1561 found 259.1548, M.P. 108-110 ºC. 
6-ethyl-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (139·HCl) 
To a solution of 153 in THF was added triethylaluminium (1M solution in THF, 2 equiv, 
718 µmol) and tetrakis(triphenylphosphine)palladium (0.1 equiv) and reaction was run 
under reflux and inert conditions. THF was then striped off. Silica gel was added and the 
solvent evaporated to obtain a plug. Purification by column chromatography using hexanes 
and ethyl acetate (10:1 to 1:2) afforded a light brown semisolid in 58 % yield. TLC Rf 0.68 
(EtOAc: Hex; 1:1), 1H NMR (400 MHz, DMSO-d6): δ 1.25 (s, 3H), 2.58 (s, 2H),  2.59 (s, 
3H, 2CH3), 3.00 (s, 2H, NH2),  3.43 (s, 3H, 4NCH3), 3.82 (s, 3H, 4’OCH3), 6.88-6.90  (d, 
2H, J = 8.8 Hz), 6.99-7.01  (d, 2H, J = 8.8 Hz), C15H20N4O, HPLC –99.5% pure, HRMS 
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calculated for C15H21N4O [M + H]+ 273.1717, found 273.1729, M.P. for 139·HCl = 200-
203 ºC. 
N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5,6-triamine (140) 
6-chloro-2-methylpyrimidine-4,5-diamine (50 mg, 1 equiv, 315 µmol), 4-methoxy aniline 
(65 mg, 1.5 equiv, 473 µmol) and catalytic amount of conc. HCl (1-2 drops) were added to 
a microwave vial in 15 mL dioxane and heated at 120 ºC for 2 h. The reaction was stopped 
and dioxane was stripped off and reaction mixture neutralized to pH 8. The resulting plug 
was loaded on to a silica gel column (2 × 12 cm) and eluted with CHCl3 followed by 3% 
MeOH in CHCl3 and then 5% MeOH in CHCl3. Fractions containing the product were 
pooled and evaporated to afford a white solid in 42 % yield. TLC Rf  0.75 (CH3OH: CHCl3; 
1:5), 1H NMR (DMSO-d6, 400MHz): δ 2.22 (s, 3H, CH3), 3.15 (s, 3H, 4NCH3),  3.70 (s, 
3H, 4’OCH3), 3.70-3.75 (s, 2H, 5NH2), 6.31 (s, 2H, 6NH2),   6.71-6.73 (d, C’2, 6 aromatic), 
6.81-6.83(d, C’3, 5), Analysis calculated for C13H17N5O. 0.23 H2O: C, 60.21; H, 6.61; N, 
27.01, Found C = 59.17%, H = 6.41, N = 26.76%, M.P. = 179-181 ºC. 
5-amino-6-((4-methoxyphenyl)(methyl)amino)-2-ethylpyrimidine-4-carbonitrile 
(141) 
Iodopyridine 142 (0.45 g, 1.22 mmol) was dissolved in 10 mL DMF and reaction is heated 
to 120 ºC with stirring and copper cyanide (3 equiv, 3.65 mmol) was added. There was 
complete conversion in 10 min. The reaction mixture was cooled to room temp. and filtered 
using Buchner funnel. Silica gel was added and the solvent evaporated to obtain a plug. 
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Purification by column chromatography using hexanes and ethyl acetate (10:1 to 1:2) 
afforded 141 in 22% yield as a yellow solid: TLC Rf 0.66 (EtOAc: Hex, 1:1); 1H NMR 
(400 MHz, DMSO-d6): δ 2.40 (s, 3H), 3.33 (s, 3H), 3.77 (s, 3H), 4.67 (s, 2H), 6.96-6.98 
(d, J = 8.9 Hz, 2H), 7.13-7.15 (d, J = 8.9 Hz, 2H) Anal. calcd. for C14H15N5O. 0.1 H2O: C, 
62.02; H, 5.65; N, 25.83, Found C = 61.99%, H = 5.52%, N = 25.58%, M.P. = 126.0-129.0 
ºC. 
6-iodo-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (142) 
Pyrimidine 122 (1g, 3.59 mmol) was added in portions in stirring aqueous HI (57 wt % aq., 
25 mL) at 0 ºC and then stirred overnight. The reaction mixture was then neutralized by 
adding 15 mL of ammonium hydroxide and then extracted using ethyl acetate and dried 
under magnesium sulfate. Silica gel was added and the solvent evaporated to obtain a plug. 
Purification by column chromatography using hexanes and ethyl acetate (10:1 to 1:2) 
afforded 0.92 g (65%) as a greenish solid: TLC Rf 0.65 (EtOAc: Hex, 1:1); 1H NMR 
(CDCl3) δ 1H NMR (400 MHz, CDCl3) δ 2.56 (s, 3H), 3.43 (s, 3H), 3.83 (s, 3H), 3.90 (s, 
2H), 6.88-6.89 (d, J = 8.8 Hz, 2H), 7.02-7.03 (d, J = 8.8 Hz, 2H) Anal. calcd. for 
C13H15IN4O: C, 42.18; H, 4.08; N, 15.13; I, 34.28, Found C = 42.48%, H = 4.24%, N = 
15.15%, I = 34.15%, M.P. = 88.8-91.0 ºC. 
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N4-(4-methoxyphenyl)-N4,2-dimethyl-6-(trifluoromethyl)pyrimidine-4,5-diamine 
(143) 
Trifluoromethylation was done using phenanthroline−CuCF3 complex reagent (1.3 equiv, 
122 mg, 0.389 mmol) and 10 mL DMF as solvent in microwave at 80 ºC in 8 hours. DMF 
is then stripped off. Silica gel was added and the solvent evaporated to obtain a plug. 
Purification by column chromatography using hexanes and ethyl acetate (10:1 to 1:2) 
afforded 143 in 85% yield as a dark brown solid: TLC Rf 0.82 (EtOAc: Hex, 1:1); 1H NMR 
(400 MHz, DMSO-d6): δ 2.43 (s, 3H), 3.30 (s, 3H), 3.74 (s, 3H), 4.35 (s, 2H), 6.93-6.96 
(dd, J = 3.6Hz, J = 8.8Hz, 2H), 7.06-7.08 (dd, J = 3.5Hz, J = 8.9Hz, 2H) HPLC – 98.8% 
pure, HRMS calculated for C14H15F3N4O [M + H]+ 313.1278, found 313.1261, M.P. = 125-
126 °C. 
6-chloro-N4-(4-methoxyphenyl)-N4-methylpyrimidine-4,5-diamine (144) 
4,6-dichloropyrimidin-5-amine (80 mg, 1equiv, 485 µmol), 4-methoxyaniline (101 mg, 
0.73 mmol, 1.5 equiv) and catalytic amount of conc. HCl were added to a microwave vial 
in 15 mL dioxane and heated at 120 ºC for 2 h. The reaction was stopped and dioxane was 
stripped off and reaction mixture neutralized to pH 8. Silica gel was added and the solvent 
evaporated to obtain a plug. Purification by column chromatography using hexanes and 
ethyl acetate (10:1 to 1:2) afforded a grey solid in 68 % yield. TLC Rf 0.39 (EtOAc: Hex; 
1:1), 1H NMR (CDCl3, 400MHz): δ 3.46 (s, 3H, 4NCH3), 3.84 (s, 3H, 4’OCH3), 3.5-3.8 (s, 
2H, 5NH2), 6.90-6.91 (d, C’2, 6 aromatic), 7.06-7.07 (d, C’3, 5), 8.2 (s, 1H, 2-H), Anal. 
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calcd. for C12H13ClN4O: C, 54.45; H, 4.95; N, 21.17; Cl, 13.39, Found C = 54.72%, H = 
5.00%, N = 20.93%, Cl = 13.12 %, M.P. = 126.0-129.0 ºC. 
6-chloro-2-ethyl-N4-(4-methoxyphenyl)-N4-methylpyrimidine-4,5-diamine 
(145·HCl) 
 
 
2-ethyl-4,6-dichloropyrimdine (100 mg, 0.52 mmol, 1 equiv.) and the N-methyl-4-
methoxyaniline (0.62 mmol, 1.2 equiv.) were dissolved in butanol (15 mL). To this 
solution, was added 37% HCl (cat.). The mixture was heated at 120 ºC in microwave with 
stirring for 1.5 h. Then the reaction mixture was cooled to room temperature. Neutralization 
was done by the addition of aq. NH4OH. The butanol is then stripped off. Silica gel was 
added and the solvent evaporated to obtain a plug. Purification by column chromatography 
using hexanes and ethyl acetate (10:1 to 1:2) afforded a grey solid in 68 % yield. TLC Rf 
0.75 (EtOAc: Hex; 1:1), 1H NMR (CDCl3, 400MHz): δ 1.35 (s, 3H, 2CH3), 2.84 (s, 2H, 
2CH2), 3.48 (s, 3H, 4NCH3), 3.84 (s, 3H, 4’OCH3), 6.92-6.94 (d, 2H, J = 8.8 Hz), 7.07-
7.08 (d, 2H, J = 8.8 Hz), Anal. calcd. for C14H17ClN4O.0.95H2O. 0.95HCl: C, 48.80; H, 
5.80; N, 16.26; Cl, 20.07; Found C = 48.92%, H = 5.82%, N = 15.94%, Cl = 20.04 %, M.P. 
= 135-136.0 ºC. 
 
6-chloro-2-ethyl-N4-(4-methoxyphenyl)-N4,N5-dimethylpyrimidine-4,5-diamine 
(146)  
 
 
Compound 145 (100 mg, 1 equiv, 0.36 mmol) was taken in a 3 necked round bottom flask 
covered with septums, and adapter. NaH (1.1 equiv, 0.39 mmol)  was added  and was 
diluted with 3 mL of DMF. The reaction is kept under argon for the entire time. After 10 
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min, methyl iodide (1.1 equiv., 0.39 mmol) was added and remaining DMF (2 mL) was 
added. The reaction was allowed to run under argon for 4 hrs at room temperature. DMF 
was stripped off using high pressure. The product was then extracted using ethyl acetate 
and dried under sodium sulfate. Silica gel was added and the solvent evaporated to obtain 
a plug. Purification by column chromatography using hexanes and ethyl acetate (10:1 to 
1:2) afforded a brown solid in 35 % yield. TLC Rf 0.21 (EtOAc: Hex; 1:1), 1H NMR (400 
MHz, DMSO-d6): δ 1.35 (s, 3H, 2CH3), 2.84 (s, 2H, 2CH2), 3.48 (s, 3H, 4NCH3), 3.84 (s, 
3H, 4’OCH3), 6.92-6.94  (d, 2H, J = 8.8 Hz), 7.07-7.08  (d,2H, J = 8.8 Hz), Anal. calcd. for 
C12H14ClN5O: C, 51.53; H, 5.04; N, 25.04; Cl, 12.67, Found  C = 51.70%, H = 5.13%, N 
= 24.98%, Cl = 12.53 %, M.P.  = 141-142 ºC. 
6-chloro-N5,2-diethyl-N4-(4-methoxyphenyl)-N4-methylpyrimidine-4,5-diamine 
(147) 
Compound 146 (100 mg, 1 equiv, 0.36 mmol) was taken in a 3 necked round bottom flask 
covered with septums and an adapter. NaH (1.1 equiv, 0.39 mmol)  was added and was 
diluted with 3 mL of DMF. The reaction is kept under argon for the entire time. After 10 
min, methyl iodide (1.1 equiv., 0.39 mmol) was added and remaining DMF (2 mL) was 
added. The reaction was allowed to run under argon for 4 hrs at room temperature. DMF 
was stripped off using high pressure. The product was then extracted using ethyl acetate 
and dried under sodium sulfate. Silica gel was added and the solvent evaporated to obtain 
a plug. Purification by column chromatography using hexanes and ethyl acetate (10:1 to 
1:2) afforded 147 (65 % yield as a light brown solid). TLC Rf 0.30 (EtOAc: Hex; 1:1),  1H 
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NMR (400 MHz, DMSO-d6): δ 1.35 (s, 3H, 2CH3), 2.84 (s, 2H, 2CH2), 3.48 (s, 3H, 
4NCH3), 3.84 (s, 3H, 4’OCH3), 6.92-6.94  (d, 2H, J = 8.8 Hz), 7.07-7.08    (d,2H, J = 8.8 
Hz), ), Anal. calcd. for C13H16ClN5O: C, 53.15; H, 5.49; N, 23.84, Cl, 12.07, Found  C = 
53.36%, H = 5.58%, N = 23.56%, Cl = 11.84 %, M.P. = 155-156ºC. 
6-chloro-N4-(4-methoxyphenyl)-N4-methylpyrimidine-2,4,5-triamine (148) 
4,6-dichloropyrimidine-2,5-diamine (40 mg, 1 equiv, 223 µmol), 4-methoxyaniline (46 
mg, 0.34 mmol, 1.5 equiv) and catalytic amount of conc. HCl were added to a microwave 
vial in 15 mL dioxane and heated at 120 ºC for 2 h. The reaction was stopped and dioxane 
was stripped off and reaction mixture neutralized to pH 8. Silica gel was added and the 
solvent evaporated to obtain a plug. Purification by column chromatography using hexanes 
and ethyl acetate (10:1 to 1:2) afforded a dark brown solid in 72 % yield. TLC Rf 0.45 
(EtOAc: Hex; 1:1) 1H NMR (CDCl3, 400MHz): 2.96 (s, 2H, 2NH2), δ 3.18 (s, 3H, 4NCH3), 
3.84 (s, 3H, 4’OCH3), 4.70 (s, 2H, 5NH2), 6.90-6.91 (d, C’2, 6 aromatic), 7.06-7.07 (d, 
C’3, 5). Anal. calcd. for C14H18ClN5O: C, 54.63; H, 5.90; N, 22.75; Cl, 11.52, Found C = 
54.83%, H = 5.86%, N = 22.55%, Cl = 11.36 %, M.P. = 172-174 ºC. 
6-chloro-N4-(4-methoxyphenyl)-N4,N5-dimethylpyrimidine-2,4,5-triamine (149) 
 
 
Compound 148 (100 mg, 1 equiv, 0.36 mmol) was taken in a 3 necked round bottom flask 
covered with septums, and an adapter. NaH (1.1 equiv, 0.39 mmol)  was added  and was 
diluted with 3 mL of DMF. The reaction is kept under argon for the entire time. After 10 
min, methyl iodide (1.1 equiv, 0.39 mmol) was added and remaining DMF (2 mL) was 
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added. The reaction was allowed to run under argon for 4 hrs at room temperature. DMF 
was stripped off using high pressure. The product was then extracted using ethyl acetate 
and dried under sodium sulfate. Silica gel was added and the solvent evaporated to obtain 
a plug. Purification by column chromatography using hexanes and ethyl acetate (10:1 to 
1:2) afforded a light brown solid in 22 % yield.  TLC Rf 0.6 (EtOAc: Hex; 1:1) 1H NMR 
(400 MHz, DMSO-d6): 2.92 (s, 2H, 2NH2), 2.97 (s, 3H, 4NCH3), 3.40 (s, 3H, 4’OCH3), 
3.83 (s, 3H, 5NCH3), 4.84 (s, 2H, 5NH), 6.90-6.91 (d, C’2, 6 aromatic), 7.06-7.07 (d, C’3, 
5), Anal. calcd. for C13H16ClN5O: C, 53.15; H, 5.49; N, 23.84; Cl, 12.07, Found  C = 
53.36%, H = 5.58%, N = 23.56%, Cl = 11.84 %, M.P. = 148-150 ºC. 
6-chloro-N5-ethyl-N4-(4-methoxyphenyl)-N4-methylpyrimidine-2,4,5-triamine (150) 
Compound 148 (100 mg, 1 equiv, 0.36 mmol) was taken in a 3 necked round bottom flask 
covered with septums, and an adapter. NaH (1.1 equiv, 0.39 mmol)  was added and was 
diluted with 3 mL of DMF. The reaction is kept under argon for the entire time. After 10 
min, ethyl iodide (1.1 equiv., 0.39 mmol) was added and remaining DMF (2 mL) was 
added. The reaction was allowed to run under argon for 4 hrs at room temperature. DMF 
was stripped off using high pressure. The product was then extracted using ethyl acetate 
and dried under sodium sulfate. Silica gel was added and the solvent evaporated to obtain 
a plug. Purification by column chromatography using hexanes and ethyl acetate (10:1 to 
1:2) afforded a dark brown solid in 53 % yield. TLC Rf 0.6 (EtOAc: Hex; 1:1),  1H NMR 
(400 MHz, DMSO-d6): 2.92 (s, 2H, 2NH2), 2.97 (s, 3H, 4NCH3), 3.40 (s, 3H, 4’OCH3), 
3.83 (s, 3H, 5NCH3), 4.84 (s, 2H, 5NH), 6.90-6.91 (d, C’2, 6 aromatic), 7.06-7.07 (d, C’3, 
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5)., Anal. calcd. for C14H18ClN5O: C, 54.63; H, 5.90; N, 22.75; Cl, 11.52, Found  C = 
54.83%, H = 5.86%, N = 22.55%, Cl = 11.36 %, M.P. = 90-92 ºC. 
 
6-chloro-N4,2-dimethyl-N4-(4-(methylthio)phenyl)pyrimidine-4,5-diamine (151) 
 
2-methyl-4,6 dichloro-5-aminopyrimdine (1 g, 5.44 mmol), N-methyl-4-
(methylthio)aniline (1.1 g, 7.18 mmol, 1.2 equiv) and catalytic amount of conc. HCl were 
added to a microwave vial in 15 mL dioxane and heated at 120 ºC for 2 h. The reaction 
was stopped and dioxane was stripped off and reaction mixture neutralized to pH 8. Silica 
gel was added and the solvent evaporated to obtain a plug. Purification by column 
chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded a light brown solid 
in 73 % yield. TLC Rf 0.80 (EtOAc: Hex; 1:1) 1H NMR (DMSO-d6, 400MHz): δ 2.39 (s, 
3H, CH3), 2.46 (s, 3H, 4NCH3), 3.34 (s, 3H, 4’OCH3), 4.32 (s, 2H, 5NH2), 6.92-6.94 (d, 
C’2, 6 aromatic), 7.22-7.25(d, C’3, 5). Anal. calcd. for C13H15ClN4S. 0.2C6H14: C, 54.17; 
H, 5.21; N, 18.41; Cl, 11.66; S, 10.54, Found C = 54.54%, H = 5.41%, N = 18.08%, Cl = 
11.34 %, S = 10.39 %, M.P. = 93-94 ºC. 
4-chloro-6-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylpyrimidin-5-amine 
(152) 
 
2-methyl-4,6-dichloro-5-aminopyrimdine (1 g, 5.62 mmol), 6-methoxy-1,2,3,4-
tetrahydroquinoline (1.1 g, 6.74 mmol, 1.2 equiv) and catalytic amount of conc. HCl were 
added to a microwave vial in 15 mL dioxane and heated at 120 ºC for 2 h. The reaction 
was stopped and dioxane was stripped off and reaction mixture neutralized to pH 8. Silica 
gel was added and the solvent evaporated to obtain a plug. Purification by column 
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chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded a solid in 20 % 
yield. TLC Rf 0.67 (EtOAc: Hex; 1:1), 1H NMR (DMSO-d6, 400MHz): δ 1.91-1.94 (t, 2H, 
CH2), 2.35 (s, 3H, CH3), 2.76-2.79 (t, 2H, CH2), 3.61-3.64 (t, 2H, CH2), 3.70 (s, 3H, 
4’OCH3), 4.61 (s, 2H, 5NH2), 6.28-6.31 (d, 1H, C’8 aromatic), 6.60-6.63(dd, 1H, C’7), 
6.74 (s, 1H, C’5), Anal. calcd. for C15H17ClN4O: C, 59.11; H, 5.62; N, 18.38; Cl, 11.63, 
Found C = 58.82%, H = 5.59%, N = 18.16%, Cl = 11.50 %, M.P. = 107-109 ºC. 
6-chloro-N4-(2,3-dihydrobenzofuran-5-yl)-N4,2-dimethylpyrimidine-4,5-diamine 
(153) 
2-methyl-4,6-dichloro-5-aminopyrimdine (100 mg, 0.562 mmol, 1 equiv) and N-methyl-
2,3-dihydrobenzofuran-5-amine (0.674 mmol, 1.2 equiv) were dissolved in dioxane (5 
mL). To this solution, was added 37 % HCl (cat.). The mixture was heated at 120 º C in 
microwave with stirring for 2 h. Then the reaction mixture was cooled to room temperature. 
Neutralization was done by the addition of NH4OH. The dioxane is then stripped off. Silica 
gel was added and the solvent evaporated to obtain a plug. Purification by column 
chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded 70 mg (42 %) as a 
light brown solid: TLC Rf  = 0.45 (EtOAc: Hex, 1:1); M; 1H NMR (400 MHz, DMSO-d6): 
δ 2.38 (s, 3H), 3.14-3.19 (t, J = 8.7 Hz, 2H), 3.28 (s, 3H), 3.98 (s, 2H), 4.52-4.56 (t, J = 8.7 
Hz, 2H), 6.73-6.75 (d, J = 8.4 Hz, 1H), 6.82-6.84 (dd, J = 2.3 Hz, J = 8.4 Hz, 1H), 7.06 (s, 
1H). Anal. calcd. for C14H15ClN4O: C, 57.83; H, 5.20; N, 19.27; Cl, 12.19, Found C = 
57.74%, H = 5.20%, N = 19.21%, Cl = 12.03%, M.P. = 101.5-103.7 ºC. 
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6-chloro-N4-(4-methoxyphenyl)-2-methylpyrimidine-4,5-diamine (154) 
 
2-methyl-4,6-dichloro-5-aminopyrimdine (2 g, 11.23 mmol, 1 equiv) and the 4-methoxy 
aniline (10.11 mmol, 1.25 equiv) were dissolved in butanol (15 mL). To this solution, was 
added 37 % HCl (cat.). The mixture was heated at 120 ºC in microwave with stirring for 
1.5 h. Then the reaction mixture was cooled to room temperature. Neutralization was done 
by the addition of aq. NH4OH. The butanol is then stripped off. Silica gel was added and 
the solvent evaporated to obtain a plug. Purification by column chromatography using 
hexanes and ethyl acetate (10:1 to 1:2) afforded 154 (75%) as a grey solid: TLC Rf 0.42 
(EtOAc: Hex, 1:1); 1H NMR (400 MHz, DMSO-d6): δ 2.27 (s, 3H), 3.75 (s, 3H), 5.11 (s, 
2H), 6.90-6.93 (d, J = 9.1 Hz, 2H), 6.59-6.62 (d, J = 9.1 Hz, 2H), 8.40 (s, 1H) 
(C12H13ClN4O), Anal. calcd. for C12H13ClN4O: C, 54.45; H, 4.95; N, 21.17; Cl, 13.39; 
Found C = 54.49%, H = 5.05%, N = 21.02%, Cl = 13.40%, M.P.= 170.1 °C. 
6-chloro-2-methyl-N4-(4-(methylthio)phenyl)pyrimidine-4,5-diamine (155) 
 
2-methyl-4,6-dichloro-5-aminopyrimdine (100 mg, 0.562 mmol, 1 equiv) and the 4-
(methylthio)aniline (0.674 mmol, 1.2 equiv) were dissolved in butanol (15 mL). To this 
solution, was added 37 % HCl (cat.). The mixture was heated at 120 ºC in microwave with 
stirring for 1.5 h. Then the reaction mixture was cooled to room temperature. Neutralization 
was done by the addition of aq. NH4OH. The butanol is then stripped off. Silica gel was 
added and the solvent evaporated to obtain a plug. Purification by column chromatography 
using hexanes and ethyl acetate (10:1 to 1:2) afforded 155 (85%) as a grey solid: TLC Rf 
= 0.49 (EtOAc: Hex, 1:1); 1H NMR (400 MHz, DMSO-d6): δ 2.31 (s, 3H), 2.46 (s, 3H), 
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5.12 (s, 2H), 7.25-7.27 (d, J = 8.8 Hz, 2H), 7.70-7.72 (d, J = 8.8 Hz, 2H), 8.53 (s, 1H), 
Anal. calcd. for C12H13ClN4S: C, 51.33%, H, 4.67%, N, 19.95%, Cl, 12.63%, S, 11.42%, 
Found C = 51.26%, H = 4.67%, N = 19.80%, Cl = 12.52%, S = 11.32%, M.P. = 209-211 
ºC. 
N4,N6-bis(4-methoxyphenyl)-N4,N6,2-trimethylpyrimidine-4,5,6-triamine (156) 
2-methyl-4,6-dichloro-5-aminopyrimdine (1 g, 5.62 mmol), 4-methoxyaniline (1.55 g, 
11.24 mmol, 2 equiv) and catalytic amount of conc. HCl were added to a microwave vial 
in 15 mL dioxane and heated at 160 ºC for 3 h. The reaction was stopped and dioxane was 
stripped off and reaction mixture neutralized to pH 8. Silica gel was added and the solvent 
evaporated to obtain a plug. Purification by column chromatography using hexanes and 
ethyl acetate (10:1 to 1:2) afforded a dark brown solid in 60 % yield. TLC Rf 0.18 (EtOAc: 
Hex; 1:1) 1H NMR (DMSO-d6, 400MHz):  δ 2.39 (s, 2-C 3H), 3.01 (s, NH2 2H), 3.27 (s, 
4,6-N- 6H), 3.70 (s, 4’O-CH3, 6H), 6.81-6.86 (m, aromatic, 8H) Anal. calcd. for 
C21H25N5O2: C, 66.47; H, 6.64; N, 18.46; Found C = 66.50%, H = 6.59%, N = 18.22%, 
M.P. = 101-103 ºC. 
N4,N6,2-trimethyl-N4,N6-bis(4-(methylthio)phenyl)pyrimidine-4,5,6-triamine (159) 
2-methyl-4,6-dichloro-5-aminopyrimdine (1 g, 5.62 mmol), 4-methoxy N-methylaniline 
(1.55 g, 11.24 mmol, 2 equiv) and catalytic amount of conc. HCl were added to a 
microwave vial in 15 mL dioxane and heated at 160 ºC for 3 h. The reaction was stopped 
and dioxane was stripped off and reaction mixture neutralized to pH 8. Silica gel was added 
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and the solvent evaporated to obtain a plug. Purification by column chromatography using 
hexanes and ethyl acetate (10:1 to 1:2) afforded a greyish solid in 32 % yield. TLC Rf 0.25 
(EtOAc: Hex; 1:1), 1H NMR (DMSO-d6, 400MHz):  δ 2.39 (s, 2-C 3H), 2.41 (s, 4,6-N- 
6H), 3.32 (s, 4’O-CH3, 6H), 3.50 (s, NH2 2H), 6.73-6.78  (m, aromatic, 4H), 7.15-7.20 (m, 
aromatic, 4H), Analysis calculated for C21H25N5S2: C, 61.28; H, 6.12; N, 17.02; S, 15.58, 
Found  C = 61.00%, H = 6.09%, N = 17.28%, S = 15.34%, M.P. -117-119 º C. 
4,6-bis(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylpyrimidin-5-amine (160) 
 
2-methyl-4,6-dichloro-5-aminopyrimdine (100 mg, 0.562 mmol, 1 equiv) and the 6-
methoxy-1,2,3,4-tetrahydroquinoline (0.674 mmol, 1.2 equiv) were dissolved in 1,4 
dioxane (5 mL). To this solution was added 37 % HCl (2-3 drops). The mixture was heated 
at 150 ºC in microwave with stirring for 2 h. Then the reaction mixture was cooled to room 
temperature. Neutralization was done by the addition of NH4OH. Solvents are then stripped 
off. Silica gel was added and the solvent evaporated to obtain a plug. Purification by 
column chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded 160 in  65% 
yield as an off-white solid: TLC Rf 0.56 (EtOAc: Hex, 1:1); 1H NMR (400 MHz, DMSO-
d6): δ 1.94-1.97 (p, 4H), 2.32 (s, 3H), 2.79-2.82 (t, J = 6.5Hz, 3H), 3.59-3.62 (t, 4H), 3.69 
(s, 6H), 3.73 (s, 2H), 6.25-6.28 (d, J = 8.8Hz, 2H) 6.62-6.65 (dd, J = 2.9Hz, J = 8.8Hz, 2H), 
6.69-6.70 (d, J = 2.8Hz, 2H). Analysis calculated for C25H29N5O2. 0.1H2O: C, 69.29; H, 
6.79; N, 16.16, Found C = 69.08%, H = 6.57%, N = 16.14%, M.P. = 166.5 °C. 
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N-(2,3-dihydrobenzofuran-5-yl)-N,2-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
(162) 
  
 
4-chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine (100 mg, 0.562 mmol, 1 equiv) and N-
methyl-2,3-dihydrobenzofuran-5-amine  (0.674 mmol, 1.2 equiv) were dissolved in n-
butanol (5 mL). To this solution was added 37 % HCl (2-3 drops). The mixture was heated 
at 150 ºC in microwave with stirring for 2 h. Then the reaction mixture was cooled to room 
temperature. Neutralization was done by the addition of NH4OH. Solvents are then stripped 
off. Silica gel was added and the solvent evaporated to obtain a plug. Purification by 
column chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded 162 in 65% 
yield as an off-white solid: TLC Rf  0.90 (EtOAc: Hex, 1:1; 1H NMR (500 MHz, DMSO-
d6):) δ 2.44 (s, 3H), 3.18-3.20 (t, J = 8.4 Hz, 2H), 3.43 (s, 3H), 4.58-4.60 (t, J = 8.4 Hz, 
2H), 4.58 (s, 1H), 6.73 (s, 1H), 6.81-6.83 (d, J = 8.2 Hz, 1H), 7.01-7.03 (d, J = 7.9 Hz, 1H), 
7.20 (s, 1H), 11.26 (s, 1H). Analysis calculated for C16H16N4O: C, 68.55; H, 5.75; N, 19.99, 
Found C = 68.34%, H = 5.73%, N = 19.88%, M.P. = 243-245 ºC. 
N-(5-methoxypyridin-2-yl)-N,2-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (163) 
4-chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine (100 mg, 0.562 mmol, 1 equiv) and 5-
methoxy-N-methylpyridin-2-amine (0.674 mmol, 1.2 equiv) were dissolved in butanol. To 
this solution was added 37 % HCl (2-3 drops). The mixture was heated at 110 ºC with 
stirring for 5 h. Neutralization was done by the addition of NH4OH. Solvents are then 
stripped off. The resulting plug was loaded on to a silica gel column (2 × 12 cm) and eluted 
with CHCl3 followed by 3% MeOH in CHCl3 and then 5% MeOH in CHCl3. Fractions 
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containing the product were pooled and evaporated to afford  163 in 42% yield as a brown 
solid: TLC Rf 0.75 (chloroform/methanol: 5:1); 1H NMR (400 MHz, DMSO-d6):  δ 2.49 
(s, 3H), δ 3.52 (s, 3H), δ 3.88 (s, 3H),  4.75 (s, 1H), 6.88 (s, 1H), 7.30 (d, J = 8.7 Hz, 1H), 
7.49 (dd, J = 2.8 Hz, J = 8.7 Hz, 1H), 8.22 (d, J = 2.6Hz, 1H), 11.45 (s, 1H), Analysis 
calculated for C14H15N5O. 0.25H2O: C, 61.41; H, 5.71; N, 25.58, Found C = 61.38%, H = 
5.65%, N = 25.53%, M.P. = 217 -219 ºC. 
N-(5-methoxynaphthalen-1-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (164) 
4-chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine (100 mg, 0.562 mmol, 1 equiv)  and 5-
methoxynaphthalen-1-amine (0.674 mmol, 1.2 equiv) were dissolved in n-butanol. To this 
solution was added 37 % HCl (2-3 drops). The mixture was heated at 120 ºC in microwave 
with stirring for 2 h. Then the reaction mixture was cooled to room temperature. 
Neutralization was done by the addition of NH4OH. Solvents are then stripped off. To the 
reaction mixture was added silica gel (1 g), and the solvent was evaporated reduced 
pressure. The resulting plug was loaded on to a silica gel column (2 × 12 cm) and eluted 
with CHCl3 followed by 3% MeOH in CHCl3 and then 5% MeOH in CHCl3.  Fractions 
containing the product were pooled and evaporated to afford  164 in 55% yield as a grey 
solid: TLC Rf 0.50 (chloroform/methanol: 5:1); 1H NMR (400 MHz, DMSO-d6): 2.50 (s, 
3H), 3.60 (s, 3H), 4.01 (s, 3H), 6.53-6.54 (m, 1H), 7.00-7.20 (d, J = 7.6Hz, 1H), 7.25-7.27 
(d, J = 8.4Hz, 1H), 7.38-7.42 (m, 1H), 7.57-7.67(m, 2H), 8.29 (dd, J = 1.7Hz, J = 7.9Hz, 
1H), 11.23 (s, 1H) Analysis calculated for C18H16N4O .0.105 H2O: C, 70.59; H, 5.34; N, 
18.30, Found C = 70.59%, H = 5.36%, N = 18.33%, M.P. = 281-283 ºC. 
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5-((2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)naphthalen-1-ol (165) 
4-chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine (100 mg, 0.562 mmol, 1 equiv) and 5-
aminonaphthalen-1-ol (0.674 mmol, 1.2 equiv) were dissolved in dioxane. To this solution 
was added 37 % HCl (2-3 drops). The mixture was heated at 140 ºC in microwave with 
stirring for 2 h. Then the reaction mixture was cooled to room temperature. Neutralization 
was done by the addition of NH4OH. Solvents are then stripped off. To the reaction mixture 
was added silica gel (1 g), and the solvent was evaporated reduced pressure.  The resulting 
plug was loaded on to a silica gel column (2 × 12 cm) and eluted with CHCl3 followed by 
3% MeOH in CHCl3 and then 5% MeOH in CHCl3. Fractions containing the product were 
pooled and evaporated to afford 165 in 51% yield as a dark brown solid: TLC Rf 0.30 
(chloroform/methanol: 5:1); 1H NMR (400 MHz, DMSO-d6): δ 2.35 (s, 3H), δ 5.90 (s, 
1H),  6.88-6.90 (d, J = 7.3 Hz, 1H), 6.94 (s, 1H), 7.26-7.30 (t, J = 7.9 Hz, 1H), 7.45-7.49 
(t, 2H), 7.60-7.61 (d, Hz, 1H), 8.06-8.08 (d, J = 8.3 Hz, 1H), 9.27 (s, 1H), 10.19 (s, 1H), 
11.39 (s, 1H). Analysis calculated for C17H14N4O. 0.3H2O: C, 69.04; H, 4.98; N, 18.95, 
Found C = 68.67%, H = 5.13%, N = 18.61%, M.P. = 293-295 ºC. 
 
N-(5-methoxynaphthalen-2-yl)-N,2-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
(166) 
 
 
4-chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine (100 mg, 0.562 mmol, 1 equiv)  and 5-
methoxy-N-methylnaphthalen-2-amine (0.674 mmol, 1.2 equiv) were dissolved in n-
butanol. To this solution was added 37 % HCl (2-3 drops). The mixture was heated at 120 
ºC in microwave with stirring for 2 h. Then the reaction mixture was cooled to room 
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temperature. Neutralization was done by the addition of NH4OH. Solvents are then stripped 
off. To the reaction mixture was added silica gel (1 g), and the solvent was evaporated 
reduced pressure. The resulting plug was loaded on to a silica gel column (2 × 12 cm) and 
eluted with CHCl3 followed by 3% MeOH in CHCl3 and then 5% MeOH in CHCl3. 
Fractions containing the product were pooled and evaporated to afford 166 in 65% yield as 
a grey solid: TLC Rf 0.55 (chloroform/methanol: 5:1); 1H NMR (400 MHz, DMSO-d6): 
2.50 (s, 3H), 3.60 (s, 3H), 4.01 (s, 3H),4.45-4.46(s, 1H), 6.69-7.00 (d, J = 7.6Hz, 1H), 7.00-
7.02 (d, J = 8.4Hz, 1H), 7.42-7.46 (m, 3H), 7.85-7.86 (m, 1H), 8.20 (dd, J = 1.7Hz, J = 
7.9Hz, 1H), 11.35 (s, 1H), Analysis calculated for C19H18N4O. 0.2H2O: C, 70.87; H, 5.76; 
N, 17.40, Found C = 70.94%, H = 5.78%, N = 17.40%, M.P. = 280-282 ºC. 
N,2-dimethyl-N-(4-(methylthio)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (167) 
4-Chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine  (100 mg, 0.562 mmol, 1 equiv) and N-
methyl-4-(methylthio)aniline (0.674 mmol, 1.2 equiv) were dissolved in n-butanol (5 mL). 
To this solution was added 37 % HCl (2-3 drops). The mixture was heated at 120 ºC in 
microwave with stirring for 2 h. Then the reaction mixture was cooled to room temperature. 
Neutralization was done by the addition of NH4OH. Solvents were then stripped off. Silica 
gel was added and the solvent evaporated to obtain a plug. Purification by column 
chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded 167 in 62% yield 
as a white solid: TLC Rf 0.45 (EtOAc:Hex, 1:1); 1H NMR (400 MHz, DMSO-d6):  δ 2.47 
(s, 3H), 2.53 (s, 3H), 3.48 (s, 3H), 4.64-4.66 (dd, J = 2Hz, J = 3.5Hz, 1H), 6.78-6.80 (dd, J 
= 2.4Hz, J = 3.5Hz, 1H), 7.25-7.27 (d, 2H, J = 8.8 Hz), 7.32-7.35 (d, 2H, J = 8.8 Hz), 11.34 
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(s, 1H). Analysis calculated for C15H16N4S:  C, 63.35; H, 5.67; N, 19.70; S, 11.27, Found 
C = 63.44%, H = 5.64%, N = 19.71%, S = 11.28%, M.P. = 155 °C.  
2-(tert-butyl)-N-(4-methoxyphenyl)-N,5-dimethyloxazolo[5,4-d]pyrimidin-7-amine 
(171) 
Compound 122 (50 mg, 1 equiv, 0.18 mmol) was dissolved in pivalic anhydride (6 mL) 
and the reaction was run at 150 ºC for 12 h. The solvent was stripped off. Silica gel was 
added and the solvent evaporated to obtain a plug. Purification by column chromatography 
using hexanes and ethyl acetate (10:1 to 1:2) afforded a grey solid in 60 % yield. TLC Rf 
0.25 (EtOAc: Hex; 1:1); 1H NMR (CDCl3, 400MHz): δ 1.34 (s, 9H, CH3), 2.55 (s, 3H, 
2CH3), 3.77 (s, 3H, 4NCH3), 3.87 (s, 3H, 4’OCH3), 6.94-6.96 (d,2H, J = 8.8 Hz), 7.22-7.25 
(d,2H, J = 8.8 Hz). Analysis calculated for C18H24N4O2:  C, 65.83; H, 7.26; N, 17.06; Found 
C = 65.96%, H = 6.88, N = 17.08%, M.P. = 120-122 ºC. 
N4,N9-bis(4-methoxyphenyl)-N4,N9,2,7-tetramethylpyrimido[4,5-g]pteridine-4,9-
diamine (172) 
Compound 122 (500 mg, 1.79 mmol) was taken and added to benzylpotassium 
trifluroboate (355 mg, 1.79 mmol, 1 equiv) in a microwave vial and cesium carbonate (2 
equiv) was added in addition to tetrakistriphenylphosphine palladium (0.05 equiv) in 
acetonitrile. The reaction was run for 3 hrs at 120 ºC and after the reaction was done, 
acetonitrile was stripped off. Silica gel was added and the solvent evaporated to obtain a 
plug. Purification by column chromatography using hexanes and ethyl acetate (10:1 to 1:2) 
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afforded a red solid in 15 % yield. TLC Rf 0.25 (EtOAc: Hex; 1:1); 1H NMR (CDCl3, 
400MHz): δ 2.59 (s, 6H, 2CH3), 3.89 (s, 6H, 4NCH3), 3.98 (s, 6H, 4’OCH3), 6.96-6.98 (d, 
4H, J = 8.8 Hz), 7.19-7.21 (d, 4H, J = 8.8 Hz). Analysis calculated for C26H26N8O2. 
0.2CH3COOC2H5:  C, 64.36; H, 5.56; N, 22.40; Found C = 64.47%, H = 5.54%, N = 
22.45%, M.P. = 243-245 ºC. 
 
N4-(2-bromo-4-methoxyphenyl)-6-chloro-2-methylpyrimidine-4,5-diamine (241) 
 
2-Methyl-4,6-dichloropyrimdine (2 g, 11.23 mmol, 1 equiv) and the 2-bromo-4-methoxy 
aniline (10.11 mmol, 1.25 equiv) were dissolved in butanol (15 mL). To this solution, was 
added 37 % HCl (cat.). The mixture was heated at 120 ºC in microwave with stirring for 
1.5 h. Then the reaction mixture was cooled to room temperature. Neutralization was done 
by the addition of aq. NH4OH. The butanol is then stripped off. Silica gel was added and 
the solvent evaporated to obtain a plug. Purification by column chromatography using 
hexanes and ethyl acetate (10:1 to 1:2) afforded 241 (79%) as a grey solid: TLC Rf 0.55 
(EtOAc:Hex, 1:1); 1H NMR (400 MHz, DMSO-d6): δ 2.17 (s, 3H), 3.79 (s, 3H), 5.11 (s, 
2H), 6.97-7.01 (dd, 1H), 7.25-7.26 (d, J = 9.1 Hz, 2H), 7.41-7.43 (d, J = 9.1 Hz, 2H) Anal. 
calcd. for C12H12BrClN4O: C, 41.95; H, 3.52; N, 16.31; Cl, 10.32; Br, 23.25, Found C = 
42.08%, H = 3.58%, N = 16.15%, Cl = 10.18%, Br = 23.11%, M.P. = 135-136 ºC. 
N-methyl-4-(methylthio)aniline (193) 
Aniline 192 (5 g, 1 equiv) was added to a suspension of NaOMe (5 equiv) in MeOH (8-15 
mL). The resulting solution was poured into a suspension of paraformaldehyde (1.4 equiv.) 
in MeOH (5-10 mL). The reaction was stirred at rt for 4.5 h and then sodium borohydride 
207 
(1.2 equiv.) was added and solution heated to reflux for 2 h. The reaction mixture was 
allowed to cool to room temperature and then filtered with methanol washings. Silica gel 
was added and the solvent evaporated to obtain a plug. Purification by column 
chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded 4.90 g (90%) as a 
dark red liquid: TLC Rf 0.80 (EtOAc:Hex, 1:1); δ 1H NMR (400 MHz, DMSO-d6) δ 2.34 
(s, 3H), 2.64-2.66 (d, J = 5.1 Hz, 3H), 5.72-5.73 (q, 1H), 6.50-6.52 (d, J = 8.6 Hz, 2H), 
7.11-7.13 (d, J = 8.6 Hz, 2H).1H NMR matches prior synthesis.248 
N-methyl-2,3-dihydrobenzofuran-5-amine (196) 
Aniline 195 (1 g, 1 equiv) was added to a suspension of NaOMe (5 equiv.) in MeOH (8-
15 mL). The resulting solution was poured into a suspension of paraformaldehyde (1.4 
equiv.) in MeOH (5-10 mL). The reaction was stirred at rt for 5 h and then sodium 
borohydride (1.2 equiv.) was added and solution heated to reflux for 2 h. The reaction 
mixture was allowed to cool to room temp. and then filtered with methanol washings. Silica 
gel was added and the solvent evaporated to obtain a plug. Purification by column 
chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded 0.93 g (85%) as a 
brown liquid: TLC Rf  0.90 (EtOAc:Hex, 1:1; 1H NMR (DMSO-d6) δ 1H NMR (400 MHz, 
DMSO-d6) δ 2.61 (s, 3H), 3.04-3.08 (t, J = 8.5 Hz, 2H), 4.36-4.40 (t, J = 8.6 Hz, 2H), 5.09 
(s, 1H), 6.25-6.28 (dd, J = 2.4 Hz, J = 8.4 Hz, 1H), 6.48-6.49 (s, 1H), 6.51-6.54 (d, J = 8.5 
Hz, 1H). The reaction was carried on without additional characterization. 
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5-methoxy-N-methylnaphthalen-1-amine (200) 
Aniline 199 (5 g, 1 equiv) was added to a suspension of NaOMe (5 equiv) in MeOH (8-15 
mL). The resulting solution was poured into a suspension of paraformaldehyde (1.4 equiv.) 
in MeOH (5-10 mL). The reaction was stirred at rt for 4.5 h and then sodium borohydride 
(1.2 equiv.) was added and solution heated to reflux for 2 h. The reaction mixture was 
allowed to cool to room temperature and then filtered with methanol washings. Silica gel 
was added and the solvent evaporated to obtain a plug. Purification by column 
chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded (75%) as a grey 
solid: TLC Rf 0.15 (EtOAc:Hex, 1:1); 1H NMR (400 MHz, DMSO-d6): δ 1H NMR (400 
MHz, DMSO) 2.84 (d, J=4.8Hz, 3H), 3.93 (s, 3H), 6.23-6.25 (q, J = 4.5Hz, 1H), 6.44-6.46 
(d, J = 7.1Hz, 1H), 6.90-6.92 (d, J = 7.6Hz, 1H), 7.26-7.33 (m, 2H), 7.37-7.39 (d, 1H), 
7.64-7.66 (d, J = 8.6Hz, 1H), M.P. = 195 ºC. The reaction was carried on without additional 
characterization. 
Ethyl 4-hydroxybenzoate (207a) 
4-Hydroxybenzoic acid (1.37 g, 10 mmol) was dissolved in a minimum amount of absolute 
ethanol (15 mL). As 1 mL of concentrated sulfuric acid was added, a white suspension 
formed which was vigorously stirred and refluxed for 3 h to give a clear solution. The 
reaction mixture was cooled to 40 ˚C and poured into a saturated solution of sodium 
bicarbonate in water (100 mL). Vigorous effervescence was observed with the precipitation 
of a white solid. The precipitate was filtered and dried in air at room temperature to afford 
207a (62%) as a white solid: TLC Rf  = 0.80 (EtOAc:Hex, 1:1); 1H NMR (400 MHz, 
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DMSO-d6): δ 1.31 (t, 3H), 4.28 (q, 2H), 7.38-7.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J = 
1.9 Hz, 2H). M.P. = 131 ºC. M.P. matches prior synthesis.249 
Ethyl 4-((6-hydroxyhexyl)oxy)benzoate (208a) 
A mixture of 207a (0.3 g, 3.2 mmol), K2CO3 (1.3 g, 9.6 mmol) and 6-bromo-hexanol (0.34 
ml, 4.8 mmol) in MeCN (25 mL) was heated for 6 h at 90 ° C. The mixture was cooled to 
room temperature and then H2O was added and the mixture was diluted with Et2O. The 
organic layer was separated, and the aqueous layer was extracted with Et2O. The combined 
organic layers were washed with brine, dried over MgSO4 and concentrated under reduced 
pressure. Silica gel was added and the solvent evaporated to obtain a plug. Purification by 
column chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded 208a (45%) 
as a liquid: TLC Rf 0.50 (EtOAc:Hex, 1:1); 1H NMR (400 MHz, DMSO-d6): δ 1.31 (t, 
3H), 1.41 (m, 2H), 1.58 (m, 2H), 1.73 (m, 2H), 2.46 (m, 2H), 3.81 (m, 2H), 4.03 (m, 2H),  
4.28 (q, 2H), 7.38-7.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J = 1.9 Hz, 2H). Rf matches prior 
synthesis.250 The reaction was carried on without additional characterization. 
Ethyl 4-((6-oxohexyl)oxy)benzoate (209a) 
To a solution of DMP (3.7 g, 14.4 mmol) in CH2Cl2 (14 mL) was added a solution of 
208a (1.85 g, 12 mmol) in CH2Cl2 (60 mL) at 0 ° C, and the mixture was stirred for 4 hours 
at room temperature. The aldehyde product was extracted with organic solvent CH2Cl2, 
and the combined extracts were washed with brine, dried over anhydrous Na2SO4, and 
concentrated under reduced pressure. Silica gel was added and the solvent evaporated to 
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obtain a plug. Purification by column chromatography using hexanes and ethyl acetate 
(10:1 to 1:2) afforded aldehyde 209a (1.64 g, 10.8 mmol) in 90% yield as a transparent oil. 
TLC Rf=0.40 (10% EtOAc/hexanes).251 Fractions containing the product were pooled and 
evaporated to afford  (75%) as a liquid: TLC Rf 0.70 (EtOAc:Hex, 1:1); 1H NMR (400 
MHz, DMSO-d6): δ 1.31 (t, 3H), 1.41 (m, 2H), 1.58 (m, 2H), 1.73 (m, 2H), 2.46 (m, 2H), 
3.81 (m, 2H), 4.28 (q, 2H), 7.38-7.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J = 1.9 Hz, 2H), 
9.67 (s, IH). The reaction was carried on without additional characterization. 
Ethyl-4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butoxy)benzoate (211a)252  
To a solution of bromine (0.1 mL) –dioxane (0.3 mL) solution, 1 mL DCM was added. The 
viscous solution was stirred for 10 min at 0 ° C, and then a solution of 209a (5.00 g, 37.26 
mmol) in DCM was added dropwise to it at 0 ° C. The mixture was stirred at 25°C for 1 h. 
After 1 h, the mixture was poured into water and extracted with DCM. The combined 
organic layers were washed with brine, dried (Na2SO4) and evaporated to give the crude 
title product, which was used directly in the next step reaction. To a suspension of 2,4-
diamino-6-hydroxypyrimidine (4.7 g, 37.26 mmol) and sodium acetate (6.11 g, 74.53 
mmol) in water was added methyl 4-((5-bromo-6-oxohexyl)oxy)benzoate (210a, 7.94 g, 
37.26 mmol) in DMF The reaction mixture was stirred at 40 °C  for 12 h. Silica gel was 
added and the solvent evaporated to obtain a plug. Purification by column chromatography 
using hexanes and ethyl acetate (10:1 to 1:2) afforded 211a. (20%) as a solid: TLC Rf 0.65 
(chloroform: methanol, 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.31 (t, 3H), 1.61 (m, 2H), 
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1.72 (m, 2H), 2.6 (m, 2H), 3.1 (m, 2H), 4.28 (q, 2H), 7.38-7.40 (d, J = 1.9 Hz, 2H), 7.84-
7.86 (d, J = 1.9 Hz, 2H), 8.58(s, IH), 10.3 (s, 2H), M.P. = 220-222 ºC. The reaction was 
carried on without additional characterization. 
4-((4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)thio)benzoic acid (212a) 
The ethyl ester of 211a (0.5 g, 0.37 mmol was hydrolyzed using 5 mL 1N sodium 
hydroxide solution at room temperature for 5 hours to produce acid 212a. The pH of the 
reaction mixture was reduced to 2 (acidic) using 1N HCl solution. The precipitates formed 
were filtered and dried to yield 212a (88%) as a solid: TLC Rf 0.65 (chloroform: methanol, 
5:1); 1H NMR (DMSO-d6) δ 1.61 (m, 2H), 1.72 (m, 2H), 2.6 (m, 2H), 3.1 (m, 2H), 7.38-
7.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J = 1.9 Hz, 2H), 8.58(s, IH), 12.5 (s, 2H), M.P. = 
225-227 ºC. The reaction was carried on without additional characterization. 
Diethyl(4-((4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)thio)benzoyl)-L-glutamate (213a) 
The acid 212a was coupled with commercially available L-glutamate-diethylester in the 
presence of the base NMM, and CDMT to give coupled product 213a.The solvents were 
stripped off, the silica was added and the resulting plug was loaded on to a silica gel column 
(2 × 12 cm) and eluted with CHCl3 followed by 3% MeOH in CHCl3 and then 5% MeOH 
in CHCl3.Fractions containing the product were pooled and evaporated to afford 213a 
(85%) as a solid: TLC Rf = 0.5 (chloroform: methanol, 5:1); 1H NMR (400 MHz, DMSO-
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d6): δ 1.2 ( 1.61 (m, 2H), 1.72 (m, 2H), 2.6 (m, 2H), 3.1 (m, 2H), 4.0-4.01 (m, 4H), 4.39-
4.41 (m, 1H), 7.38-7.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J = 1.9 Hz, 2H), 8.58(s, IH), 12.5 
(s, 2H), Decomposes above 250 ºC. The reaction was carried on without additional 
characterization. 
(4-((4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)thio)benzoyl)-L-glutamic acid (173) 
The ethyl ester of 213a was hydrolyzed using 1 N sodium hydroxide solution at room 
temperature for 5 hours to produce acid 173. The pH of the reaction mixture was reduced 
to pH = 2 (acidic) using 1N HCl solution. The precipitates formed were filtered and dried 
to yield final compound 173 (75%) as a solid: TLC Rf 0.5 (chloroform: methanol, 5:1); 1H 
NMR (DMSO-d6) δ 1.70-1.80 (m, 4H, CH2), 1.95-1.97 (m, 1H, CH2), 2.07-2.09 (m, 1H, 
CH2), 2.35 (m, 2H, CH2), 2.63 (m, 2H, CH2), 4.04 (t, 2H, OCH2), 4.39 (t, 1H, CH), 5.98 
(d, 2H, 2-NH2, exch), 6.38 (s, 1H, 6-CH), 6.98-7.00 (d, 2H, Ar-CH, J = 8 Hz), 7.84−7.86 
(d, 2H, Ar-CH, J = 8 Hz), 8.44-8.46 (d, 1H, Ar-CONH, J = 8 Hz, exch), 10.12 (s, 1H, 3-
NH, exch), 10.65 (s, 1H, 7-NH, exch), 12.38-12.41 (s, 2H, COOH, exch). Analysis 
calculated for C22H25N5O7. 1.43H2O:  C, 53.14; H, 5.65; N, 14.08; Found C = 53.22%, H 
= 5.37%, N = 13.69%, decomposes above 250 ºC.  
Ethyl 4-mercaptobenzoate (207b) 
4-Mercaptobenzoic acid (1.1 g, 10 mmol was dissolved in a minimum amount of absolute 
ethanol (15 mL). As 1 mL of concentrated sulfuric acid was added, a white suspension 
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formed which was vigorously stirred and refluxed for 3 h to give a clear solution. The 
reaction mixture was cooled to 40 ˚C and poured into a saturated solution of sodium 
bicarbonate in water (100 mL). Vigorous effervescence was observed with the precipitation 
of a white solid. The precipitate was filtered and dried in air at room temperature to afford 
a white solid in 62 % yield. TLC Rf 0.6 (EtOAc: Hex; 1:1) TLC Rf 0.6 (CH3OH: CHCl3; 
1:10) 1H NMR (400 MHz, DMSO-d6) δ7.79-7.81 (2H, d), δ7.41-7.43 (2H, d), 5.99 (1H, s), 
4.29 (2H, q), 1.30 (3H, t). M.P. = 220-221 ºC. 1H NMR matches prior synthesis.253 
Ethyl 4-((6-hydroxyhexyl)thio)benzoate (208b) 254 
 
A mixture of 207a (0.3 g, 3.2 mmol), Cs2CO3 (1.3 g, 9.6 mmol) and 6-bromo-hexanol (0.34 
mL, 4.8 mmol) in DMF (25 mL) was heated for 6 h at 90 ° C. The mixture was cooled to 
room temperature and then H2O was added and the mixture was diluted with Et2O. The 
organic layer was separated, and the aqueous layer was extracted with Et2O. The combined 
organic layers were washed with brine, dried over MgSO4 and concentrated under reduced 
pressure. Silica gel was added and the solvent evaporated to obtain a plug. Purification by 
column chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded 208b (75%) 
as a liquid: TLC Rf 0.50 (EtOAc:Hex, 1:1); 1H NMR (DMSO-d6) δ 1.31 (t, 3H), 1.41 (m, 
2H), 1.58 (m, 2H), 1.73 (m, 2H), 2.46 (m, 2H), 3.81 (m, 2H), 4.03 (m, 2H),  4.28 (q, 2H), 
7.38-7.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J = 1.9 Hz, 2H). The reaction was carried on 
without additional characterization. 
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Ethyl 4-((6-oxohexyl)thio)benzoate (209b) 
To a solution of DMP (3.7 g, 14.4 mmol) in CH2Cl2  (14 mL) was added a solution of 
208b (1.85 g, 12 mmol) in CH2Cl2 (60 mL) at 0 ° C, and the mixture was stirred for 4 hours 
at room temperature. The aldehyde product was extracted with  organic solvent CH2Cl2, 
and the combined extracts were washed with brine, dried over anhydrous Na2SO4, and 
concentrated under reduced pressure. Silica gel was added and the solvent evaporated to 
obtain a plug. Purification by column chromatography using hexanes and ethyl acetate 
(10:1 to 1:2) afforded aldehyde 209b (1.64 g, 10.8 mmol) in 65% yield as a transparent oil. 
TLC Rf=0.40 (10% EtOAc:Hex).251 (75%) as a liquid: TLC Rf 0.70 (EtOAc:Hex, 1:1); 1H 
NMR (400 MHz, DMSO-d6): δ 1.31 (t, 3H), 1.41 (m, 2H), 1.58 (m, 2H), 1.73 (m, 2H), 
2.46 (m, 2H), 3.81 (m, 2H), 4.28 (q, 2H), 7.38-7.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J = 
1.9 Hz, 2H), 9.67 (s, IH). The reaction was carried on without additional characterization. 
Ethyl-4-((4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
l)butyl)thio)benzoate (211b) 252    
To a solution of bromine (0.1 mL) –dioxane (0.3 mL) solution, 1 mL DCM was added. The 
viscous solution was stirred for 10 min at 0 °C, and then a solution of 209b in DCM was 
added dropwise to it (5.00 g, 37.26 mmol) at 0 °C. The mixture was stirred at 25 °C for 1 
h. After 1 h, the mixture was poured into water and extracted with DCM. The combined 
organic layers were washed with brine, dried (Na2SO4) and evaporated to give the crude 
title product, which was used directly in  
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the next step reaction. To a suspension of 2,4-diamino-6-hydroxypyrimidine (4.7 g, 37.26 
mmol) and sodium acetate (6.11 g, 74.53 mmol) in water was added ethyl 4-((5-bromo-6-
oxohexyl)thio)benzoate (210b, 7.94 g, 37.26 mmol) in DMF The reaction mixture was 
stirred at 40 °C  for 12 h. To the reaction mixture was added silica gel, and the solvent was 
evaporated under reduced pressure.  The resulting plug was loaded on to a silica gel column 
(2 × 12 cm) and eluted with CHCl3 followed by 3% MeOH in CHCl3 and then 5% MeOH 
in CHCl3 afforded  211b  (35%) as a solid: TLC Rf 0.65 (chloroform: methanol, 5:1); 1H 
NMR (400 MHz, DMSO-d6): δ 1.31 (t, 3H), 1.61 (m, 2H), 1.72 (m, 2H), 2.6 (m, 2H), 3.1 
(m, 2H), 4.28 (q, 2H), 7.38-7.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J = 1.9 Hz, 2H), 8.58(s, 
IH), 10.3 (s, 2H). M.P. = 241-243 ºC. The reaction was carried on without additional 
characterization. 
4-((4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)thio)benzoic acid (212b) 
The ethyl ester of 211b was hydrolyzed using 1N sodium hydroxide solution at room 
temperature for 5 hours to produce acid 212b. The pH of the reaction mixture was reduced 
to 2 (acidic) using 1N HCl solution. The precipitates formed were filtered and dried to yield 
final product (93%) as a solid: TLC Rf = 0.65 (chloroform: methanol, 5:11H NMR (400 
MHz, DMSO-d6): δ 1.61 (m, 2H), 1.72 (m, 2H), 2.6 (m, 2H), 3.1 (m, 2H), 7.38-7.40 (d, J 
= 1.9 Hz, 2H), 7.84-7.86 (d, J = 1.9 Hz, 2H), 8.58(s, IH), 12.5 (s, 2H). The reaction was 
carried on without additional characterization. 
 
216 
Diethyl(4-((4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)thio)benzoyl)-L-glutamate (213b) 
The acid 212b was coupled with L-glutamate-diethylester in the presence of the base 
NMM, and CDMT to give coupled product 213b.The solvents were stripped off and the 
plug was made using silica powder. The resulting plug was loaded on to a silica gel column 
(2 × 12 cm) and eluted with CHCl3 followed by 3% MeOH in CHCl3 and then 5% MeOH 
in CHCl3. Fractions with desired Rf (TLC) were pooled and evaporated to afford 213b 
(65%) as a solid: TLC Rf 0.5 (chloroform: methanol, 5:1); 1H NMR (DMSO-d6) δ 1.2 ( 
1.61 (m, 2H), 1.72 (m, 2H), 2.6 (m, 2H), 3.1 (m, 2H), 4.0-4.01 (m, 4H), 4.39-4.41 (m, 1H), 
7.38-7.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J = 1.9 Hz, 2H), 8.58(s, IH), 12.5 (s, 2H). 
Decomposes above 250 ºC.  The reaction was carried on without additional 
characterization. 
(4-((4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)thio)benzoyl)-L-glutamic acid (174) 
The ethyl ester of 213b was hydrolyzed using 1 N sodium hydroxide solution at room 
temperature for 5 hours to produce acid 174. The pH of the reaction mixture was reduced 
to 2 (acidic) using 1N HCl solution. The precipitates formed were filtered and dried to yield 
final 174 (92%) as a solid: TLC Rf 0.5 (chloroform: methanol, 5:1); 1H NMR (DMSO-d6) 
δ 1.59-1.62 (m, 1H, CH2), 1.73-1.76 (m, 1H, CH2), 1.95-1.97 (m, 1H, CH2), 2.08-2.10 (m, 
1H, CH2), 2.35 (m, 2H, CH2), 2.63 (m, 2H, CH2), 3.04 (t, 2H, SCH2), 4.39 (t, 1H, CH), 
6.00 (d, 2H, 2-NH2, exch), 6.36 (s, 1H, 6-CH), 7.34-7.36 (d, 2H, Ar-CH, J = 8 Hz), 
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7.82−7.84 (d, 2H, Ar-CH, J = 8 Hz), 8.56-8.58 (d, 1H, Ar-CONH, J = 8 Hz, exch), 10.14 
(s, 1H, 3-NH, exch), 10.65 (s, 1H, 7-NH, exch), 12.35-12.65 (s, 2H, COOH, exch). 
Analysis calculated for C22H25N5O6S. 1.38H2O:  C, 52.14; H, 5.39; N, 12.28; S, 5.62; 
Found C = 52.10%, H = 5.48%, N = 12.17%, S = 5.93%, calculated MW = 497.23, 
Decomposes above 250 ºC. 
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VI. SUMMARY 
This dissertation describes the design and synthesis of pyrimidine-based heterocycles as 
single agents with combination chemotherapy potential. These efforts led to the 
identification of structural features that are necessary for inhibition of tubulin 
polymerization. Structural modifications also led to the identification of antiangiogenic 
agents which inhibit one or more of the receptor tyrosine kinases (RTKs)- vascular 
endothelial growth factor receptor-2, platelet derived growth factor receptor-β and 
epidermal growth factor receptor. Single agents with both antiangiogenic activities as well 
as cytotoxicity would afford single entities that circumvent pharmacokinetic problems of 
multiple agents, avoid drug-drug interactions, could be used at lower doses to alleviate 
toxicity, devoid of overlapping toxicities, and delay or prevent tumor cell resistance. This 
dissertation also describes selective tumor targeting with 5-substituted pyrrolo[2,3-
d]pyrimidines with heteroatom bridge substitution as GARFTase inhibitors circumventing 
both dose-limiting toxicity and tumor resistance associated with most prescribed antitumor 
agents like pemetrexed. 
 
The novel target compounds synthesized as part of this study are listed below: 
 
1. 6-chloro-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (122) 
2. 6-chloro-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (123) 
3. 6-chloro-N4-(4-methoxyphenyl)-N4,N5,N5,2-tetramethylpyrimidine-4,5-diamine 
(124) 
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4. 6-chloro-N5-ethyl-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine 
(125) 
5. 6-chloro-N4-(4-methoxyphenyl)-N4,2-dimethyl-N5-propylpyrimidine-4,5-diamine 
(126) 
6. N5-butyl-6-chloro-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine 
(127) 
7. 6-chloro-N5-isobutyl-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine 
(128) 
 
8. 6-benzyl-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (130) 
9. N4-(4-methoxyphenyl)-N4,2-dimethyl-6-phenethylpyrimidine-4,5-diamine (131) 
10. N4-(4-methoxyphenyl)-N4,2-dimethyl-6-(phenylethynyl)pyrimidine-4,5-diamine 
(132) 
11. N-(4-chloro-6-((4-methoxyphenyl)(methyl)amino)-2-methylpyrimidin-5-
yl)acetamide (133) 
12. N-acetyl-N-(4-chloro-6-((4-methoxyphenyl)(methyl)amino)-2-methylpyrimidin-5-
yl)acetamide (134) 
13. N-(4-chloro-6-((4-methoxyphenyl)(methyl)amino)-2-methylpyrimidin-5-
yl)pivalamide (135) 
14. 6-chloro-N-(4-methoxyphenyl)-N,2-dimethyl-5-nitropyrimidin-4-amine (136) 
15. N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (137) 
 
16. N`4-(4-methoxyphenyl)-N4,2,6-trimethylpyrimidine-4,5-diamine (138) 
 
17. 6-ethyl-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (139) 
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18. N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5,6-triamine (140) 
19. 5-amino-6-((4-methoxyphenyl)(methyl)amino)-2-ethylpyrimidine-4-carbonitrile 
(141) 
20. 6-iodo-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (142) 
21. N4-(4-methoxyphenyl)-N4,2-dimethyl-6-(trifluoromethyl)pyrimidine-4,5-diamine 
(143) 
22. 6-chloro-N4-(4-methoxyphenyl)-N4-methylpyrimidine-4,5-diamine (144) 
23. 6-chloro-2-ethyl-N4-(4-methoxyphenyl)-N4-methylpyrimidine-4,5-diamine (145) 
24. 6-chloro-2-ethyl-N4-(4-methoxyphenyl)-N4,N5-dimethylpyrimidine-4,5-diamine 
(146)  
 
25. 6-chloro-N5,2-diethyl-N4-(4-methoxyphenyl)-N4-methylpyrimidine-4,5-diamine 
(147) 
 
26. 6-chloro-N4-(4-methoxyphenyl)-N4-methylpyrimidine-2,4,5-triamine (148) 
27. 6-chloro-N4-(4-methoxyphenyl)-N4,N5-dimethylpyrimidine-2,4,5-triamine (149) 
28. 6-chloro-N5-ethyl-N4-(4-methoxyphenyl)-N4-methylpyrimidine-2,4,5-triamine 
(150) 
 
29. 6-chloro-N4,2-dimethyl-N4-(4-(methylthio)phenyl)pyrimidine-4,5-diamine (151) 
 
30. 4-chloro-6-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylpyrimidin-5-amine 
(152) 
 
31. 6-chloro-N4-(2,3-dihydrobenzofuran-5-yl)-N4,2-dimethylpyrimidine-4,5-diamine 
(153) 
32. 6-chloro-N4-(4-methoxyphenyl)-2-methylpyrimidine-4,5-diamine (154) 
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33. 6-chloro-2-methyl-N4-(4-(methylthio)phenyl)pyrimidine-4,5-diamine (155) 
34. N4,N6-bis(4-methoxyphenyl)-N4,N6,2-trimethylpyrimidine-4,5,6-triamine (156) 
35. N4,N6-bis(4-methoxyphenyl)-N4,N6,2-trimethylpyrimidine-4,5,6-triamine (157) 
36. N4,N6,2-trimethyl-N4,N6-bis(4-(methylthio)phenyl)pyrimidine-4,5,6-triamine (158) 
37. N4,N6,2-trimethyl-N4,N6-bis(4-(methylthio)phenyl)pyrimidine-4,5,6-triamine (159) 
38. 4,6-bis(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylpyrimidin-5-amine (160) 
39. N-(2,3-dihydrobenzofuran-5-yl)-N,2-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
(162) 
 
40. N-(5-methoxypyridin-2-yl)-N,2-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (163) 
41. N-(5-methoxynaphthalen-1-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (164) 
42. 5-((2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)naphthalen-1-ol (165) 
43. N-(5-methoxynaphthalen-2-yl)-N,2-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
(166) 
 
44. N,2-dimethyl-N-(4-(methylthio)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (167) 
 
45. N-(4-methoxyphenyl)-N,2,5-trimethyloxazolo[5,4-d]pyrimidin-7-amine (170) 
 
46. 2-(tert-butyl)-N-(4-methoxyphenyl)-N,5-dimethyloxazolo[5,4-d]pyrimidin-7-amine 
(171) 
 
47. N4,N9-bis(4-methoxyphenyl)-N4,N9,2,7-tetramethylpyrimido[4,5-g]pteridine-4,9-
diamine (172) 
48. N4-(2-bromo-4-methoxyphenyl)-6-chloro-2-methylpyrimidine-4,5-diamine  
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49. (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butoxy)benzoyl)-L-glutamic acid (173) 
50. (4-((4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)thio)benzoyl)-L-glutamic acid (174) 
51. (4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)ethoxy)benzoyl)-L-glutamic acid (175) 
52. 6-chloro-N4-(4-methoxyphenyl)-N4,N5,N5-trimethylpyrimidine-2,4,5-triamine 
(188) 
53. 6-chloro-N4-(4-methoxyphenyl)-N2,N4,N5,N5-tetramethylpyrimidine-2,4,5-
triamine (189) 
 
7-Benzyl-pyrrolo[3,2-d]pyrimidine 129 maintained the cytotoxic antitubulin activity of 
pyrrolo[3,2-d]pyrimidine 121, but also showed improved activity against VEGFR2 and 9-
fold improvement of antiangiogenic effects over 121. These observations are consistent 
with combination chemotherapeutic potential in a single agent.180, 199  
Compounds 130 and 131 were designed as open chain analogs of 129, to explore dual 
antiangiogenic and microtubule properties with the potential for multikinase inhibition. 
The compounds turned out to be inactive in tubulin assays. They are currently being tested 
for their multikinase inhibition properties. Compound 122 is an open chain 
conformationally flexible analog of 121. This was an intermediate in the synthesis of 130 
and 131. Compound 122 showed potent activity against bovine tubulin assembly (IC50 = 
2.1 ± 0.04 µM), and in a VEGFR2 expressing cell line, it was determined that 122 (IC50 
223 
=33.2 nM) was 5-fold more active than 121 in this assay. Importantly, this is only 2-fold 
less potent than the standard sunitinib. These results are remarkable as VEGFR2 is the 
principal mediator of angiogenesis. Compound 122, an open chain monocyclic flexible 
pyrimidine displayed increased dual potency in both tubulin assays. 
There could be multiple reasons why 122 is more active than pyrrolo[2,3-d]pyrimidine 
121. Electron withdrawing 6-chloro group in 122 is an obvious place to start an analysis. 
Any electron donating group at 6-position such as OH, NH2 or an alkyl group was not 
tolerated. But replacement with electron withdrawing groups at the 6-position like 
trifluoromethyl or iodo, was tolerated. Another reason might be the size of the chloro 
group. However, replacement of Cl with a methyl moiety was not tolerated. A third reason 
might be the availability of lone pair of 5-NH2 in 122. Compared to the 121, the lone pair 
of electrons at 5-NH2 in 122 may be available for hydrogen bonding as either a hydrogen 
bond donor and/or acceptor. The nitrogen lone pair of compound 121 are unavailable due 
to conjugation. The equivalent lone pair of 122 NH2 might be involved in conjugation with 
the pyridine ring but could still form hydrogen bonds. 
So, it is likely the electron withdrawing nature of the Cl, or the hydrogen bonding acceptor 
properties of 5-NH2 results in improved activity compared to 121.  
The effect of homologation at the N5 position of 122 on tubulin and RTK activity was 
examined. Optimum chain length of the N5-substituent was determined. Compound 125 
was found to be 18 nM (IC50) in β-III overexpressing HeLa cells, and 22.2 nM (IC50) in P-
gp overexpressing NC/DR-Res cells. Increased lipophilicity of 125 may also permit better 
penetration across cell membranes, and produce better cellular activity. Compound 125 
224 
displayed more effective interactions with Ala316, Val315, Val181 in the tubulin site, 
Leu840 and Leu1035 in the VEGFR site, Ala719 in the EGFR site, and Val665 and Phe845 
in the PDGFR homology model.   
Compound 125 displayed combination chemotherapeutic properties in a single agent. The 
next goals could examine changes at other positions keeping the 6-Cl substitution 
unchanged. Substituted anilines could be introduced at the 4-position of the pyrimidine 
ring of 125 replacing the 4´-OMe aniline. The 4ʹ-thiomethyl group was the best tolerated, 
and so should be examined.  
Compound 125 could also be substituted with other halogens. Exploration of other electron 
withdrawing groups at other positions could have favorable effects in the biological assays 
examined.  
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VIII. APPENDIX 
 
APPENDIX-1 
 
The biological evaluations of were performed by Dr. Michael Ihnat (Department of 
Pharmaceutical Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, 
OK 73117), Dr. Ernest Hamel (Screening Technologies Branch, Developmental 
Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National 
Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 21702), Dr. 
Susan Mooberry (Department of Pharmacology, University of Texas Health Science 
Center at San Antonio, San Antonio, TX 78229), National Cancer Institute (Developmental 
Therapeutics Program) and Luceome Biotechnologies (1775 S. Pantano Rd, Suite 100, 
Tucson, AZ 85710) 
Biological evaluations 
 The EC50 (concentration required to cause 50% loss of cellular microtubules) was 
determined in A-10 cells1. The effects of the compounds on interphase and mitotic 
microtubules were evaluated using indirect immunofluorescence techniques, and the EC50 
values were calculated from a minimum of three experiments.  
 Antiproliferative effects were evaluated against the drug sensitive MDA-MB-435 
melanoma cells using sulforhodamine B assay and the IC50 values (concentration required 
to cause 50% inhibition of proliferation) were calculated. 
 In experiments with purified tubulin, the control compound was combretastatin A-
4 (CSA4), a potent colchicine site agent generously supplied by Dr. G. R. Pettit, Arizona 
State University, Tempe AZ. Tubulin polymerization was measured by turbidimetry at 350 
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nm in Beckman DU7400 and DU7500 recording spectrophotometers equipped with 
temperature controllers. In brief, 10 µM bovine brain tubulin, purified as described 
previously 2, was preincubated for 15 min in a 0.24 mL volume at 30°C containing 0.75 M 
monosodium glutamate (adjusted to pH 6.6 with HCl in a 2 M stock solution), varying 
compound concentrations, and 4% (v/v) dimethyl sulfoxide (compound solvent). 
Following the preincubation, which permits detection of activity in slow binding 
compounds such as colchicinoids 3, samples were chilled on ice, and 10 µL of 10 mM GTP 
was added (0.4 mM). The addition of GTP is an absolute requirement for assembly under 
these reaction conditions. All concentrations refer to the final 0.25 mL reaction volume. 
Samples were transferred to cuvettes held at 0°C in the recording spectrophotometers, and 
the temperature was jumped to 30°C, which takes less than a minute. Assembly at 30°C 
was followed for 30 min, and the compound concentration to inhibit extent of assembly 
after 30 min was determined by interpolation of data obtained with individual compound 
concentrations. After determining the likely range for the IC50 value, 2-4 individual 
determinations were made, and the average from these determinations are presented in 
Table 1. 
 The binding of [3H]colchicine to tubulin was performed by the DEAE-cellulose 
filter technique 4 with a stack of two filters, as described in detail previously 5. In brief, 
reaction mixtures contained, in a 0.10 mL volume, 1.0 µM purified tubulin, 5.0 µM 
[3H]colchicine, potential inhibitor at 5.0 µM, 5% (v/v) dimethyl sulfoxide (the compound 
solvent), and other components previously found to stabilize the colchicine binding activity 
of tubulin for prolonged periods at 37°C 6. Incubation was at 37°C for 10 min, at which 
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time samples were diluted with 2 mL of ice-cold water and poured over the DEAE-filters 
under mild suction, with several rinses of the reaction vessel and of the filtration chamber. 
The amount of radiolabel bound to the filters was determined by liquid scintillation 
counting, and samples containing test compounds were compared to reaction mixtures 
without compound. The percent inhibition relative to the control was determined for each 
compound in 2-4 independent experiments. 
 
Table 1. Effects in cellular assays and on purified tubulin  
Compd. 
 
EC50 Microtubule  
Depolymerization 
(nM) 
MDA-
MB-435 
IC50±SD 
(nM) 
Inhibition of 
Lab 
Record 
book 
no. 
Tubulin 
Assembly 
IC50±SD 
(µM) 
% Colchicine 
Binding 
inhibited at 
 5µM 
compound 
concentration 
130 284 - - >20 17 ± 0.4                                                         
131 281 - - >20 11 ± 3                                                            
132 280 - - >20  
122 46 3800 160 ± 32 2.1 ± 0.04 81 ± 0.3 
123 65 169 30.3 ± 4.0 1.6 ± 0.3 91 ± 0.04 
124 61 - - 2.4 ± 0.3 63 ± 1 
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125 70 45 17.3 ± 1.1 1.5 ± 0.2 95 ± 2 
126 90 46 ± 4 82 1.4 ± 0.2 93 ± 0.4 
127 109 - - 2.0 ± 0.2 89 ± 0.6 
128 112 - - 1.2 ± 0.05 87 ± 4 
133 114 - - > 20 - 
134 115 - - > 20 - 
135 84 - - > 20  
136 136 - - 4.0 ± 0.2  
137 66 - - 11 ± 0  
138 89 9400 580 ± 71 18 ± 2     
139 88 > 10000 830 ± 90 > 20  
140 231 - - > 20  
141 203 - - > 20  
142 157 5100 220 ± 15 3.4 ± 0.07  
143 
273 
6.5 µM 
238.2 ± 
21.4 
6.0 ± 0.1  
144 140 - - 11 ± 0.2  
145 159 - - 4.9 ± 0.6    
146 159b - - Inactive  
147 159c - - Inactive  
148 142 > 10 µM - Inactive  
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149 147 - - Inactive  
150 149 - -- Inactive  
151 223 - - 2.6 ± 0.03 65 ± 0.4 
152 234 - - 3.0 ± 0.2        51 ± 4 
153 215 - - 8.8 ± 0.5  
154 235 - - > 20  
155 236 - - 16 ± 0.5  
156 29 - - > 20 - 
159 209 - - > 20  
160 224 6400 195 ± 18 > 20  
162 228 8 µM 550 ± 86   
163 249 > 10 µM -   
164 275 > 10 µM    
165 259 > 10 µM -   
166 295 365 37.1 ± 9.4   
167 222 8.1 µM 198 ± 23   
170 93 - - 12 ± 0.6  
172 79 - - > 20  
CSA4  0.0131 3.47 ± 0.6 1.2 ± 0.01 98 ± 0.3 
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Antibodies 
 The PY-HRP antibody was from BD Transduction Laboratories (Franklin Lakes, NJ). 
Antibodies against VEGFR-2 were purchased from Cell Signaling Technology (Danvers, 
MA).  
 
Phosphotyrosine ELISA 
 Cells used were tumor cell lines naturally expressing high levels of VEGFR-2 (U251). 
Expression levels at the RNA level were derived from the NCI Developmental 
Therapeutics Program (NCI-DTP) web site public molecular target information. Briefly, 
cells at 60–75% confluence are placed in serum-free medium for 18 h to reduce the 
background phosphorylation. Cells were always >98% viable by trypan blue exclusion. 
Cells were then pretreated for 60 min with a dose-response relation of 100-1.4 µM 
compound followed in ⅓ Log increments by 100 ng/mL VEGF for 10 min. The reaction 
was stopped and cells permeabilized by quickly removing the media from the cells and 
adding ice-cold Tris-buffered saline (TBS) containing 0.05% Triton X-100, protease 
inhibitor cocktail and tyrosine phosphatase inhibitor cocktail. The TBS solution was then 
removed and cells fixed to the plate for 30 min at 60 °C with a further incubation in 70% 
ethanol for an additional 30 min. Cells were exposed to a blocking solution (TBS with 1% 
BSA) for 1 h, washed, and then a horseradish peroxidase (HRP)-conjugated 
phosphotyrosine (PY) antibody was added overnight. The antibody was removed, and the 
cells were washed again in TBS, exposed to an enhanced luminol ELISA substrate (Pierce 
Chemical EMD, Rockford, IL) and light emission was measured using a UV Products 
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(Upland, CA) BioChemi digital darkroom. Data were graphed as a percent of cells 
receiving growth factor alone, and IC50 values were calculated from two to three separate 
experiments (n = 8–24) using non-linear regression dose-response relation analysis. 
 
OVCAR-8, NCI/ADR-RES and HeLa cells 
The OVCAR-8 and the Pgp overexpressing NCI/ADR-RES cell lines were generously 
provided by the Drug Screening group of the Developmental Therapeutics Program, NCI. 
The wild-type and β-III overexpressing HeLa cells were generous gifts, respectively, of 
Dr. Richard F. Ludueña and Dr. Susan L. Mooberry. The OVCAR-8 and NCI/ADR-RES 
cells were grown in RPMI 1640 medium with 5% fetal bovine serum at 37 °C in a 5% CO2 
atmosphere for 96 h in the presence of varying compound concentrations. The HeLa cells 
were grown in MEM supplemented with Earle’s salts, nonessential amino acids, 2 mM L-
glutamine, and 10% fetal bovine serum at 37 °C in a 5% CO2 atmosphere for 96 h in the 
presence of varying compound concentrations. In all cultures, the DMSO concentration 
was 0.5%. Protein was the parameter measured by the sulforhodamine B technique,8 and 
the IC50 was defined as the compound concentration causing a 50% reduction in the 
increase in cell protein as compared with cultures without compound addition. 
 
Chorioallantoic membrane assay of angiogenesis 
The CAM assay is a standard assay for testing antiangiogenic agents. The CAM assay used 
in these studies was modified from a procedure by Sheu and Brooks and as published 
previously. Briefly, fertile leghorn chicken eggs (CBT Farms, Chestertown, MD) were 
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allowed to grow until 10 days of incubation. The proangiogenic factors human VEGF-165 
and bFGF (100 ng each) were then added at saturation to a 6 mm microbial testing disk 
(BBL, Cockeysville, MD) and placed onto the CAM by breaking a small hole in the 
superior surface of the egg. Antiangiogenic compounds were added 8 h after the 
VEGF/bFGF at saturation to the same microbial testing disk and embryos allowed to 
incubate for an additional 40 h. After 48 h, the CAMs were perfused with 2% 
paraformaldehyde/3% glutaraldehyde containing 0.025% Triton X-100 for 20 sec, excised 
around the area of treatment, fixed again in 2% paraformaldehyde/3% glutaraldehyde for 
30 min, placed on Petri dishes, and a digitized image taken using a dissecting microscope 
(Wild M400; Bannockburn, IL) at 7.5X and a SPOT enhanced digital imaging system 
(Diagnostic Instruments, Sterling Heights, MI). A grid was then added to the digital CAM 
images and the average number of vessels within 5–7 grids counted as a measure of 
vascularity. Sunitinib and semaxanib were used as a positive control for antiangiogenic 
activity. Data were graphed as a percent of CAMs receiving bFGF/VEGF only and IC50 
values calculated from two to three separate experiments (n = 5–11) using non-linear 
regression dose-response relation analysis.  
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Table 2. Inhibitory data for multiple kinases 
Compd.(Lab 
record book 
no) 
EGFR 
Inhibition 
CAM VEGFR-
2 
inhibition 
PDGFR-
β 
inhibition 
A431 
cytotoxicity 
MDA-
MB-
231 
123 (65) 335.3 ± 
4.0 
24.5 ± 
4.0 
34.2 ± 4.0 
137.0 100.2 >1000 
124 (61) 146.2 ± 
18.9 
18.5 ± 
3.1 
15.4 ± 2.1 98.5 40.2 ± 8.2 193.2 ± 30.2 
125 (70) 255.6 ± 
30.2 
30.1 ± 
4.3 
32.5 ± 5.0 193.1 47.2 ± 5.9 227.2 ± 4.1 
156 (29) 100.3 ± 
14.8 
10.3 ± 
1.9 
7.9 ± 1.8 108.5 33.2 ± 5.8 227.2 ± 30.3 
122 (46) 415.4 ± 
50.1 
20.6 ± 
3.1 
33.2 ± 4.1 183.2 121.0 ± 19.9 
343.3 
± 42.1 
137 (66) 356.3 ± 
52.3 
36.2 ± 
5.0 
21.6 ± 
3.81 209.2 
109.5 ± 
22.2 >1000 
139 (88) 288.4 ± 
39.0 
16.4 ± 
2.1 
21.8 ± 3.6 283.1 89.4 ± 15.0 >1000 
126 (90) 152.6 ± 
20.4 
19.9 ± 
2.8 
15.2 ± 2.5 183.3 30.1 ± 5.7 292.4 ± 39.1 
172 (79) 23.2 ± 4.6  52.1 ± 8.2 >200 7.8 ± 0.9  
135 (84) 189.2  ± 
23.6 
 >200 >200 650 ± 79.3  
127 
(109·HCl) 
58.2 ± 
10.5 
±  26.3 ± 4.1 70.6 ± 
10.2 80.8 ± 10.7 
 
128 (112) 18.6 ± 2.1  22.7 ± 3.1 103.2 ± 
14.0 7.6 ± 0.51 
 
133 (114) 198.6 ± 
16.6 
17.7±5.5 208.6 ± 
28.5 
326.3 ± 
50.3 
626.7 ± 
105.1 
 
134 (115) 26.0  ± 
3.8 
 32.6 ± 4.1 40.6 ± 5.0 8.2 ± 0.76  
PD153035 0.21 ± 
0.002 
     
Cisplatin     7.65 ± 1.4  
SU5416  0.041 ± 
0.009 
12.9    
DOX  0.04 ± 
0.0031 
  1.35 ± 0.03  
Suntinib 172.1 ± 
19.4µM 
1.3 ± 
0.07 
18.9 ± 2.7 83.1 ± 
10.1 
  
Erlotinib 1.2 ± 
0.2µM 
29.1 ± 
1.9 
124.7 ± 
18.2 
12.2 ± 1.9   
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Table 3: Inhibition of growth of β-III and P-gp overexpressing cells. 
 
Lab 
Record 
book 
no. 
WT 
HeLa 
IC50 (nM) 
β-III 
overexpressing 
HeLa 
IC50 (nM) 
Parental 
OVCAR-8 
IC50 (nM) 
P-gp 
overexpressing 
NCI/DR-RES 
IC50 (nM) 
130 284 - - > 5,000 4,400 ± 900 
131 281 - - > 5,000 > 5,000 
122 46 188 ± 24 186 ± 20 311 ± 15 516 ± 98 
123 65 27.3 ± 3.3 35.1 ± 0.6 47.2 ± 8.9 67.3 ± 13.0 
124 61 610 ± 20 610 ± 20   
125 70 16.5 ± 2.2 18.0 ± 0.6 20.5 ± 2.7 22.2 ± 3.8 
126 
90 
16.5 ± 2.2 18.0 ± 0.6 20.5 ± 2.7 22.2 ± 3.8 
127 109 59.8 ± 
17.7 60.3 ± 1.9 70.4 ± 9.2 87.0 ± 3.7 
128 112   63 ± 6 37 ± 10 
133 114   > 10,000 > 10,000 
134 115   > 10,000 > 10,000 
135 84 > 5,000 > 5,000   
136 136 5000 5000   
137 
66    1700 ± 
500   
2500 ± 0   
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138 89   2,200 ± 500                              610 ± 20
139 
88 1600 ± 
300 
2500 ± 0      
140 231   > 5000 > 5000 
141 203   4,400 ± 900                           2,300 ± 400 
142 157   450 ± 70                                   250 ± 70
144 140 5000 5000   
145 159   1,250 ± 0                                    700 ± 300 
151 223   310 ± 100                                  170 ± 7
152 234   500 ± 100                                  210 ± 10
153 215   3,100 ± 900                              630 ± 40
154 235    > 5000  > 5000 
155 236    > 5000  > 5000 
156 29 > 10,000 > 10,000   
159 209   > 5,000                                  > 5,000                                  
160 224   > 5,000                                  > 5,000                             
167 222 
190 ± 19 151 ± 14 260 ± 26 440 ± 56 
170 93   > 5,000 > 5,000 
172 79 > 5,000 > 5,000   
CSA4  5.6 ± 0.3  5.7 ± 0.4 6.9 ± 0.1 3.0 ± 0.3 
Paclitaxel  1.9 ± 0.3 32.9 ± 5.8 6.3 ± 0.4 1,187.2 ± 265.2 
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Tubulin immunofluorescence assay  
MDA-MB-435 cells were plated in chamber slides at ~30% confluency and allowed to 
attach overnight. Cells were then treated with drug at the IC50 concentration for 2 h in 
serum free media. After 2 h, drug was removed, cells were washed and then fixed in 3.7% 
buffered formalin for 10 min. Fixed cells were then washed 3x with PBS, permeabilized 
with 0.5% Triton 100-X in PBS for 10 min at RT then blocked in 10% goat serum for 30 
min at RT. Slides were washed again with PBS 3x and then incubated with anti-alpha-
tubulin Alexa Fluor® 488 (Invitrogen, Carlsbad CA) in PBS containing 10% goat serum 
at a concentration of 2.5 µg/mL for 1 h at RT in the dark. After incubation, cells were 
washed, chambers removed, SlowFade Gold (Molecular Probes/Invitrogen, Carlsbad CA) 
added and a cover slip applied. Slides were imaged using a fluorescent microscope, Leica 
DM4000 B (Wetzlar, Germany) at EX488 nm/EM519 nm.  
 
Maximum tolerated dose in mice  
To determine the maximum tolerated dose (MTD) of compounds and drugs, a dose finding 
study was performed using BALBc/J mice (Jackson Laboratories, Bar Harbor, ME). Drugs 
were first dissolved at 50 mg/mL in DMSO and frozen in aliquots at -80 °C. Solutol-15 
(BASF, Ludwigshafen, Germany) was melted at 60 °C for 5-10 min, then mixed in a ratio 
of 1 part DMSO/drug to 1.8 parts solutol-15 to 7.2 parts sterile dextrose 5% in water (D5W). 
This solvent mixture was used for all drugs. Starting at 10 mg/kg and 15 mg/kg body weight 
(n = 2 mice per treatment), mice were weighed and doses increased in 10 mg/kg increments 
every other day until weight loss was observed. At this point the MTD was estimated to be 
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the approximate dose of first weight loss. The MTD of docetaxel was found to be 35 mg/kg, 
sunitinib 30 mg/kg and 126 [RM/AG-90·HCl] 50 mg/kg, temozolomide 30 mg/kg.  
 
U251 flank xenograft model 
Human U251 glioblastoma cells (500,000) in media were implanted into the lateral flank 
of 8 wk old male NCr athymic nu/nu nude mice (Charles River, Wilmington, DE). Tumor 
sizes (length, width, depth) were measured twice weekly. When volumes reached 75-100 
mm3 (day 8 after implantation), treatment with drugs at their MTD (above) was begun and 
animal weights and tumor volumes measured twice weekly. At the end of the experiment, 
animals were humanely euthanized using the AALAC approved method of carbon dioxide 
asphyxiation. Tumors were removed, fixed in neutral buffered formalin, paraffin 
embedded, sectioned and sections stained against CD31/PECAM-1 using an antibody from 
Abcam (ab28364) and staining done using a Vectastain ABC kit (Vector Laboratories, 
Burlingame, CA Vessel density was assessed by counting the number of CD31-positive 
vessels in a 200x microscope field in a blinded fashion and graphed as a percent vessel 
density of carrier treated animals.  
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Figure 1: Treatment with 126 [RM/AG-90·HCl] decreased primary tumor growth and 
tumor vascular density in U251 flank xenograft mouse model. * P<0.05, ** P<0.01, *** 
P<0.001 by one way ANOVA with Neuman-Keuls post test. U251 human glioma cells 
were implanted into the lateral flank of NCr athymic nu/nu nude mice at 500,000 cells, and 
the mice were treated with carrier temozolomide or 126 [RM/AG-90·HCl] twice weekly at 
their MTD’s until the end of the experiment. Data is representative of 6-8 animals. (A) 
Tumor size was determined as described in the legend of Figure 3. Statistics on this graph 
were two way ANOVA with repeated measures post test. (B) Graphical representation of 
percent change in animal weight as determined by measuring animal weight at the 
beginning and end of experiment. 
 
  
257 
Table 4. Cancer cell growth inhibitory activity (GI50, nM) of 126 (RM/AG-90.HCl) (NCI 
60 cell line panel) 
Panel/ Cell 
line 
GI50 
(nM) 
Panel/ Cell 
line 
GI50 
(nM) 
Panel/ Cell 
line 
GI50 
(nM) 
Panel/ 
Cell line 
GI50 
(nM) 
Leukemia   Colon Cancer   Melanoma   
Renal 
Cancer 
  
CCRF-CEM 43.5 COLO 205 24.8 LOX IMVI 55.6 786-0 36.5 
HL-60(TB) 2.7.2 HCC-2998 35.2 M14 21.4 A498 28.8 
MOLT-4 62.8 HCT-116 32.6 
MDA-MB-
435 
16.7 ACHN 83.9 
RPMI-8226 47.7 HCT-15 31.0 SK-MEL-2 66.5 CAKI-1 40.4 
SR 42.0 KM12 40.0 SK-MEL-28 76.5 RXF 393 25.5 
NSCLC   SW-620 39.2 SK-MEL-5 33.9 SN12C 88.1 
A549/ATCC 39.7 CNS Cancer   UACC-257 
34.9 
(µM) 
TK-10 78.3 
HOP-62 43.6 SF-268 67.3 UACC-62 31.7 UO-31 427 
HOP-92 80.0 SF-295 24.6 
Ovarian 
cancer 
    
NCI-H226  SF-539 27.3 IGROVI 168 
Breast 
Cancer  
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NCI-H23 61.8 SNB-19 51.3 OVCAR-3 33.3 MCF7 31.0 
NCI-H322M 
100 
(µM) 
SNB-75 22.3 OVCAR-4 98.1 MDA-MB-231/ 
ATCC 
40.4 
NCI-H460 36.8 U251 43.3 OVCAR-5 44.6 HS 578T 36.7 
NCI-H522 53.3 
Prostate 
Cancer 
  OVCAR-8 46.3 BT-549 32.7 
  PC-3 44.6  
NCI/ADR-
RES 
35.6 T-47D 71.7 
  DU-145  44.8 SK-OV-3 41.0 
MDA-
MB-468 
26.4 
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APPENDIX-2 
 
The biological evaluations of the analogs listed in the following tables were performed 
by Dr. Larry H. Matherly (Developmental Therapeutics Program, Barbara Ann Karmanos 
Cancer Institute and the Cancer Biology Program and Department of Pharmacology, 
Wayne State University School of Medicine) against GARFTase, RFC-expressing PC43-
10 cells, FRα-expressing RT16 cells, FRβ-expressing D4 cells and hPCFT-expressing 
R2/hPCFT4 cells. 
 
Cell Lines and Assays of Antitumor Drug Activities. RFC- and FRR-null 
MTXRIIOuaR2-4 (R2) CHO cells were gifts from Dr. Wayne Flintoff (University of 
Western Ontario) and were cultured in R-minimal essential medium (MEM) supplemented 
with 10% bovine calf serum (Invitrogen, Carlsbad, CA), penicillin- streptomycin solution 
and L-glutamine at 37 °C with 5% CO2. PC43-10 cells are R2 cells transfected with hRFC. 
RT16 cells are R2 cells transfected with human FRα, and D4 cells are R2 cells transfected 
with human FRβ. R2/hPCFT4 cells were prepared by transfection of R2 cells with an 
hPCFT cDNA, epitope tagged at the C-terminus with Myc-His6 (hPCFTMyc-His6) and 
cloned in pCDNA3.1. All the R2 transfected cells (PC43- 10, RT16, D4, R2/hPCFT4) were 
routinely cultured in R-MEM plus 1.5 mg/mL G418. Prior to the cytotoxicity assays (see 
below), RT16 and D4 cells were cultured in complete folate-free RPMI1640 (without 
added folate) for 3 days. KB human cervical cancer cells were purchased from the 
American Type Culture Collection (Manassas, VA), whereas IGROV1 ovarian carcinoma 
cells were a gift of Dr. Manohar Ratnam (Medical University of Ohio). Cells were routinely 
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cultured in folate-free RPMI1640 medium, supplemented with 10% fetal bovine serum, 
penicillin-streptomycin solution, and 2 mM L-glutamine at 37 °C with 5% CO2. For growth 
inhibition assays, cells (CHO, KB, or IGROV1) were plated in 96 well dishes (∼2500-
5000 cells/well, total volume of 200 µL medium) with a broad range of antifolate 
concentrations. The medium was RPMI1640 (contains 2.3 µM folic acid) with 10% 
dialyzed serum and antibiotics for experiments with R2 and PC43-10 cells. For RT16, D4, 
KB, and IGROV1 cells, the cells were cultured in folate-free RPMI media with 10% 
dialyzed fetal bovine serum (Invitrogen) and antibiotics supplemented with 2 nM LCV. 
The requirement for FR mediated drug uptake in these assays was established in a parallel 
incubation including 200 nM folic acid. For R2/hPCFT4 cells, the medium was folate-free 
RPMI1640 (pH 7.2) containing 25 nM LCV, supplemented with 10% dialyzed fetal bovine 
serum (Invitrogen) and antibiotics. Cells were routinely incubated for up to 96 h, and 
metabolically active cells (a measure of cell viability) were assayed with Cell Titer-blue 
cell viability assay (Promega, Madison, WI), with fluorescence measured (590 nm 
emission, 560 nm excitation) using a fluorescence plate reader. Raw data were exported 
from Softmax Pro software to an Excel spreadsheet for analysis and determinations of 
IC50s, corresponding to the drug concentrations that result in 50% loss of cell growth. For 
some of the in vitro growth inhibition studies, the inhibitory effects of the antifolate 
inhibitors on de novo thymidylate biosynthesis (i.e., TS) and de novo purine biosynthesis 
(GARFTase and AICARFTase) were tested by coincubations with thymidine (10 µM) and 
adenosine (60 µM), respectively. For de novo purine biosynthesis, additional protection 
experiments used AICA (320 µM) as a means of distinguishing inhibitory effects at 
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GARFTase from those at AICARFTase. For assays of colony formation in the presence of 
the antifolate drugs, KB cells were harvested and diluted, and 200 cells were plated into 
60mmdishes in folate-free RPMI1640 medium supplemented with 2 nM LCV, 10% 
dialyzed fetal bovine serum, penicillin-streptomycin, and 2 mM L-glutamine in the 
presence of antifolate drugs. The dishes were incubated at 37 °C with 5% CO2 for 10-14 
days. At the end of the incubations, the dishes were rinsed with Dulbecco’s phosphate-
buffered saline (DPBS), 5%trichloroacetic acid, and borate buffer (10 mM, pH 8.8), 
followed by 30 min incubation in 1% methylene blue in the borate buffer. The dishes were 
rinsed with the borate buffer, and colonies were counted for calculating percent colony-
forming efficiency normalized to control.  
 
FR Binding Assay. [3H]Folic acid binding was used to assess levels of surface FRs. 
Briefly, cells (e.g., RT16 or D4; ∼1.6 × 106) were rinsed twice with Dulbecco’s phosphate-
buffered saline (DPBS) followed by two washes in acidic buffer (10 mM sodium acetate, 
150 mM NaCl, pH 3.5) to remove FR-bound folates. Cells were washed twice with ice-
cold HEPES-buffered saline (20 mM HEPES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, 5 
mM glucose, pH 7.4; HBS), then incubated in HBS with [3H]folic acid (50 nM, specific 
activity 0.5 Ci/mmol) in the presence and absence of a range of concentrations of unlabeled 
folic acid or antifolate for 15 min at 0 °C. The dishes were rinsed three times with ice-cold 
HBS, after which the cells were solubilized with 0.5 N sodium hydroxide and aliquots 
measured for radioactivity and protein contents. Protein concentrations were measured 
with Folin phenol reagent. Bound [3H]folic acid was calculated as pmol/mg protein. 
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Relative binding affinities for assorted folate/antifolate substrates were calculated as the 
inverse molar ratios of unlabeled ligands required to inhibit [3H]folic acid binding by 50%. 
By definition, the relative affinity of folic acid is 1.  
 
Transport Assays. For transport assays, R2/hPCFT4, PC43- 10, and R2(VC) CHO cells 
grown as monolayers were used to seed spinner flasks. For experiments to determine the 
inhibitions of transport by antifolate substrates, cells were collected and washed with DPBS 
and resuspended in 2 mL of physiologic Hank’s balanced salts solution (HBSS) for PC43-
10 cells and in HBS adjusted to pH 7.2 or 6.8 or 4-morpholinepropanesulfonic acid (MES)-
buffered saline (20 mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, and 5 mM 
glucose) adjusted to pH 6.5, 6.0, or 5.5 for R2/hPCFT4 cells. In either case, uptakes of 
[3H]MTX (0.5 µM) were measured over 2 min at 37 °C in the presence and absence of 
unlabeled antifolates (10 µM). Uptakes of [3H]MTX were quenched with ice-cold DPBS. 
Cells were washed with icecold DPBS (3×) and solubilized with 0.5 N NaOH. Levels of 
intracellular radioactivity were expressed as pmol/mg protein, calculated from direct 
measurements of radioactivity and protein contents of cell homogenates. Protein 
concentrations were measured with Folin phenol reagent. Percent MTX transport inhibition 
was calculated by comparing level of [3H]MTX uptake in the presence and absence of the 
inhibitors. Kinetic constants (Kt, Vmax) and Kis were calculated from Lineweaver-Burke and 
Dixon plots, respectively.  
 
263 
In Vitro GARFTase Enzyme Inhibition Assay. Purified recombinant mouse GARFTase 
enzyme was a gift from Dr. Richard Moran (Virginia Commonwealth University, 
Richmond, VA). Briefly, enzyme activity was assayed spectrophotometrically at 37 °C 
using GARFTase (0.75 nM), α,β-GAR (11 µM), and coenzyme 10-formyl-5,8-dideazafolic 
acid (10 µM) in HEPES buffer (75 mM, pH 7.5) with or without antifolate inhibitor (10-
30 000 nM). The absorbance of the reaction product, 5,8-dideazafolic acid, was monitored 
at 295 nM over the first minute as a measure of the initial rate of enzyme activity. IC50s 
were calculated as the concentrations of inhibitors that resulted in a 50% decrease in the 
initial velocity of the GARFTase reaction.  
 
In Situ GARFT Enzyme Inhibition Assay. Incorporation of [14C]glycine into 
[14C]FGAR, as an in situ measure of endogenous GARFTase activity, was described by 
Beardsley et al. and modified by Deng et al. For these experiments, KB cells were seeded 
in 4 mL of complete folate-free RPMI1640 plus 2 nM LCVin 60 mm dishes at a density of 
2 × 106 cells per dish. On the next day, the medium was replaced with 2 mL of fresh 
complete folate-free RPMI1640 plus 2 nM LCV (without supplementing glutamine). 
Azaserine (4 µM final concentration) was added in the presence and absence of the 
antifolate inhibitors (0.1, 1, 10, 100, or 1000 nM). After 30 min, L-glutamine (final 
concentration, 2 mM) and [14C]glycine (tracer amounts; final specific activity 0.1 mCi/L) 
were added. Incubations were at 37 °C for 15 h, at which time cells were washed (one-
time) with ice-cold folate-free RPMI1640 plus serum. Cell pellets were dissolved in 2mL 
of 5% trichloroacetic acid at 0 °C. Cell debris was removed by centrifugation (the cell 
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protein contents in the pellets were measured), and the supernatants were extracted twice 
with 2 mL of ice-cold ether. The aqueous layer was passed through a 1 cm column of AG1 
× 8 (chloride form), 100-200 mesh (Bio-Rad), washed with 10 mL of 0.5 N formic acid 
and then 10 mL of 4 N formic acid, and finally eluted with 8 mL of 1 N HCl. The elutants 
were collected and determined for radioactivity. The accumulation of radioactive FGAR 
was calculated as pmol per mg protein over a range of inhibitor concentrations. IC50s were 
calculated as the concentrations of inhibitors that resulted in a 50% decrease in FGAR 
synthesis. 
 
Antifolate 
KB 
(nM) 
RFC/FR 
/PCFT 
PC43-
10  
(nM) 
RFC 
 
R2 
(nM) 
Null 
RT16 
(nM) 
FR 
D4 
(nM) 
FR 
R2/ 
PCFT4 
(nM) 
PCFT 
 
68  138 894 42 60 13.2 
 
7.94 56.6 >1000 8.57 6.99 840 
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Table 1. IC50 values (nM) for 5-substituted pyrrolo[2,3-d]pyrimidine antifolates and the 
clinically used classical antifolate PMX in RFC-, PCFT-, and FR-expressing Chinese 
hamster ovary (CHO) cell lines and KB human tumor cells. The data shown summarize 
results from 3 to 10 experiments. The results are presented as mean IC50 values 
corresponding to the concentrations that inhibit growth by 50% relative to cells incubated 
without drug. 
 
20.1 194.6 >1000 33.5 - 
 
>1000 
 
4.63 768 >1000 40.3 0.13 199.8 
 
29.3 319 >1000 9.61 3.32 30.7 
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APPENDIX-3 
 
Fig. 1 Protection studies for compounds 173 (RM/AG-293) and 174 (RM/AG-306) 
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The synthetic strategy required the substituted indole 30 which was synthesized in two steps from 
3-bromo-2-chloronitrobenzene 28 by a potassium t-butoxide induced displacement with 
cyanoacetate to 29, followed by Zn-dust catalyzed reduction. Cyclocondensation of 30 with 
chloroformamidine in methylsulfone at 120 °C for 5 h or guanidine hydrochloride in DMF under 
reflux conditions did not afford 31.7 
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Intermediate 3 was synthesized from commercially available 2,4-diamino-6-hydroxypyrimidine 
2 and chloroacetaldehyde in sodium acetate-water solution. The cyclocondensation was 
regiospecific and afforded 3 in 82% yield. The 2-amino group was pivaloyated and then 
chloromercuration of 4 was carried out by adding mercuric acetate in glacial acetic acid, followed 
by the addition of saturated sodium chloride solution. The precipi tated white sol id was 
f i l tered and washed thoroughly with water  to give a 10:1 mixture of  6-
chloromercuri derivative 5 and 5-chloromercuri derivative in 50% overall yield. The 
resulting mixture of c h l o r o m e r c u r i  d e r i v a t i v e s  w a s  t r e a t e d  w i t h  i o d i n e  
i n  dichloromethane to afford the corresponding 6-iodo and 5-iodo derivatives from which the 
desired 6-iodo 6 was readily separated by column chromatography in 64% yield.8 
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Compound 8 were readily prepared from 7 using the Vilsmeier reagent with DMF/POCl3  in 70% 
yield.9 5-Arylthiophene-2-carboxylate 9 were then synthesized by reacting β-chlorovinyl aldehyde 
8 with mercaptoacetate in the presence of potassium carbonate. 10 Then, two step, one pot 
palladium catalyzed borylation/Suzuki coupling reaction11 was attempted  with iodo 6 tilizing bis-
boronic acids but did not provide the desired compound 12. 
 
 
The aldehyde 6 was alpha-brominated using bromine to yield 7 which was then cyclized using 
commercially available 2,4-diamino-6-hydroxypyrimidine to furnish 8 which was then pivylated 
to afford 9. Bromination of 9 was then attempted but did not give the desired product 10. 
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Commercially available acid 2 was esterified with ethanol to afford 3 which was then alkylated 
with 3-bromo-1-propanol to afford alkylated intermediate 4. The intermediate 4were then oxidized 
using Dess-Martin Oxidation but gave a series of side products which could not be isolated. 
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Gangjee et al. reported12 the synthesis of the pivaloyl-protected pyrrolo[2,3-d]pyrimidine 2 beore. 
A Mannich reaction was carried out on 2.13 The Mannich reagent 3 was prepared by the slow 
addition of 37% aqueous formaldehyde to a cold (0 °C) solution of N,N-dimethylamine in glacial 
acetic acid. Compound 4 was added to the cold reagent solution, and the mixture was heated to 50 
°C for 48 h to afford 5 as a crude product in 55 % yield. Compound 5 was not purified and directly 
taken to next step which was hydrolysis using  1 N NaOH to afford 6. The peptide with (L)-diethyl 
glutamate esters using N-methylmorpholine and 6-chloro-2,4-dimethoxytriazine as the activating 
agents did not afford the final product 7. 
 
 
 
